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“In my view, all that is necessary for faith is the belief  
that by doing our best we shall succeed in our aims”  
- Rosalind Franklin. 
 
“If we knew what we were doing, 
 it wouldn’t be called research, would it?”    
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The Chilean salmon industry is considered one of the most important aquaculture industries 
worldwide, only bypassed by Norway. In Chile, salmon represents the second-biggest export product 
after copper. Due to the fast development of the industry and the introduction of Atlantic salmon to 
the Pacific Ocean, the industry has been affected by infectious diseases caused by viruses, bacteria 
and parasites. Piscirickettsiosis is the infectious disease that has produced the highest economic losses 
during the last 30 years in Chilean aquaculture; around USD 700 million per year. The disease was 
described for the first time in 1989, in the Los Lagos region, a southern part of Chile. The salmonid 
species that are susceptible to piscirickettsiosis are coho salmon (Oncorhynchus kisutch), Atlantic 
salmon (Salmo salar L.), rainbow trout (Oncorhynchus mykiss) and chinook salmon (Oncorhynchus 
tshawytscha). Piscirickettsiosis is an aggressive systemic disease with mortalities that can fluctuate 
between 30-90% of the affected fish. In general, the outbreaks develop after transfer of the fish to the 
sea and close to harvest. The etiological agent of the disease is Piscirickettsia salmonis; a Gram-
negative, non-motile, intracellular facultative bacterium. The most common pathological changes in 
fish infected with P. salmonis are lethargy, darkness of the skin, erratic swimming, and anorexia. 
Internally, the visceral tissues (liver, kidney and spleen) are most affected, but heart, brain, ovaries 
and skeletal muscle are also compromised. The control measurements used by the Chilean industry 
to reduce the casualties of the disease are among others the use of antibiotics (as treatment and 
prophylactic) and vaccination.  
The frequent and widespread outbreaks of piscirickettsiosis account for the high use of antibiotics 
in Chilean salmon farms. In 2014, the use of antibiotics reached a total of 563.2 tonnes in comparison 
with the Norwegian aquaculture industry that used only 0.5 tonnes the same year. Vaccination is 
frequently used to prevent outbreaks of piscirickettsiosis. There are 57 vaccines registered for 
salmonid fish in Chile, of which 32 vaccines include a P. salmonis component. From the 32 vaccines 
with P. salmonis antigens, there are seven monovalent and 25 multivalent vaccines. The 32 vaccines 
with P. salmonis antigens comprise 28 inactivated vaccines, three subunit vaccines and one live-
attenuated vaccine.  
Experimental challenge trials represent an important tool for evaluation of the efficacy of health 
feeds, pharmaceutical treatments, prophylactic measurements and genetic resistance. In vivo 
challenge trials have been used for many years for the evaluation of vaccine efficacy. The challenge 
models commonly used are challenge by intraperitoneal injection of the test fish, cohabitation of i.p. 
injected shedders fish with test fish and by immersion of the test fish.     
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The main objective of this thesis was to increase the knowledge on experimental challenge models 
with Piscirickettsia salmonis and define the in vivo model of preference for evaluation of efficacy of 
vaccines intended for Atlantic salmon. In addition, the aim was to increase the understanding on 
piscirickettsiosis’ pathogenesis and to characterize a P. salmonis isolate in vitro.  To achieve this, three 
sub-goals were defined: 1) To compare the progression of piscirickettsiosis development after 
experimental challenge by intraperitoneal injection or cohabitation; 2) To compare the protection 
induced by experimental vaccines against P. salmonis after immunization and experimental challenge 
by intraperitoneal injection or cohabitation; and 3) To characterize the P. salmonis isolate used for in 
vivo experimental trials after cultivation in broth media. 
As a result of this investigation, three scientific articles were written, each with the objective to 
answer the specific goals. Article I, “Development of piscirickettsiosis in Atlantic salmon 
(Salmo salar L.) smolts after intraperitoneal and cohabitant challenge using an EM90-like isolate: A 
comparative study”, demonstrated that there were no significant differences in disease development 
after challenge by intraperitoneal injection compared with  cohabitation. Furthermore, changing the 
bacterial cultivation from solid agar to liquid medium to produce the inoculum did not affect the 
disease development in a controlled environment. Article II, “Comparative study of experimental 
challenge by intraperitoneal injection and cohabitation of Atlantic salmon (Salmo salar L.) after 
vaccination against Piscirickettsia salmonis (EM90-like)”, revealed that the protection induced by 
experimental vaccines is similar after challenge by intraperitoneal injection or cohabitation. Article III 
“Cultivation and characterization of a Piscirickettsia salmonis EM90-like isolate used for in vivo 
challenge of Atlantic salmon (Salmo salar L.)”, provided new insight to the growth dynamics of 
P. salmonis. Furthermore, phylogenetic studies confirmed that the isolate used in the current work 
belongs to the EM90 genogroup and that there is a phylogenetic separation between the genogroups 
EM90 and LF89. Moreover, the study demonstrates that the change of cultivation media from solid 
agar to liquid broth did not affect the virulence of the isolate.   
Further investigations should be done to obtain a better understanding of P. salmonis and its 
interaction with its host during infection. The use of experimental challenge models must be carefully 
evaluated to apply a model that most closely mimics real-life conditions in the field. The present work 
reveals that the protection induced by vaccination is similar whether the fish are challenged by i.p. 
injection or cohabitation. However, further work is needed to refine the model to better separate the 








Den chilenske laksenæringen regnes som en av de viktigste oppdrettsnæringene over hele verden, 
kun forbigått av Norge. Laks representerer Chiles nest største eksportprodukt etter kobber. På grunn 
av den raske utviklingen av oppdrettsnæringen og innføringen av atlantisk laks til Stillehavet, har 
industrien blitt påvirket av smittsomme sykdommer forårsaket av virus, bakterier og parasitter. 
Piscirickettsiose er laksesykdommen som har medført de største økonomiske tapene de siste 30 årene 
i chilensk akvakultur, og de tapte verdiene er beregnet til rundt 700 millioner US dollars per år. 
Piscirickettsiose ble beskrevet for første gang i 1989, i Los Lagos-regionen i den sørlige delen av Chile. 
Artene av laksefisk som er mottagelige for piscirickettsiose er coho-laks (Oncorhynchus kisutch), 
atlantisk laks (Salmo salar L.), regnbueørret (Oncorhynchus mykiss) og chinook-laks (Oncorhynchus 
tshawytscha). Piscirickettsiose er en aggressiv systemisk sykdom med dødelighet som varierer mellom 
30-90% av den smittede populasjonen.  Sykdomsutbrudd opptrer vanligvis etter overføring av fisken 
til sjø, samt i perioden før fisken er slakteklar.  Sykdommens kausale agens er Piscirickettsia salmonis; 
en Gram-negativ, amotil, fakultativ intracellulær bakterie. De vanligste symptomene hos fisk som er 
smittet med P. salmonis er slapphet, pigmentforandringer i huden, unormal svømming og anoreksi. 
Patologiske forandringer sees først og fremst i viscerale organer (lever, nyre og milt), men hjerte, 
hjerne, eggstokker og skjelettmuskulatur kan også affiseres. Forebyggende tiltak mot sykdommen er 
bruk av antibiotika (både profylaktisk og som behandling) og vaksinasjon. Stor geografisk utbredelse, 
samt hyppige utbrudd har medført høy bruk av antibiotika. I 2014 nådde bruken av antibiotika totalt 
563,2 tonn sammenlignet med den norske oppdrettsnæringen som bare brukte 0,5 tonn samme år. 
Vaksinasjon brukes ofte for å forhindre utbrudd av piscirickettsiose. Det er registrert 57 vaksiner for 
laksefisk i Chile, hvorav 32 vaksiner inkluderer en P. salmonis-komponent. Blant de 32 vaksinene med 
P. salmonis-antigener er det syv monovalente og 25 multivalente vaksiner. Blant de 32 vaksinene med 
P. salmonis-antigener inneholder 28 inaktiverte vaksiner, tre underenhetsvaksiner og en levende 
attenuert vaksine. 
Eksperimentelle smitteforsøk representerer et viktig verktøy for å evaluere effekt av helsefôr, 
farmasøytiske legemidler, profylaktiske vaksiner og genetisk resistens. In vivo smitteforsøk har blitt 
brukt i mange år for å dokumentere effekt av vaksiner. Smittemodellene som ofte brukes er smitte 
ved i.p. injeksjon av forsøksfisk, kohabitasjon av i.p.-injiserte shedderfisk med forsøksfisk og 
badesmitte av forsøksfisk.  
Hovedmålet med dette arbeidet var å øke kunnskapen om eksperimentelle smittemodeller med 
P. salmonis og å vurdere hvilken smittemodell som er best egnet til å avdekke effekt av vaksiner mot 
P. salmonis i atlantisk laks. I tillegg var målet for arbeidet å øke forståelsen for sykdomsutviklingen ved 
xiii 
 
infeksjon med P. salmonis, samt å karakterisere et P. salmonis-isolat in vitro. For å oppnå dette ble tre 
spesifikke mål definert: 1) Å sammenligne utviklingen av piscirickettsiose etter eksperimentell smitte 
ved intraperitoneal injeksjon eller kohabitasjon; 2) Å sammenligne beskyttelsen indusert av 
eksperimentelle vaksiner mot P. salmonis etter immunisering og eksperimentell smitte ved 
intraperitoneal injeksjon eller kohabitasjon og 3) Å karakterisere P. salmonis-isolatet brukt i in vivo 
smitteforsøk etter dyrking i  flytende medium. 
Med bakgrunn i resultatene ble tre vitenskapelige artikler utarbeidet.  Artikkel I, "Development of 
piscirickettsiosis in Atlantic salmon (Salmo salar L.) smolts after intraperitoneal and cohabitant 
challenge using an EM90-like isolate: A comparative study", viste at det ikke var noen signifikante 
forskjeller i sykdomsutvikling etter smitte ved intraperitoneal injeksjon sammenlignet med 
kohabitasjon. Endring av dyrkingsforhold for bakterien fra fast agar til flytende medium  påvirket ikke 
sykdomsutviklingen i et kontrollert smitteforsøk. Artikkel II, "Comparative study of experimental 
challenge by intraperitoneal injection and cohabitation of Atlantic salmon (Salmo salar L.) after 
vaccination against Piscirickettsia salmonis (EM90-like)", viste at beskyttelsen indusert av 
eksperimentelle vaksiner er tilnærmet lik etter smitte ved intraperitoneal injeksjon eller kohabitasjon. 
Artikkel III " Cultivation and characterization of a Piscirickettsia salmonis EM90-like isolate used for in 
vivo challenge of Atlantic salmon (Salmo salar L.)" ga ny innsikt i vekstdynamikken til P. salmonis. 
Videre bekreftet fylogenetiske studier at isolatet som ble brukt i dette arbeidet tilhører EM90-
genogruppen, og at det er et fylogenetisk skille mellom genogruppene EM90 og LF89. Forsøkene viste 
videre at endring av dyrkingsmedium fra agar til flytende medium ikke påvirket virulensen til isolatet. 
Ytterligere undersøkelser bør gjøres for å få en bedre forståelse av P. salmonis sin interaksjon med 
verten under et infeksjonsforløp. Bruken av eksperimentelle smittemodeller må evalueres nøye for å 
benytte en modell som best etterligner kommersielle oppdrettsforhold i felt. Dette arbeidet viser at 
beskyttelsen indusert ved vaksinasjon er lik om fisken deretter blir smittet ved i.p. injeksjon eller 
kohabitasjon. Det er imidlertid nødvendig med ytterligere arbeid for å optimalisere modellen for 













La industria del salmón Chilena es considerada como una de las más importantes a nivel mundial, 
posicionándose en segundo lugar de exportación de salmón después de Noruega. Al interior del país 
la industria es de gran importancia económica quedando, como producto de exportación, en segundo 
lugar después del cobre. Debido al rápido crecimiento, la industria ha tenido que enfrentar dificultades 
en diferentes aspectos como las relacionadas con enfermedades infecciosas producidas por virus, 
bacteria y parásitos. Piscirickettsiosis es la enfermedad infecciosa que mayores pérdidas económicas 
ha producido en los últimos treinta años para la acuicultura chilena con pérdidas que bordean los 700 
millones de dólares al año. Se describió por primera vez en el año 1989, en la región de Los Lagos, al 
sur de Chile. Las especies susceptibles son salmón coho (Oncorhynchus kisutch), salmón del Atlántico 
(Salmo salar L.), trucha arcoíris (Oncorhynchus mykiss) y salmón chinook (Oncorhynchus tshawytscha). 
Piscirickettsiosis es una enfermedad sistémica agresiva con mortalidades que pueden fluctuar entre 
30-90% de los individuos. Por lo general, los brotes se presentan luego de la transferencia de los peces 
al mar, más específicamente cuando están cercanos a la cosecha. El agente etiológico de esta 
enfermedad es Piscirickettsia salmonis, una bacteria Gram-negativa, no motil e intracelular 
facultativa. Los signos patológicos más comunes presentes en los peces afectados por P. salmonis son 
letargia, oscurecimiento de la piel, nado errático y anorexia. Internamente, los tejidos más afectados 
son los viscerales (hígado, riñón y bazo), pero también se ven afectados el corazón, cerebro, ovarios y 
musculo esquelético. Dentro de las medidas de control empleadas en el país para disminuir las 
causalidades de la enfermedad se encuentran el uso de antibióticos (como tratamiento y profiláctico) 
y la vacunación. Debido a que piscirickettsiosis es la enfermedad infecciosa que produce el mayor 
porcentaje de mortalidad, se le ha responsabilizado por el uso excesivo de antibióticos en la industria 
salmonera Chilena, llegando a utilizar la cantidad más alta en el año 2014 con un total de 563.2 
toneladas en comparación con Noruega que solo utilizo 0.5 toneladas ese mismo año. En Chile, existen 
57 vacunas registradas para el uso en peces, de las cuales 32 son contra P. salmonis, de estas, 25 son 
multivalente y siete son monovalente. De las vacunas específicas contra la enfermedad 28 son 
inactivadas, tres son sub-unitaria y una viva atenuada.  
Los desafíos experimentales con peces son una herramienta importante no solo para la evaluación 
de la eficacia de muchos productos como alimentos, fármacos como tratamientos para enfermedades, 
medidas profilácticas y estudios genéticos. Para la evaluación de la eficacia de las vacunas se han 
utilizado por muchos años los ensayos de desafío in vivo. Los modelos para los ensayos de desafío 
comúnmente utilizados son el de inyección intraperitoneal de los peces, de cohabitación con peces 
inyectados intraperitonealmente y el de inmersión.  
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El objetivo principal de este estudio fue incrementar el conocimiento sobre modelos de desafío 
con Piscirickettsia salmonis y definir el modelo in vivo de preferencia para la evaluación de la eficacia 
de vacunas desarrolladas para salmón del Atlántico. Junto con ello, el objetivo era aumentar la 
comprensión sobre la patogenia de piscirickettsiosis y caracterizar un aislado de P. salmonis in vitro. 
Para ello tres objetivos específicos fueron definidos: 1) comparar la progresión de la enfermedad 
después del desafío experimental de peces por inyección intraperitoneal o cohabitación; 2) comparar 
la protección inducida por vacunas experimentales después de la inmunización de los peces y desafío 
experimental de los mismos por inyección intraperitoneal o cohabitación; 3) caracterizar el aislado de 
P. salmonis usado para ensayos de desafío in vivo después del cultivo en medio líquido.    
Como resultado de esta investigación se desarrollaron tres artículos científicos, cada uno con el fin 
de responder cada uno de los objetivos específicos. Artículo I, “Development of piscirickettsiosis in 
Atlantic salmon (Salmo salar L.) smolts after intraperitoneal and cohabitant challenge using an EM90-
like isolate: A comparative study.”, demuestra que el cambio en la forma de cultivo de la bacteria no 
cambia el desarrollo de la enfermedad bajo ambientes controlados. Al mismo tiempo, se puede 
observar la ausencia de diferencias importantes entre ambos modelos de desafío. Articulo II, 
“Comparative study of experimental challenge by intraperitoneal injection and cohabitation of 
Atlantic salmon (Salmo salar L.) after vaccination against Piscirickettsia salmonis (EM90-like).”, donde 
luego de comparar los dos modelos de desafío, esta vez después de la inmunización de los peces, se 
confirmaría las similitudes presentes en ambos modelos. Junto con ello se evaluaron algunos 
inmunogenes que dan como resultados algunas directrices relacionadas con la respuesta 
inmunológica de los peces frente a la vacunación y al desafío de los individuos contra P. salmonis. 
Además de contribuir con mayores antecedentes relacionados con la patogénesis de piscirickettsiosis. 
Finalmente, articulo III, “Cultivation and characterization of a Piscirickettsia salmonis EM90-like isolate 
used for in vivo challenge in Atlantic salmon (Salmo salar L.)”, proporciona nuevas ideas relacionadas 
con la dinámica de crecimiento de P. salmonis. Además, el estudio filogenético confirmó que el aislado 
utilizado en este estudio pertenece al genogrupo EM90 y la separación entre los genogrupos EM90 y 
LF89. También, se demostró que el cambio de medio de cultivo de agar a liquido no afecto la virulencia 
del aislado.  
Futuras investigaciones deberían desarrollarse para lograr un mejor entendimiento de P. salmonis 
y su interacción con el hospedero durante la infección. El uso de modelos de desafío experimental 
debería ser cuidadosamente evaluado para poder aplicar el modelo que simula más realísticamente 
las condiciones en terreno. Este trabajo revela que la protección generada por la vacunación es similar 
entre peces desafiados con el modelo intraperitoneal o por cohabitación. Sin embargo, es necesario 
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desarrollar más investigaciones con el fin de perfeccionar el modelo que logre separar de una mejor 
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Chilean salmon industry  
Cultivation of fish species has been undertaken for centuries around the world. Freshwater species 
were reared in ponds and over time, the cultivation of salmonid species gradually developed to include 
both a freshwater and a seawater phase as is natural of an anadromous species. The breakthrough for 
farming of Atlantic salmon, as we know it today, started in Norway in the 1970s by fishermen and 
coastal businesses. Since then, the salmon industry has developed rapidly because of technological 
improvements and governmental support promoting the economic development of the industry1, 2. 
The salmon production around the world is dominated by four countries: Norway, Chile, Scotland and 
Canada3. The coastlines and suitable water temperatures are key factors for the location of the salmon 
farms around the world (Figure 1). 
 
 
Figure 1. Worldwide distribution of salmon farms. Source: Living Oceans, 2013. 
 
In Chile, the salmon industry had its inception in 19794, when Chile was considered a suitable 
location based on its geography and seasonal characteristics and initial investment was made by 
companies producing other farmed animals5. By 1992, Chile was the second largest producer of 
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farmed salmonids after Norway4. Chile maintained its position until 2007 when the industry was 
affected by the viral disease infectious salmon anemia (ISA). The production rapidly decreased from 
379 000 tonnes in 2007 to around 211 000 tonnes in 20096. More recently, the Chilean salmon industry 
has returned to be the second largest aquaculture industry worldwide with a production of 605 800 
tonnes annually of Atlantic salmon (Salmo salar L.) in 20167 and an export value of US $2.6 billion8. 
The Chilean salmon industry is responsible for the second largest national export product after copper. 
Currently, in Chile there are a total of 15 companies producing salmon, of those, five are international 
companies and 10 are national9. The farms are located in the southern part of the country, 
concentrated in the Los Lagos and Magallanes regions5, 10. The importance of the Los Lagos region to 
the aquaculture and fisheries reveals the growing importance of the Chilean salmon aquaculture to 
raise the national profile in the global economy5. The Chilean production of salmonids comprises three 
species: coho salmon (Oncorhynchus kisutch), Atlantic salmon (Salmo salar L.) and rainbow trout 
(Oncorhynchus mykiss). In 2018, 70% of the salmonid species produced by marine farms were Atlantic 
salmon. Rainbow trout and coho salmon accounted for 19% and 11% of the production, respectively11 
(Figure 2).  
 
 




Figure 3. Chilean salmon farm and its cages. Source: The fish Site (https://thefishsite.com).  
 
Aquaculture has been the fastest growing food-producing sector worldwide for years12 and the 
Chilean industry is considered the fastest-growing salmon producer in the world6. The rapid growth in 
aquaculture brings along well-known challenges when it comes to keeping animals within a confined 
space. The fish are susceptible to transmittable, infectious diseases and the increased stocking density 
elevates the stress levels in fish and make them more vulnerable to diseases12. Infectious diseases 
caused by viral, bacterial and eukaryote pathogens have been a major yield-limiting problem in the 
production13, 14. The diseases that are considered as high-impact for salmonids in the Chilean industry 
are listed in Table 1 and the mortality by cause is shown in Figure 411.  
 
Table 1. List of high-impact diseases of Chilean salmon industry based on classification developed by the Fishing 
and aquaculture sub-secretary (SUBPESCA) from the Economy and tourism ministry of Chile15.   
Disease  Etiological agent  
Infectious salmon anemia (ISA) Orthomyxovirus ISA virus (ISAV) 
Infectious pancreatic necrosis (IPN) Infectous pancreatic necrosis virus (IPNV) 
Piscirickettsiosis  Piscirickettsia salmonis  
Caligidosis Caligus rogercresseyi 
Streptococcosis  Streptococcus phocae 
Flavobacteriosis Flavobacterium psychrophilum 
Atypical furunculosis  Atypical Aeromonas salmonicida 
Vibriosis  Vibrio ordalii; Listonella anguillarum 
Amoebic gill disease  Neoparamoeba perurans 
Smolt hemorrhagic syndrome Not identified 
Heart and skeletal muscle inflammation (HSMI) Piscine reovirus (PRV) 





Figure 4. Production mortality by cause. In Atlantic salmon, by primary cause (A) and by disease (B). In rainbow 
trout (Oncorhynchus mykiss), by primary cause (C) and by disease (D). In coho salmon (Oncorhynchus kisutch), 
by primary cause (E) and by disease (F). Source: SERNAPESCA.  
 
The most common measures against disease are prophylactic vaccines, and treatment with 
antibiotics. The Chilean salmon industry uses a high amount of antibiotics, reaching a maximum 
amount in 2014 with 563.2 tonnes16. The amount was reduced to 322.7 tonnes in 201817. In 2018, the 
most commonly used antibiotics were oxytetracycline in freshwater and florfenicol in seawater, and 
the treatments are primarily targeting diseases in Atlantic salmon17. The amount of antibiotics used in 
Chile leaves the industry in a distant position in relation to the Norwegian salmon industry where only 
0.641 tonnes was used in 201718. The frequent use of antibiotics in Chile has an impact on the farmed 
salmon, but also the environment19. The constant use of antibiotics in the sea produced alterations in 
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the bacterial flora in the aquatic environment, and the repeated use will eventually increase the 




Piscirickettsiosis is one of the most challenging diseases to the sustainability of the Chilean salmon 
industry21-25. This disease is the main cause of infection-related mortality in the Chilean aquaculture26-
28, and has been estimated to account for up to 83.3% of the mortalities depending on the affected 
species11. The causative agent is the bacterium Piscirickettsia salmonis22, 23, 29-31, and the disease affects 
mainly salmonid species, including Atlantic salmon (Salmo salar L.), rainbow trout (Oncorhynchus 
mykiss), coho salmon (Oncorhynchus kisutch) and chinook salmon (Oncorhynchus tshawytscha)29, 32, 33. 
Piscirickettsiosis can be present mainly in brackish water and seawater, however the disease has also 
been described in freshwater21. Piscirickettsiosis in Chile is present in the Los Lagos and Aysén 
regions34. The number of reported outbreaks is higher during the warmer season when the water 
temperature is between 8 to 18°C in Los Lagos and reaching up to 15°C in Aysén35. Coho salmon is 
considered particularly susceptible to the disease21, 22, 36, producing high mortality rates between 30% 
and 90%24, 29, 32, 37, 38. Infections with P. salmonis are not restricted to salmonid fish, and the bacterium 
has been described to cause a disease similar to piscirickettsiosis in non-salmonid hosts, such as white 
seabass (Atractoscion nobilis), yellow perch (Perca flavescens) and muskellunge (Esox masquinongy)21, 
39, 40. Piscirickettsiosis was reported for the first time in 1989 in Calbuco, Los Lagos, Chile in coho 
salmon41, 42. The disease is responsible for enormous economic losses in the Chilean salmon industry7, 
43, with an estimation US $700 million in 201723, 44.  
Piscirickettsiosis has also been reported in Ireland45, Norway46, Canada47, Scotland48 and recently 
in Turkey44. Outside of Chile, piscirickettsiosis outbreaks are sporadic and the mortality can be as low 
as 0.06%24. Worldwide piscirickettsiosis has been recognized as an emerging problem due to the 
increment of outbreak reports over the last years7, 21, 24, 31, 42. This could be due to differences in 
virulence related to the geographical origin of the P. salmonis isolates21, 44 and could also be related 
with the non-native nature of salmonids in Chile49.  
 
Environmental impact 
Mortality related to piscirickettsiosis has been noted in salmon as early as 10-14 days after 
introduction to infected seawater areas in Chile21, 50, but outbreaks typically occur 6-12 weeks after 
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healthy fish are introduced into seawater22, 24, 29, 32, 43, 51. This could suggest the endemic nature of the 
bacterium, endemic bacteria usually only cause sporadic disease but may induce an epizootic in the 
confined cages of aquaculture24. Disease outbreaks are less frequently observed during the freshwater 
stage of the salmonid life cycle39. Stress has been described to play an important role in the 
development of piscirickettsiosis, and this could be induced by multiple factors such as smolt transfers, 
water temperature changes and severe storms, among others24. The higher incidence of 
piscirickettsiosis outbreaks is independent of the geographic location52. During the last years the 
climate changes have affected many areas and environments including rise in seawater temperature, 
which may contribute to different patterns of pathogen transmission53. As mentioned previously, in 
Chile the temperature of the seawater in summer could rise up to 18°C and in winter can go below 
5°C, but not reaching freezing point35. This variation in the seawater temperature could be the reason 
for the massive problem that piscirickettsiosis creates in the Chilean industry. On the contrary, in the 
Norwegian seawater the temperature goes from 14.7°C in the summer to 4.2°C in the winter, a range 
that could avoid development of the disease54.    
 
Pathological signs 
Piscirickettsiosis is a septicemic disease affecting multiple organs of salmonids39, 51, 55. Clinical signs 
of piscirickettsiosis in fish are lethargy, anorexia, skin lesions, respiratory distress, pale gills and surface 
swimming22, 29, 32, 39. At the same time, some fish could present just minor signs of disease21, 24, 56. The 
skin lesions include darkness, perianal and periocular haemorrhages, petechia in the abdomen and 
shallow hemorrhagic ulcers (Figure 5B). Additionally, bilateral exophthalmia and ulcerative stomatitis 
have been described22. Organs commonly affected are liver, spleen, intestine and hematopoietic 
tissue of the kidney38. The most characteristic internal lesions observed in heavily infected fish are off-
white to yellow sub-capsular nodules throughout the liver, ascites, peritonitis, general pallor, diffuse 
swelling and presence of multifocal pale areas in the kidney and spleen (Figure 5A)29, 38. Petechia and 
ecchymosis on the serosa surfaces of the pyloric caeca, swim bladder and caudal intestine have also 
been reported in Atlantic salmon22, 57. In coho salmon, the renal lesions have been interpreted as 
chronic damage characterized by fibrosis22. Pale organs have been described in natural cases of 
piscirickettsiosis and a low hematocrit value is commonly found. The hematocrit values could fall to 
2-20% compared to the normal 40-45%, but it is not clear whether anemia is a characteristic of the 
disease24, 29, 32, 38. The most typical microscopic lesions are found in the liver, kidney, spleen and 
intestine but pathological changes in the brain, heart, ovary and gill can also be observed as severe 
multifocal necrosis and inflammation, and mild injury in the cardiac, pancreatic and ovarian tissues32, 
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38, 43, 57. Granulomas of macrophages and neutrophils as perivascular infiltration are also typical 
findings43. Differences in the severity of the lesions may be due to variations in the host species such 
as age, mode of infection, chronicity of the infections, and water temperature38.  
The disease has been reproduced fulfilling the Koch´s postulates by experimental infection of the 
fish with P. salmonis demonstrating a dose-response with mortality reaching nearly 100% in some 
groups of coho and Atlantic salmon injected with the bacterium38, 51, 58-60. Fish experimentally infected 




Figure 5. A, Coho salmon (Oncorhynchus kisutch) infected with Piscirickettsia salmonis (Source: Fryer and Mauel, 
1997). B, Atlantic salmon (Salmon salar L.) affected by piscirickettsiosis, cutaneous presentation (Source: 
Patología en acuicultura, Marco Godoy).  
 
Diagnostics 
Piscirickettsiosis is preliminarily diagnosed by clinical signs21, 62. Other methods include solid culture 
of P. salmonis coupled with Gram and Giemsa stain techniques24, 63. Isolation of the bacteria by 
cultivation is considered one of the best methods for detection, however, bacterial isolation in the 
field is complicated due to the difficulty to obtain a pure P. salmonis culture and for the requirement 
of special media for cultivation24. Molecular diagnostic techniques, such as conventional PCR, real-
time PCR, and indirect fluorescence antibody test are more accurate and sensitive than culture 
techniques28, 29, 64. The tissues of choice for isolation of P. salmonis include kidney, liver and blood 
during active infection57. Smears or impressions of the kidney, liver, spleen or infected cell cultures on 
glass or plastic substrates can be fixed and stained with Gram, Giemsa or methylene blue solutions for 




Treatment and prevention 
The most common treatment against piscirickettsiosis is use of antibiotics distributed as medicated 
feed. The drug of choice is florfenicol, however oxytetracycline is also commonly used65, 66. Disease 
prevention strategies include reduced stress, improved husbandry practices, screening of brood stock 
and vaccination43, which all depend on good management practices21. In addition to antimicrobial 
drugs and vaccines23, selective breeding for resistance against infectious diseases represents a realistic 
and more sustainable strategy to control disease outbreaks in aquaculture species. Recent evidence 
demonstrates the presence of significant variation for resistance against P. salmonis in Atlantic salmon 
and coho salmon population and it has been demonstrated a significant heritability for resistance 
against P. salmonis in Atlantic and coho salmon50, 67. This low-susceptibility of some Atlantic salmon 
families has been suggested to be related with a reduced intracellular iron content, which may suggest 
that iron deprivation could work as an innate immune defense mechanism against P. salmonis50, 68, 69. 
Piscirickettsiosis has evolved over time and the control of the disease has been proven to be 
difficult70. New outbreaks are typically increasingly insidious and refractory to treatments, and often 
show increased bacterial virulence as well as increased clinical and pathological severity21, 36, 71. To 
reduce the amount of antibiotics that has been used during the last years, the industry must continue 
focus on best sustainability practice in farming, like regulating reduced stocking densities and 
developing prophylactic measurements against piscirickettsiosis, such as vaccines.  
 
Piscirickettsia salmonis    
Bacterial properties 
Piscirickettsia salmonis is a facultative intracellular, aerobic and non-motile Gram-negative 
bacterium. The pleomorphic bacterial cells are mainly coccoid ranging in size from 0.5 to 1.8 um in 
diameter22, 33, 37, 41, 72, 73. This is a marine bacterium that mainly induces clinical disease in seawater, 
though it has been reported in freshwater as well43. P. salmonis was the first rickettsia-like organism 
recognized as a fish pathogen, affecting several cultured salmonid species22, 24.  
P. salmonis replicates by binary fission within membrane-bound cytoplasmic vacuoles in cells of 
susceptible fish hosts or fish cell lines inducing a characteristic cytopathological effect21, 62, 64. Despite 
its rickettsia-like properties, the 16S rRNA sequence of the organism shows that it is a member of the 
gammaproteobacteria21, 74, which includes the genera Francisella, Coxiella and Legionella24, 42, 64.  
In a recent description developed by Nourdin-Galindo, et al (2017)75, P. salmonis isolates were re-
classified in two genogroups; LF89 and EM90. The genogroups differ in phenotype, geographic 
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location, antibiotic resistance, host specificity and clinical manifestation52, 61, 75. Virulence factors 
analyzed at genome level revealed that both genogroups carry similar genes encoding for endotoxins, 
enzymes and surface components, and functions for adherence, iron uptake and stress response. 
However, some of the virulence factors were also considered genogroup specific75.  
The EM90 genogroup is widely disseminated and responsible for a major proportion of the 
piscirickettsiosis cases. This genogroup is more prevalent in the Aysén region of Chile, while the LF89 
genogroup is reported to be predominant in the Los Lagos region52. Both genogroups have been 
identified in fish from a single outbreak of piscirickettsiosis in Chile30, 37, 52. The isolates from salmon in 
Canada, Norway and Ireland appear to be serologically and genetically related to the original Chilean 
isolate of P. salmonis (LF89), but different to the Chilean isolate EM9030. The geographical distribution 
has demonstrated differences in virulence, and the Chilean isolates are in general more virulent than 
the Norwegian isolates21, 24, 33. 
 
Phenotypic characterization and growth conditions 
The colonies of P. salmonis are slightly convex, grey-white, shiny, and centrally opaque with 
translucent, slightly undulating margins. No distinctive colony or cell morphology differences have 
been observed between genogroups37. As for all bacteria, P. salmonis has nutrient requirements for 
cultivation. Iron is considered essential for P. salmonis growth and the bacterium has developed 
strategies to capture iron from endogenous (interaction with proteins that contain iron) and 
exogenous (siderophores) sources69, 76, 77. The amino acid cysteine has been suggested to be essential 
for the cultivation of P. salmonis63. In contrast, fetal bovine serum (FBS) and glucose has been 
demonstrated not to be essential for P. salmonis growth72. Peptone concentration has been 
documented to be more significant for P. salmonis  growth compared to the concentration of yeast 
extract72. Culture media for P. salmonis are highly nutritive and non-selective, therefore they can 
easily  become contaminated by other bacteria28.  
By being a facultative intracellular bacterium, cell-free in vitro cultivation of P. salmonis is 
challenging. In vitro cultivation of P. salmonis was initially performed using eukaryotic cell lines 
susceptible to infection, such as chinook salmon embryo (CHSE 214) and insect tissue cells22, 72, 74. 
Susceptible fish cell lines for P. salmonis also includes EPC, CSE-119, RTG-2, FHM and CHH64, 78. Cell 
culturing has been the gold standard for the isolation of P. salmonis63. In those cell lines, the bacterium 
produces a cytopathological effect. Experiments have suggested that P. salmonis has the potential to 
continue to be viable in invertebrates and non-fish poikilotherms due to the possibility of replication 
in insect and frog-derived cell lines21.  
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In 2007, the cultivation of P. salmonis in an artificial cell-free medium was reported for the first 
time79. Studies reveal that P. salmonis remains pathogenic in vitro after growing in cell-free media72. 
The two first cell-free agar media developed for cultivation of P. salmonis were based on cysteine 
heart agar supplemented with 5% bovine blood (CHAB) and an enriched sheep blood agar with 
cysteine addition (BFCG)63, 79, 80. After the introduction of these first cultivation media, several cell-free 
media have been developed through the last years. Cell-free cultivation is less resource-intensive 
compared to the time-consuming and costly maintenance of cell lines, and the method also eliminates 
contamination from host cell debris. In addition, the ability to isolate and culture P. salmonis on 
artificial media simplifies the identification of piscirickettsiosis in remote fish-culturing facilities and 
the early detection of the agent enhances treatment and prevention strategies21, 63. However, the 
growth of P. salmonis on agar media is not suitable for determining the number of bacteria present in 
an in vitro culture, because bacterial growth is slow and the phenotypic properties of P. salmonis make 
it difficult to count on plates. Growth on solid media usually takes from four to eight days for visible 
colonies to appear62. From 2009, the cultivation of the bacterium in cell-free liquid media became 
possible62, 81. Marine broth medium supplemented with L-cysteine, named AUSTRAL-SRS broth, is one 
of many liquid media that facilitated the growth of P. salmonis strains62. The incubation period for the 
cultivation of P. salmonis in broth has been described to be between 6 to 13 days62, 72, 81.  
The optimal temperature for cultivation of P. salmonis is reported to be 15-18°C. The bacterial 
growth rate is inhibited at temperatures below 10°C and above 20°C, and growth does not occur above 
25°C21, 24, 37, 52, 72. The generation time of the bacterium is approximately 5-7 hours in cell-free media41. 
After growing P. salmonis with gentle shaking there has been described a lag phase of approximately 
18 hours, followed by a logarithmic growth of 126 hours and a stationary phase of 96 hours62.  
During bacterial cultivation, it has been reported an increment in pH that could be a consequence 
of the degradation of amino acids present in the peptone and yeast extract components acids in the 
growth media, as well as a consequence of  assimilation of organic acids72. 
There is an interest to achieve pure high cell density growth of P. salmonis in a liquid medium free 
from eukaryotic contaminants72 for possible vaccine development. 
 
Transmission and host specificity 
Vertical transmission of P. salmonis has been suggested due to its presence in the milt and celomic 
fluid of adult brood fish and in fry43, 82. Nevertheless, the low incidence of the disease in freshwater 
suggests that vertical transmission may not be common for P. salmonis21. The bacterium has been 
demonstrated to be transmitted horizontally, mainly in seawater, between fish29, 51. It has been 
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documented that the bacterium remains viable in seawater however without a capacity to grow70. In 
vitro experiments have demonstrated that P. salmonis in salt water maintains its infectivity for 10 to 
15 days51. Due to the length of survival time in salt water, horizontal transmission may occur without 
a vector24, 43. Recently it was confirmed that stress could be responsible for the formation of biofilm 
in this bacterium41, 42, 83. Biofilm formation could be the reason that P. salmonis may survive and 
remain latent for long periods in the ocean without a host. 
A vector or reservoir related with P. salmonis has not been demonstrated22, 29, however a marine 
reservoir for P. salmonis has been suggested14, 39. At the same time, previous studies suggest that 
ectoparasites could have an important role in the transmission of P. salmonis21. Furthermore, the 
crowded hatchery or aquaculture conditions may influence in the dissemination of the disease39. 
Initially, P. salmonis was believed to be a pathogen only affecting salmonids but some reports have 
suggested a broader host range that includes European seabass (Dicentrarchus labrax) in Greece and 
white seabass (Atractoscion nobilis) in southern California, USA42. Together with this, genetic material 
from a P. salmonis-like organism has been found in native fish, such as Eleginops maclovinus, 
Odontesthes regia, Sebastes capensis, Callionymus lyra, Oreochromis nilótico, Panaque suttoni, 
Parapristipoma trilineatum, Epinephelus melanostigma, Oreochromis mossambicus, Sarotherodon 
melanotheron and Salilota australis69, 84. In addition, the EM90 genogroup was previously suggested 
to be specie-specific to Atlantic salmon33, but this genogroup has also been isolated from Atlantic 
salmon, coho salmon and rainbow trout.  
The incubation period of the disease is dependent on the bacterial isolate and infection method, 
and environmental and host factors61.  
 
Pathogenesis and virulence factors  
The pathogenesis of the bacterium is unclear. There is no doubt that P. salmonis is an intracellular 
pathogen, however, it has not been determined in detail if P. salmonis spreads from cell to cell via the 
extracellular space or uses mechanisms that spreads intracellularly between cells43.  
The portal of entry of infection is not fully clarified, but studies suggest that the pathogen enters 
into the host through the oral route, gills or skin21, 22, 43. After P. salmonis has entered the host, the 
bacterium firmly attaches to macrophages (target) surfaces, after this the host immune system may 
be manipulated by P. salmonis to permit enhanced microbial growth and survival85. P. salmonis is then 
carried and disseminated through the circulatory system within leukocytes and reaches the main 
organs by infecting the endothelial cells of blood vessels38. 
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The virulence mechanisms of P. salmonis can be related to the stimulation of the innate immune 
response and inhibition of the adaptive humoral and cell-mediated immune response to evade the 
host reaction86. Even though the virulence mechanisms have not been established, some virulence 
factors have been described. It has been suggested that P. salmonis has the potential to develop a 
flagellum controlled by a transcriptional cascade42. It has also been described the presence of genes 
that modulate a pili-like structure in P. salmonis87. Studies developed by Chilean and Norwegian 
researchers described the presence of outer membrane vesicles (OMV) in P. salmonis and the 
possibility that OMV stimulate the immune system of the fish88, 89. Previous studies suggested that 
iron could be a crucial element in the growth and virulence, this due to the existence of a set of genes 
involved in the iron metabolism69, 90, 91 as in most of living organisms92. 
The P. salmonis bacteria have been identified in cytoplasmic vacuoles in hepatocytes and 
macrophages associated with liver, kidney, spleen and peripheral blood demonstrating that the 
bacterium can infect a variety of cell types in salmonid hosts. Consequently, the bacterium has been 
considered a highly adaptable microorganism. Nevertheless, the main target cells are the 
macrophages in which this bacterium can survive and replicate extensively21, 32, 38, 88, 93. It has not been 
fully documented where the bacterium resides, if it is in the endosome/phagosome or if it is released 
from there to the cytosol43. P. salmonis-containing vacuoles are demonstrated to not fuse with 
lysosomes, this could indicate that there is an interference in the endosomal maturation process to 
ensure the bacterial survival through the evasion of the phagocyte-lysosome fusion, and enabling 
P. salmonis to avoid the fish’s primary immune defense21, 88, 94. P. salmonis affects the immune system 
of the host, activating the innate immune response in the head kidney, the muscle and the liver. This 
potentially induces inflammatory responses in the head kidney and an interferon-mediated response 
in the liver21. P. salmonis may inhibit cellular apoptosis by down-regulating apoptosis-related genes, 
whereas it may stimulate cell proliferation by up-regulating cell-proliferation-related genes21, 23, 95. 
During the beginning of the infection P. salmonis may replicate in large quantities within macrophages 
and decrease the immune cells’ apoptosis frequency, this could facilitate the survival of the bacterium 
when the disease development has started77. In addition, it has been described that P. salmonis could 
induce apoptosis in macrophages in vitro as a possible in vivo strategy to evade the host immune 
system41, and to colonize and disseminate within host tissues44. 
It has been described that P. salmonis secretes extracellular products, and at least one of the 
components has cytotoxic effects in vitro and probably mediates some tissue damage in vivo in 
salmonid fish21. The antioxidant system of the host may be affected by P. salmonis, eventually causing 




Antibiotic resistance  
The bacterium has demonstrated susceptibility to antibiotics in vitro, but treatments in the field 
are not always successful96. The use of antibiotics both prophylactically and during early outbreaks of 
piscirickettsiosis may inhibit the growth of P. salmonis, but such treatments have been largely 
unsuccessful in stopping disease outbreaks70, 97. Some reports exist about the development of 
antibiotic resistance in P. salmonis. A study conducted by Mauel and Miller (2002)24 found that 
P. salmonis was susceptible in vitro to streptomycin, gentamicin, tetracycline, chloramphenicol, 
erythromycin, oxytetracycline, flumequine, Imequil, oxolinic acid, sarafloxacin, clarithromycin and 
resistant to penicillin, lincomycin, furazolidone, and sulfonamide-trimethoprim. Another study 
developed by Saavedra, et al (2017)52 reported that the majority of investigated LF89-like isolates 
demonstrated resistance to quinolones, florfenicol and oxytetracycline compared to the EM90-like 
isolates that were all susceptible to the tested antibiotics in that study. In 2016, Evensen (2016)43, 
described increased resistance to penicillin, streptomycin, oxolinic acid, and oxytetracycline in 
P. salmonis isolates. On the other hand, the same year, Otterlei, et al (2016)37, described that all tested 
isolates were susceptible to oxytetracycline. As mentioned previously, the most used antibiotics for 
treatment of piscirickettsiosis is florfenicol. This antibiotic, is relatively environmentally innocuous but 
may induce resistance development and the genetic determinants for this resistance can be shared 
between fish and human pathogens98. One of the concerns should be the possibility of increased 
antibiotic resistance of P. salmonis and the reduction in the efficacy of treatments. Sediments under 
salmon farms in Chile were analyzed and an increment of other bacteria resistant to florfenicol were 
found99.  
The focus of the Chilean industry is the reduction in the use of antibiotics. This could contribute to 
reduce the possibility in obtaining a highly resistant pathogen and in reducing the imprint of the 
salmon farms on the environment.  
 
Fish vaccines  
Fish immune system 
In fish as in most vertebrates, the innate and adaptive immune responses are considered essential 
components to fight pathogens. The poikilothermic nature of fish leads to some limitations in the 
adaptive immune system, such as limited repertoire of antibodies, slow kinetics of antibody responses 
and poor affinity maturation69, 100.  
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The innate immune response is on the other hand well-developed in fish. It represents the first line 
of defense against pathogen invasion and include physical barriers as well as humoral and cellular 
responses85. Macrophages primarily act as antigen-presenting cells, but these cells are also 
responsible for most phagocytic activity in addition to regulating the immune system cascade 
triggered by the secretion of pro-inflammatory cytokines85. The adaptive immune response has also a 
humoral and a cellular arm including specific antigen receptors that drives a secondary, faster and 
stronger, immune response101. In the cellular components of the immune system, there are B and T 
cells. One of the functions of B cells is the production of antibodies to neutralize pathogens and mark 
them to be removed by the immune system. On the other hand, T cells act as coordinators of the T-
helper cells involved in the immune response to kill infected cells101. B cells secrete immunoglobulins 
(Ig) or antibodies. Three types of Ig have been described in teleost fish including IgM, IgD and IgT, the 
last one designated as IgZ in zebrafish101, 102. IgM has been recognized as an important antibody in the 
teleost immune system, being the most ancient and the only isotype conserved in all jawed 
vertebrates7. The IgM produced by plasma cells and immature plasma cells located in the head kidney 
is the most abundant type of immunoglobulin44. The exact function of IgT is not clear, but IgT appears 
to be important in the gut, skin and nasal mucosa44 suggesting an important role in the mucosal 
immunity100. It has been described that non-mucosal IgT responds to viral infections101. Little is known 
in relation to IgD, but this type of antibody could be related to the mucosal immunity and together 
with IgM, IgD seems to be essential for all teleost species101. In salmonids, cytotoxic (CD8) and helper 
(CD4) T cells are present103.  These cells are mainly responsible for the immune response against viral 
infections (intracellular organisms), as demonstrated by in vitro study where leucocytes expressing 
CD8 and T cell receptor produced high levels of cytotoxicity in virus infected cells102, 104.   
Cytokines are small proteins that are involved in both the innate and the adaptive immune 
responses by mediating cell signaling. The cytokines regulate the immune function by interaction with 
specific receptors on the surface of the cell. A group of cytokines includes the interleukins (ILs)101. IL-
12 is one of the key components for efficient performance of phagocytes in teleost fish, similar to the 
roles played by IL homologs in mammals85.  
The development of long-lasting humoral immune response in fish after immunization has been 
described associated with some pathogens100. However, vaccination against piscirickettsiosis may lead 
to protection only during the first months after transfer to sea yet still represents an important tool 





Vaccination has a central role in attenuation of known and emerging diseases in fish13. Although 
the development of fish vaccines began in the 1930s, commercialization of fish vaccines did not occur 
before the second half of the 1970s105. The first licensed fish vaccine came in 1976 and was against 
enteric redmouth disease caused by Yersinia ruckeri106, 107. Since 1988, Norwegian salmonids have 
been successfully vaccinated against cold-water vibriosis108. Vaccines against furunculosis, a disease 
caused by Aeromonas salmonicida ssp salmonicida were introduced in Norway in the late 1980s with 
variable degree of protection. It was just until 1992-3 when the first oil-based vaccine to control 
furunculosis was commercialized106, 109, 110. In Chile, the use of fish vaccines started in the early 1980s 
but it was not until 1995 that the use of fish vaccines became a common practice111. Since the control 
of furunculosis by oil-based vaccines, new vaccines were developed to control bacterial diseases112. 
Viral diseases are, on the other hand, typically more difficult to prevent by vaccination110. Viral 
infections are intracellular, which makes the virus less exposed to the immune system due to their 
capacity for immune evasion by avoiding the immune detection and inhibiting the host defense103. 
The same characteristics are displayed by intracellular bacteria, which make the development of 
vaccines against intracellular bacterial infections a challenging task113. There are historically at least 
three different types of vaccines; live-attenuated, inactivated and sub-unit vaccines. The live-
attenuated vaccine are those vaccines where the pathogen has been weakened, but still keeps its 
capacity of multiplication within the host, and thus being able to develop a strong cell-mediated 
immune response106, 114. In an inactivated vaccine, the pathogen is killed by chemical or heat 
treatment, however the antigen is still able to develop an immune response. The sub-unit vaccines 
include one or more selected parts of a microorganism that is/are able to stimulate a specific immune 
response106. For the control of many bacterial diseases the use of inactivated pathogens has been 
successful115, the vaccines based on inactivated pathogens are considered environmentally safe 
because the inactivation reduces the possibility of dissemination of diseases as a result of the 
vaccination routines. It has been described that the inactivation of the pathogen could be the cause 
of the short protection provided by vaccines based on the inactivated pathogen12; this due to the 
possibility that the chemical inactivation may reduce the quality of immune stimulants in the surface 
of the bacteria116. Furthermore, it has been reported that the inactivated vaccines are less efficient 
against intracellular pathogens106, since the inactivated vaccines mainly induce humoral immunity and 
this vaccines should be considered as exogenous antigens117. In 2005, the first DNA vaccine for fish 
was registered in Canada, targeting the infectious hemorrhagic necrosis virus (IHNv)118. In 2017, a DNA 
vaccine against salmonid pancreas disease virus (SPDV) was approved in the EU and Norway119. Fish 
vaccines are typically administered by injection through the intraperitoneal (i.p.) or intramuscular 
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(i.m.) routes, by immersion or through the oral route12, 120, 121. Injectable vaccines are known to elicit a 
good, specific immune response, but intraperitoneal administration has historically been associated 
with some side effects such as tissue inflammation, adhesion and necrosis 12. Intramuscular injection, 
on the other hand, induces less adverse events, and is an efficient way to target antigen presenting 
cells located in the skin and muscle of the fish. Intramuscular vaccination seems to be the optimal 
route of administration for DNA vaccines120. Administration of vaccines by injection requires extra 
handling of each fish, which may have a negative impact with regards to stress and the following 
growth. Immersion vaccines are typically used in smaller fish in freshwater and aim to protect against 
diseases that typically appear during the earliest life stages. Oral vaccines often induce a weaker 
protection and are typically used as a booster or primer vaccination12. 
In Chile there are 57 mono- and multivalent vaccines registered for fish in 201912. Among these 57 
vaccines, 32 vaccines include a component to immunize against piscirickettsiosis44, 122. From those 32 
vaccines against piscirickettsiosis, seven are monovalent and 25 are multivalent122. The high number 
of available vaccines developed against piscirickettsiosis may imply both that the efficacy obtained is 
not very high and that the evaluation of the efficacy of those vaccines is not very discriminatory21, 37, 
44. The majority of piscirickettsiosis vaccines are inactivated and composed of P. salmonis pre-treated 
with heat or formalin7. Live-attenuated vaccines have succeeded in activating both the innate and the 
adaptive immune system, and, in many ways, mimic a natural infection upon immunization7. There is 
no available literature that documents the effect of the live-attenuated vaccine against P. salmonis43, 
but the use of Arthrobacter davidanieli as a live vaccine against P. salmonis and Renibacterium 
salmoninarum has been described to be able to induce a specific immune reaction123. For the time 
being there is only one vaccine available based on live-attenuated antigens against piscirickettsiosis122.  
 Vaccines for aquaculture may also include recombinant antigens and bacterins, however, there is 
no recombinant vaccine against piscirickettsiosis on the Chilean market today. Most of the vaccines 
with P. salmonis bacterins have demonstrated to have a reasonable effect in preventing the initial 
piscirickettsiosis outbreak when the fish are transferred from freshwater to seawater. However, the 
vaccines do not have the same efficacy in preventing more aggressive outbreaks that occur later in 
the production phase close to harvest20, 23, 44. This suggests that early infections of piscirickettsiosis do 
not produce specific antibodies to prevent later outbreaks.  
The role of both specific and non-specific cell mediated immunity in protection of fish against 
intracellular infections is receiving increased attention. As a result of P. salmonis being an intracellular 
pathogen, stimulation of cell-mediated immunity including enhanced phagocytosis and intracellular 
killing, is most likely critical for success in development of effective vaccines in order to confer 
significant protection against the disease30. Marshall, et al (2007)36 assumed that the most exposed 
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bacterial antigens might also be the most immunoreactive epitopes and those rendering immune 
protection. This makes reasonable sense to evaluate the potential immunity against piscirickettsiosis 
by purifying the bacteria and/or by searching for a single antigen36. A successful outcome from 
vaccination against piscirickettsiosis depends on an activation not only of the innate immune system 
also of the antibodies and cellular mediated immune system to provide a sufficient protection7. It has 
been reported that when the primary immunization is done by the parenteral route (i.p.) followed by 
a booster by oral delivery the circulating antibody levels have shown to be elevated43. However, the 
circulating antibodies may not be able to protect against the infection and/or piscirickettsiosis 
development43. Understanding the immune response against P. salmonis may come from examining 
the biology of other intracellular pathogens44 for example, P. salmonis has been demonstrated to be 
able to inhibit phagosome-lysosome fusion85.  
 
Vaccine regulations 
The approval and use of vaccines and pharmaceuticals are strictly regulated by the relevant 
authorities. Vaccines to be used in Norwegian aquaculture must be approved by the Norwegian 
Medicines Agency (NoMA) and for the European market must be approved by the European Medicines 
Agency (EMA)124. For those approvals, the vaccines must pass pre-clinical laboratory studies to 
demonstrate efficacy, potency and safety during the registration process for market authorization. 
The tests are performed by experimental immunization and challenge of fish in a controlled 
environment. After the market authorization has been granted, each vaccine batch must be tested 
before release to the market. In addition to the laboratory studies, some authorities require the 
conduct of clinical field studies to document large scale efficacy and safety under commercial farming 
conditions 124. Evaluation of a vaccine’s efficacy and potency is usually performed by measuring the 
mortality and calculating the relative percentage of survival (RPS)112. The RPS is a quantitative and 
dynamic measurement that express the ratio between the percentage (%) of mortality in the 
vaccinated fish over the controls 125. The most common scale utilized is with a RPS of ≥ 60% mortality 
in the control group and a vaccinated group with a mortality ≤24%125. The European regulation for fish 
vaccines is based on a monograph from 1996 and the last update and revision was in 2011126.  
In Chile, the regulation of fish vaccines is controlled by the Chilean agricultural and livestock service 
(SAG). The vaccines currently on the market are approved according to the prevailing provisional 
registration requirements for immunological products for salmonids. The protocol states that the 
RPS60 after immunization and challenge with P. salmonis should be ≥70% for vaccines administered by 
injectable and oral administration and ≥ 60% for vaccines administered by immersion127. In 2018, SAG 
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established a protocol for full registration of salmonid vaccines that applies for all products with 
provisional market authorization. The process aims to be completed by 2021128 and is likely to reduce 
the number of vaccines available on the market. In the new Chilean guideline, for full registration it is 
emphasized that to demonstrate the efficacy of fish vaccines the pharmaceutical company must apply 
the challenge model that closely mimics infection under real-life conditions and in a more reliable 
manner mimic the mortality pattern of the disease. The possible challenge models to use for 
registration are by immersion, cohabitation and intraperitoneal injection128.  
 
Experimental challenge models  
Experimental challenge of fish 
The efficacy of vaccines and pharmaceuticals intended for aquaculture are tested using experimental 
challenge of fish. Experimental challenge models represent a key tool for development of all vaccines 
and pharmaceuticals, and the quality of the models is essential for a valid result that reflects the actual 
efficacy of the products. In vivo methods of challenge are typically used for the evaluation of the 
efficacy of new vaccines under development. Challenge models are also used to document the 
consistency of vaccine batches of registered vaccines that are produced for the aquaculture industry. 
The development of robust and reproducible challenge models is a time-consuming task and 
several factors must be taken into consideration. The trials are typically conducted in well-established 
wet lab facilities that are run according to high quality standards to ensure the validity of the trials. 
The facilities must be able to closely monitor parameters such as water temperature, light, salinity 
and flow/water exchange. The quality of the test fish with regard to genetic background, individual 
variation, size and physiological status must also be taken into consideration. The test fish must be 
pathogen-free, which calls for screening of brood fish, incubated eggs and the fish population after 
start-feeding by qPCR to document the absence of known pathogens. For some trials designed to 
evaluate the efficacy of vaccines, there is an additional requirement to document the absence of 
antibodies in the test fish prior to immunization. 
The infectious material used to challenge the fish must be representative of pathogens isolated in 
field outbreaks of the disease. Whether the pathogen is a virus, a bacterium or a parasite, the 
pathogen must be re-isolated and cultivated in a pure culture to ensure a causal relationship between 
the etiological agent and disease development (Koch’s postulates). In vitro cultivation of infectious 
material can be a challenging task as pathogens often are known to lose virulence over time. 
Optimization of parameters such as cell culture, broth, temperature, agitation is crucial to ensure 
cultivation of pathogens that are still representative of the strains isolated from the field. 
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The challenge models typically applied comprise challenge by injection, cohabitation or immersion.  
The challenge models aim to mimic real-life conditions in the field as closely as possible. The validity 
of the models must be studied for each pathogen separately since the dynamics of the infections vary 
significantly. Internal trials performed at VESO Vikan, for example, revealed that fish immunized with 
vaccines against Moritella viscosa infection demonstrate different degrees of protection against 
disease dependent on the challenge model applied. Challenge by immersion will give a valid 
presentation of the protection induced by the vaccines, while challenge by i.p. injection will give a 
false impression of high protection and this has direct relation with the bacterial route of infection. It 
is therefore important to thoroughly consider which challenge model that should be applied to reveal 
the protection provided by different vaccines. For experimental challenge with P. salmonis, it was 
recently demonstrated (unpublished results, VESO Chile) that salmon families bred for different 
genetic resistance against P. salmonis classified similarly resistant independent of being challenged by 
i.p. injection or cohabitation. The current thesis aims to document whether similar conclusions can be 
drawn after immunization of fish against P. salmonis followed by i.p. or cohabitation challenge. 
Challenge models with P. salmonis are well-known to be difficult to establish due to the 
intracellular characteristics of the bacterium in addition to the high mortality rate. The virulence of 
the P. salmonis strains varies significantly, and only some strains are capable of horizontal 
transmission from i.p. injected shedder fish to naïve cohabitant fish74. The infectious pressure can be 
controlled by adjusting the injected dose or the percentage of shedders introduced. However, the 
challenge pressure must be above a certain threshold level for horizontal transmission to occur. The 
incubation period for the disease depends on the bacterial isolate, the challenge dose administered 
or the number of shedders introduced, as well as environmental factors such as temperature, 
flow/water exchange and salinity. The physiological status of the fish (parr or smolts) and age/weight 
must also be taken into consideration when designing a P. salmonis challenge trial.   
The  extensive use of fish as experimental animals has been discussed in terms of ethics and animal 
welfare by scientists for a long time129. The 3Rs principles was established in 2010 for pharmaceutical 
use130. The 3Rs focus on replacement, reduction and refinement. Replacement means to avoid or 
prefer non-animal methods in research. Reduction means to induce the use of fewer animals achieving 
comparable levels of information or to obtain more information with the same number of fish. 
Refinement means use of methods for alleviation or reduction the level of pain, suffering or distress, 




Challenge by injection  
Challenge by injection is the most cost-effective model due to shorter disease development and 
thus duration of the experiment compared to the cohabitation challenge models. In addition, the use 
of correct challenge dose is easily feasible because the pathogen is injected directly into the fish. The 
main issue with this model is the artificial route of infection132, 133. There are two different challenge 
models based on injection of the pathogen: intraperitoneal (i.p.) and intramuscular (i.m.). In the i.p. 
injection challenge, the pathogen is injected directly into the peritoneal cavity of the fish. It has been 
described that the first affected tissues in fish challenged by i.p. injection are those closer to the 
injection site134. In addition, the substances administered intraperitoneally may undergo hepatic 
metabolism before reaching the systemic circulation135. Thus, this challenge model might not, in some 
cases, be the best approach for the evaluation of diseases or vaccines.  
In case of the i.m. challenge, the pathogen is injected into the muscle tissue of the fish. This route 
of administration utilizes the high number of antigen presenting cells present in the muscle. For some 
pathogens, such as the piscine myocarditis virus (PMCV), i.m. administration of the inoculum may 
represent a good way of challenging the fish136. The method of i.m. injection requires some practice 
to be performed in a consistent manner in a large group of fish. Injection of individual fish requires 
handling that is known to be very stressful.  
 
Challenge by cohabitation 
The cohabitation challenge model is based on a certain number of shedder fish (trojans) being 
introduced to infect naïve healthy fish held in the same tank. The shedders are typically naïve fish from 
the same fish population as the test fish that are i.p. injected with infectious material. Dependent of 
the incubation time of the specific pathogen, the shedder fish will start shedding the virulent pathogen 
to the water, which will infect the naïve cohabitants through horizontal transmission by direct contact 
or through the water.  
The advantage of this type of challenge model is that it closely mimics the natural infection and 
transmission of disease in a population133. Even though the port of infection of P. salmonis has not 
been proven, the fish may be challenged orally or via the gill surface, and have been shown to display 
a systemic pattern of infection51. Thus, cohabitation challenge models accurately represent natural 
exposure and may provide predictable results for mortality21. Furthermore, the amount of infectious 
material that must be produced for the challenge is limited because typically just the 20% of the test 
fish will be injected. This is particularly important for large scale trials that include a high number of 
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fish, or for pathogens that are difficult to cultivate in vitro, which leads to limited need for supply of 
inoculum137. Another advantage of challenge by cohabitation is reduced handling of the fish in 
comparison with the injection model. Although there are several advantages of using the cohabitation 
model, it is typically more time-consuming than challenge by injection or immersion. The prolonged 
period for transmission of the pathogen from shedder to cohabitant fish results in higher costs due to 
rental of tanks and use of water. It is therefore essential to determine whether challenge by i.p. 
injection will reveal similar results when compared to challenge by cohabitation or immersion with 
regards to the efficacy of a vaccine or pharmaceutical.  
 
Challenge by immersion 
The immersion challenge model is based on submerging the fish in a pathogen broth culture for a 
certain period of time. The fish are typically kept in one tank, the water level is lowered, and the broth 
containing cultivated pathogen added138. After a set period of time, the water flow is restored, and 
the water level raised back to normal. Challenge by immersion is typically applied for pathogens that 
are known to infect the outer barriers of the fish, such as mucus and skin. The model ensures that the 
handling of the fish is reduced to a minimum, which is crucial to leave the outer barriers intact for a 
representative infection and corresponding immunity to develop. Challenge by immersion requires 
large volumes of the pathogen to be cultivated. Large scale in vitro cultivation of pathogens may be 
difficult to achieve in an efficient time, and long culture period increase the risk of losing virulence. 
Furthermore, the duration of a typical immersion challenge trial is longer than challenge by injection. 
However, the route of infection more closely resembles natural infection, and challenge by immersion 











AIMS OF STUDY  
 
The main objective of this thesis was to increase the knowledge about experimental challenge models 
with Piscirickettsia salmonis and to define the in vivo model of preference for evaluation of efficacy of 
vaccines intended for Atlantic salmon. In addition, the aim was to increase the understanding on 
piscirickettsiosis’ pathogenesis and to characterize a P. salmonis isolate in vitro.   
 
To achieve the main objective three sub-goals were defined:  
 
1. To compare the progression of development of piscirickettsiosis after experimental challenge 
by intraperitoneal injection or cohabitation. 
 
2. To compare the protection induced by experimental vaccines after immunization and 
experimental challenge by intraperitoneal injection or cohabitation with P. salmonis. 
 
3. To characterize the P. salmonis isolate used for experimental trials in vivo after cultivation in 




















SUMMARY OF ARTICLES  
 
Article I  
 
Development of piscirickettsiosis in Atlantic salmon (Salmo salar L.) smolts after intraperitoneal and 
cohabitant challenge using an EM90-like isolate: a comparative study 
Karla Meza, Makoto Inami, Alf S. Dalum, Ane M. Bjelland, Henning Sørum, Marie Løvoll.  
Journal of Fish Diseases. doi: 10.1111/jfd.13004  
 
Piscirickettsiosis, caused by the intracellular Gram-negative bacterium Piscirickettsia salmonis is at 
present the most devastating disease in the Chilean salmon industry. The aim of this study was to 
analyze disease development after challenge with a P. salmonis strain (EM90-like) under a controlled 
environment by comparing intraperitoneal challenge with cohabitation challenge. The P. salmonis 
EM90-like isolate was cultured in a liquid medium for the challenge of 400 Atlantic salmon (Salmo 
salar L.) smolts. Cumulative mortality was registered, necropsy was performed and bacterial 
distribution in the tissues and histopathological changes were analyzed. The results revealed a similar 
progression of the disease for the two different challenge models. Pathological and histopathological 
changes became more visible during the development of the clinical phase of the disease. Bacterial 
DNA was identified in all the analyzed tissues indicating a systemic infection. Bacterial tropism to 
visceral organs was demonstrated by real-time quantitative PCR and immunohistochemistry. Better 
knowledge of disease development during P. salmonis infection may contribute to further 
development of challenge models that mimic the field situation during piscirickettsiosis outbreaks. 














Comparative study of experimental challenge by intraperitoneal injection and cohabitation of 
Atlantic salmon (Salmo salar L.) after vaccination against Piscirickettsia salmonis.  
Karla Meza, Makoto Inami, Alf S. Dalum, Hege Lund, Ane M. Bjelland, Henning Sørum, Marie Løvoll.   
Accepted in Journal of Fish Diseases.  
 
The Chilean aquaculture has been challenged for many years by the bacterial disease, 
piscirickettsiosis. A common prophylactic measurement to try to reduce the impact from this disease 
is vaccination, but the development of vaccines that induce full protection of the entire fish population 
has so far not been successful. Experimental challenge models are typically used to document the 
efficacy of vaccines. The aim of this study was to evaluate the performance of experimental vaccines 
after challenge by the two most widely used challenge routes; intraperitoneal injection and 
cohabitation. A total of 1120 Atlantic salmon were vaccinated with non-commercial experimental 
vaccines with increasing amounts of an inactivated Piscirickettsia salmonis EM90-like isolate. 
Differences in mortality, macroscopic and microscopic pathological changes, bacterial load and 
immune gene expression were compared after challenge by different routes. The results revealed a 
similar progression of the disease after challenge by both routes and no gross differences reflecting 
the efficacy of the vaccines could be identified. The analysis of the immune genes could provide some 
guidelines related to the pathogenicity of P. salmonis and suggesting the possible suppression of the 
cellular immunity by CD8 T-cells and with this stimulate the bacterial survival and replication. 
Comparative studies of experimental challenge models are valuable with regards to identify the best 













Article III  
 
Cultivation and characterization of a Piscirickettsia salmonis EM90-like isolate used for in vivo 
challenge in Atlantic salmon (Salmo salar L.)    
Karla Meza, Marie Løvoll, Leif Lotherington, Cristian Bravo, Simen F. Nørstebø, Jessica Dörner, Victor 
Martinez, Henning Sørum, Ane M. Bjelland.     
Submitted to Veterinary Microbiology 
 
Piscirickettsia salmonis is one of the most widespread fish pathogens in the Chilean aquaculture and 
the causal agent of piscirickettsiosis, a disease that is responsible for big economical losses in the 
salmon industry. P. salmonis is a facultative intracellular bacterium classified in two different 
genogroups, LF89 and EM90. A majority of the published studies of P. salmonis are related with the 
reference strain LF89. The aim of this study was to characterize phylogenetically and phenotypically a 
P. salmonis EM90-like isolate cultured in FN2 liquid medium. The isolate has previously been used in 
experimental challenge trials of Atlantic salmon (Salmo salar L.). The growth dynamics of the bacteria 
in different media was studied, and the enzyme activity and the protein expression profile of the 
bacterium was described after cultivation in a new liquid medium. Optimization of cultivation is 
essential to ensure that the bacterial culture remains pure, maintains bacterial yield and virulence. 
Some differences were observed in the protein expression profile after cultivation of P. salmonis on 
CHAB agar plates compared with FN2 liquid medium. Furthermore, differences in protein expression 
were identified when comparing fresh bacteria with bacteria inactivated with formalin. A 
morphological difference in the color of the colonies was observed when comparing the P. salmonis 
EM90-like isolate cultured on CHAB agar plates with the bacteria cultured in FN2 medium. Results 
from in vivo challenge trials with fish indicated that the virulence of the bacteria was conserved 































In the current project, the objectives were to compare the challenge models used for evaluation of 
the efficacy of vaccines intended for Atlantic salmon against piscirickettsiosis. The focus was the 
addition of improvements and the intention to define which model is preponderant to study new 
vaccines against P. salmonis. Furthermore, more knowledge in relation to the pathogenesis of 
piscirickettsiosis was intended. First, the challenge models by i.p. and cohabitation were studied in 
unvaccinated fish challenged with a P. salmonis EM90-like isolate (article I). Afterwards, the same 
challenge models were studied after immunization of fish against P. salmonis (article II). Finally, the 
bacterial isolate was characterized after in vitro cultivation in liquid medium (article III). The results 
described in the three articles led to new knowledge that may be taken into consideration in further 
research. Those findings will be discussed in this section.  
 
Development of piscirickettsiosis in challenged fish  
 
To identify factors that could modify and influence the development of piscirickettsiosis and its 
mortality during challenge trials are of interested. The objective of this is to tune the mortality curve 
and to be able to obtain a higher separation between the different efficacies of tested products. In 
this case, to be able to separate the mortality curves obtain from vaccines that develop higher 
protection levels against piscirickettsiosis from those vaccines that produce lower protection. For 
P. salmonis, this has been difficult due to its inner characteristics.  
  
Modification of the environmental conditions could affect piscirickettsiosis’ pre-clinical period   
The challenge model’s setup has an impact on the results from the challenge trials. The results 
obtained from both experimental challenges conducted in this study (article I and II) suggest that the 
salinity of the water could be a factor in the disease development. In article I where the salinity was 
32‰ it was demonstrated that the mortality for unvaccinated fish challenged by i.p. injection was 
observed to occur from 14 days post challenge (dpc) and by cohabitation from 28 dpc. This, compared 
with the challenge in article II where the salinity was 25‰, the i.p. injected fish started to die at 11 
dpc and the cohabitation at 24 dpc. This could suggest that the salinity of the water has some impact 
on the incubation period of the disease. This may imply that P. salmonis holds a high preference for 
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estuarine water, which is likely since salmonids are mostly located in fjords where the salinity of the 
water is lower than in seawater, and is in that production phase where most outbreaks occur.  
Another variable to consider is the water temperature. Based on unpublished results (VESO Vikan), 
it was found that when the temperature was reduced the onset of mortality was delayed. Results from 
a trial to document the impact of temperature showed that fish kept at 15°C started to die at 17 dpc 
(i.p. injected shedders) and 40 dpc (cohabitants). Fish kept at 12°C started to die at 24 dpc (i.p. injected 
shedders) and 64 dpc (cohabitants). The reduction of temperature by 3°C resulted in seven days delay 
in mortality for the i.p. injected shedders, and a 24 days delay for the cohabitants (Figure 6). After the 
onset of mortality, the progression of the disease development and mortality rates were similar and 
independent of temperature.  
The results may suggest or reaffirm that piscirickettsiosis is an environmentally dependent disease, 
and the virulence of the bacterium may be affected by the geographical locations both with regards 
to temperature and salinity. The adjustment of these parameters are able to tune, in some cases, the 
outcome of challenge trial. That is the case of challenges with Moritella viscosa, where the reduction 
in the temperature reduces the mortality. However, this is not applicable for P. salmonis where a 
decrease in the temperature just increases the pre-clinical period, but there are not changes in the 
percentage of mortality. This has not been reflected in field outbreaks, due to in field epidemiological 
studies in Chile like the study performed by Jakob, Stryhn, Yu, Medina, Rees, Sanchez and St-Hilaire 
(2014)139, have also revealed that the temperature of the water could affect the mortality of the fish. 
There was an increase in mortality among smolts transferred to seawater in the spring-summer season 
(higher temperature), in contrast to the smolts transferred in the fall-winter season (lower 
temperature). It has been documented that Atlantic salmon is more susceptible to, for example, the 
salmonid pancreas disease virus during the Norwegian spring/summer when the water temperatures 
are increasing140. Also, it has been described that Atlantic salmon obtain higher counting of amoebas 
at higher temperatures during amoebic gill disease141. Other reason of changes in virulence of 
P. salmonis by the temperature of the water could have relation with the optimal temperature for 
bacterial grow. The water temperature in Chile during the warmer season is close to the temperature 
defined as optimal for in vitro cultivation of P. salmonis. Another possibility could be related with the 
increment of the metabolic rate that increased the activation of immune response in the fish at higher 
temperatures and in addition to the bacterial intracellular characteristics, could result in an increase 
in the development of piscirickettsiosis. This is because P. salmonis targets mainly the cells involved 
in the immune response. Moreover, the susceptibility of smolts transferred during the warmer 





Figure 6. Mortality curves from parr challenged with P. salmonis at different temperatures. A, 20% shedder fish 
and 80% cohabitants at 15°C. B, 20% shedder fish and 80% cohabitants at 12°C.   
 
 
Different percentage of shedders modified the piscirickettsiosis pre-clinical period, but not the 
percentage of mortality 
For cohabitation challenge, the percentage of shedders may to some extent influence the level of 
mortality. In the trials described in article I and II it was demonstrated that the percentage of shedders 
did not influence the percentage of fish mortality. In article I, 50% shedders were used in contrast to 
article II where only 20% shedders were added. The challenge dose was identical for both trials and 
the mortality reached 100%. The main difference found when comparing the challenge trials was in 
relation to the time when the mortality started. For the challenge with 20% shedders the cohabitant 
fish started to die 24 dpc, contrarily in the challenge with 50% shedders the cohabitants started to die 
28 dpc. This was in line with previous trials conducted at VESO Vikan (unpublished data) in which 
different percentages of shedders were compared for challenge with P. salmonis. One tank contained 
50% of i.p. injected shedders while the other tank contained 30% of i.p. injected shedders, the injected 
dose was identical and the fish were kept in freshwater at 16°C. In both tanks, cohabitant fish started 
to die just one day apart, being later in the tank with 50% shedders. The mortality of the fish 
challenged by cohabitation reached almost 100%. Different challenges presented equal characteristics 
independent of the number of shedders added into the tanks (article I, II and Figure 7). Small 
differences present in those challenges could be related with other factors as those mention 




Figure 7. Mortality curves after challenge of parr with P. salmonis with different percentages of shedders. A, 50% 
shedders and 50% cohabitants. B, 30% shedders and 70% cohabitants.  
 
 
Culture method and inoculum concentration are important for challenge trials 
The method used for bacterial cultivation may influence the outcome of a challenge trial and 
should therefore be taken into consideration when designing an experiment. In the challenge trials 
executed in this study (article I and II) the bacterium was cultured in FN2 broth (recipe in article III). 
The main difference between the two culture media was in relation to the incubation period 
demonstrated in article III, where bacteria cultivated on CHAB plates needed at least six to ten days 
to be ready for harvest while bacteria cultivated in FN2 broth only needed four days of incubation at 
18°C. The use of broth as a culture medium for preparation of P. salmonis inoculums requires a sterile 
environment (cabinet) due to the high risk of contamination. Media for cultivation of P. salmonis are 
typically highly nutritive28. For the agar media, it is also necessary to work in a clean environment, 
however, unlike with the liquid media it is possible to identify contamination by visual observation of 
the agar plate. 
Calculation of the bacterial concentration in inoculums is complicated by the growth characteristics 
of P. salmonis, which makes it difficult to count colony forming units (CFU). This was demonstrated in 
article III where P. salmonis was plated, but single colonies were not possible to count. Prior to  the 
two challenge trials performed in this study (article I and II) a theoretical challenge dose was calculated 
based on the measurements obtained by Berger (2014)97. The challenge dose resulted in 100% 
mortality after challenge by i.p. injection as well as cohabitation. It has been described that the level 
of mortality of the fish in challenge trials correlates with the concentration of the inoculum when the 
bacteria is grown in CHAB plates79. Previous challenge model development performed at VESO Vikan 
revealed that a certain degree of correlation between dose/percentage shedders and level of 
mortality could be obtained when fish are challenged by i.p. injection. At the dose needed for the 
shedder fish to transmit disease to the cohabitant fish, however, the mortality rate in the cohabitant 
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fish will be similar independent of initial challenge dose. These results are independent of cultivation 
media and are likely related to the growth characteristics and virulence displayed by P. salmonis as an 
intracellular bacterium.  
 
Culture method may not affect piscirickettsiosis development, but biomass could 
To verify that P. salmonis cultured in FN2 broth was able to induce mortality in Atlantic salmon, a small 
challenge trial (Figure 8) was conducted to evaluate the potential differences in mortality induced by 
P. salmonis cultured in CHAB plates compared with FN2 broth. In this challenge, three tanks were 
used; in each tank 10 i.p. injected (shedders) and 10 cohabitants were included. One tank was 
challenged with P. salmonis EM90-like isolate culture in FN2 broth (tank A), other with the same 
bacterial isolate culture on CHAB plates (tank B), and the third tank was challenged with a P. salmonis 
LF89-like isolate culture in FN2 broth (tank C). The fish challenged by i.p. injected in tank A started to 
die at 11 dpc, in contrast with tank B where the fish started to die at 13 dpc (article III and Figure 8). 
For the cohabitants, no mortality was obtain in fish challenged in tank A, but there was mortality in 
the cohabitants of tank B (41 dpc). For the tank C no mortality was observed. There was a difference 
in two days in the mortality, being the i.p. injected fish in tank A earlier than in tank B. The absence of 
mortality in the cohabitant fish in tank A could be related with the reduced biomass included in the 
trial. The results have been confirmed in additional trials at VESO Vikan (unpublished data). This 
demonstrated that to obtain mortality in the challenge with P. salmonis, not only the characteristics 
of the isolate are important, but also the biomass. If the biomass is too low, mortality in cohabitant 
fish may not occur. Furthermore, the absence of mortality in the fish infected with the LF89 strain, it 









Figure 8. Mortality curves after a challenge of smolts with LF89- and EM90-like isolates of P. salmonis cultivated 
in FN2 broth or CHAB agar plates. Tank A, challenged with EM90-like isolate cultured in FN2 broth; Tank B, 
challenged with EM90-like isolate cultured on CHAB agar plates; Tank C, LF89-like isolate cultured in FN2 broth. 
50% shedder fish were i.p. injected with 0.1 mL of an inoculum of 1.0 × 105 cfu mL-1 P. salmonis LF89- or EM90-
like and introduced to the naïve cohabitant fish.  
 
 
Stress caused by handling impacts the fish’s susceptibility to piscirickettsiosis; this could have an 
impact on the outcome of experimental challenge trials  
Mortality curves of the trial described in article II are shown in Figure 9A-D. All tanks were similar 
with regards to groups as well as water quality and temperature. In all tanks, the fish were exposed to 
handling during removal of morbid and dead fish once a day. In tank C and D, fish were exposed to 
additional handling during sampling once a week. Four tanks were kept in parallel, two tanks for 
sampling (Figure 9C and D) where the fish were sampled once a week and two tanks for mortality 
recording (Figure 9A and B). In the graph representing the tanks utilized solely for mortality recording 
it is possible to observe better separation of mortality curves, which reflects the dose-relation of the 
vaccines used in the study. In contrast, in the tanks where the samplings were performed, the 
mortality in the fish population challenged by cohabitation started earlier compared to the fish that 
were not exposed to handling. Furthermore, the dose-relation of the vaccines is not as clear. This 
could be explained by what has been described previously related to the stress that can result in an 
increment in the production of corticosteroids in the fish and this response is related to the increased 
susceptibility of the individuals to diseases142. In addition, the stress has been related with the 




Figure 9. A, mortality curves of fish from a tank challenged by i.p. injection without handling; B, mortality curves 
from a tank with fish challenged by cohabitation without handling; C, mortality curves of fish from a tank 
challenged by i.p. injection with handling (sampling once a week); D, mortality curves of fish from a tank 
challenged by cohabitation with handling (samplings once a week). E = control group (saline); D = 0.5× antigen 
concentration; C = vaccine 2× antigen concentration; B = vaccine 3× antigen concentration; A = vaccine 5× 
antigen concentration.  
 
 
Challenge by intraperitoneal injection or cohabitation  
 
No major differences between i.p. injection and cohabitation challenge models with P. salmonis 
were detected 
There has been a discussion related to which challenge model should be used, or not, in the 
evaluation of pharmaceutical products and prophylactic measurements in relation to piscirickettsiosis. 
Article I and II were developed with the objective to obtain an answer to this question by comparing 
the most used challenge models against P. salmonis. First, unvaccinated fish (article I) were challenged 
by i.p. injection or cohabitation. The duration of the i.p. injection study was as expected clearly shorter 
compared to the cohabitation study. Otherwise, no major differences between the challenge models 
were detected. Secondly, fish immunized (article II) with five different antigen proportions were 
tested. Again, no major differences were detected between the two challenge models. Based on these 
results, the suggestion is that the challenge model to be used depends on the aim of the study. If the 
aim of the study is the evaluation of the efficacy of vaccines, the i.p. injection challenge model could 
be the most appropriate related to cost-effectiveness and animal welfare issues. If the objective is to 
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study piscirickettsiosis as a disease, the challenge model of preference may be by cohabitation since 
this model mimics in a more natural way the disease development.  
Furthermore, it could be of interested to compare Figure 9C and Figure 9D, where even though the 
fish were under stressful conditions (handling once a week) in the tank challenged by i.p. injection the 
vaccines with highest antigen levels seem to induce better protection against the disease. On the other 
hand, in the tank challenged by cohabitation where the fish were under the same conditions there 
was no differentiation between vaccines. This could strengthen the idea of using the i.p. challenge 
model to test vaccine efficacy. The indicated, was reflected by a better separation of the mortality 
curves (Figure 9A and 9C) demonstrating that the vaccine with higher concentration of P. salmonis 
antigens was able to delay the mortality in two days compared with the control vaccine. The groups 
started to die from those with less antigen concentration to the one with highest P. salmonis antigens 
concentration. 
  
Differential evaluation of challenge models by pathology for registration of immunogenic products 
for fish should be established 
For many years, the conduct of challenge trials with fish has been accomplished by the same 
parameters for different diseases without having any consideration about the impact of the pathology 
in the target population. Every disease in every species is different and diseases in fish are not an 
exception. There are some diseases with acute presentation and with high mortality rates like 
piscirickettsiosis38, 143. Other diseases have moderate or no mortality and could be classified as chronic 
diseases like some presentation of winter ulcers (caused by Moritella viscosa), bacterial kidney disease 
(caused by Renibacterium salmoninarum) and francisellosis (caused by Francisella sp. with a mortality 
not higher than 20%)138, 144-147. In vivo trials are part of the requirements for evaluation of the 
prophylactic measurements for fish diseases. However, the same parameters are used in evaluation 
of prophylactic measures for fish diseases, even though diseases can be very different in presentation 
and pathogenicity. The regulations for the registration of pharmaceutical products for veterinary 
medicine in Europe (EMA/CVMP/IWP/314550/2010, European Pharmacopoeia (Ph Eur) monograph 
0062: vaccines for veterinary use, 92/18/EEC, 90676/EEC, CMDv/BPG/002)148 were last updated in 
2011 and they were developed based on a monograph from 1996125, 126. Based on improved scientific 
methods and animal welfare aspects, a revision of the regulations for vaccine testing could be useful. 
A similar process would be recommended for products intended for the Chilean market, where it is 
important to implement the new permanent vaccine registration regulations established by SAG.  
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The regulations would probably benefit from an update that takes into consideration the 
differences between diseases. It is known which fish diseases are considered chronic, acute or with 
moderate impact to the fish population and on the production. Each disease classification should have 
its own parameters for evaluation. For some of the diseases, the mortality as RPS value could be the 
most reliable indicator of vaccine efficacy, but for others it is necessary to find alternative outcome 
parameters. Especially, for those pathologies where the pathogenicity of the etiological agent is not 
fully understood like with piscirickettsiosis. Some of the alternatives that were suggested in this study 
(article I and II) such as histology, antibody titers, immune genes expression, and bacterial detection 
by qPCR. With the exception of histology, more studies are necessary to define if the other analysis 
are able to evaluate in a predictable manner the vaccine efficacy against piscirickettsiosis. Previous 
studies have aimed to develop less invasive methods for the documentation of protection against 
P. salmonis non-mortality based. This can be done for instance through antibody measurement, 
detection of bacterial DNA in serum and the use of mass spectrometry technologies149-151. Likewise, in 
this study (article I and II) some analyses were conducted with the objective to obtain more knowledge 
about the immune response of the fish and pathogenesis of P. salmonis, expecting to obtain some 
alternative outcome parameters other than RPS. An alternative to the RPS scale has been studied by 
Wilda, et al (2012)150, where it was established a correlation between the serum IgM levels and the 
RPS after challenge with P. salmonis. It was, however, not possible to establish a cut-off value that 
ensured a high level of specific antibodies that could be applied in the vaccine development. Probably, 
a vaccine with good efficacy could facilitate the detection of good protection markers. Those markers 
could be a less invasive alternative to evaluate vaccine efficacy. Unfortunately, the efficacy of the 
research vaccine utilized in article II was not optimal. The lacking of fish protection was demonstrated 
by reaching 100% mortality and by measuring IgM titers. Even though there was an increment in the 
levels of antibodies present in plasma, the amount was not considerable to produce a strong immune 
response; therefore, no protection markers were identified. Improvements in the research vaccine 
can be apply such as the increment in the antigen concentration, which could result in a better 
immune response based on the IgM kinetics observed in article II.  
In addition, the possibility that histology or IHC could be one of the candidates was suggested. In 
article I and II, the histology provided some guidelines related to P. salmonis infection and the IHC 
confirmed the presence of the bacterial cells in the lesions observed. It was demonstrated that 
histology and IHC are not the most sensitive analytical tools for the evaluation of the vaccine efficacy 
against piscirickettsiosis. Histopathological studies are, however, excellent tools for diagnosis of 
piscirickettsiosis. Histopathological analysis may also be utilized for vaccine safety evaluation due to 
the possibility to visualize the presence or absence of tissue damage induced by the test vaccines.    
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The European medicine agency (EMA), mentions in the “Guideline of the design of studies to 
evaluate the safety and efficacy of fish vaccines” that the mortality as an evaluation parameter should 
always be questioned, and that  humane endpoints are always preferable126. This supports the 
necessity to find an alternative scale to measure vaccine efficacy. 
From an ethical aspect, there is a strong drive to replace mortality as outcome parameter with 
other, less invasive methods. Indicators of disease that can be measured at an early stage of 
pathological changes are highly valuable candidates to replace the current mortality requirements. 
The changes may be implemented over time, but discussions are needed to make sure that the 
regulations at all times are in accordance with current scientific background.  
The Chilean salmon industry was for several years an industry with poor investment in research. 
However, during the last years there has been a change in the industry, and better understanding of 
the fact that to be able to solve any difficulty the scientific view and collaboration between the 
academia and private sector are important.  
 
In vitro studies on P. salmonis  
 
Better knowledge of P. salmonis could improve the chance to prevent the disease  
For characterization of bacteria, different in vitro methods can be utilized like microscopic 
observation, morphological description of the bacterial culture, Giemsa and Gram-staining and 
molecular techniques. Molecular techniques include among others enzymatic and biochemical 
profiling by commercial kits as well as protein profiling methods such as Western blotting, and finally 
genetic and phylogenetic characterization.  
In article I and II, an in vivo characterization of the disease and pathogenesis after experimental 
challenge was performed, with the objective to understand how the bacterium behaves in the 
different challenge models and identify other measures than mortality for vaccine efficacy. For in vivo 
studies, the efficiency in the bacterial cultivation is important, for this any improvements in the 
inoculum preparation are relevant. Even tough, in the in vivo studies developed in article I and II, was 
demonstrated that the cultivation of P. salmonis in the new broth (FN2) was more efficient than in the 
old method, in article III, a validation of this was developed. It was compared the bacterial growth in 
CHAB agar plates to the bacterial growth in FN2 agar plates demonstrating that the bacterial growth 
was faster in the FN2 agar plates. Furthermore, in challenge trial, the inoculum preparation should be 
prepare when the bacteria is in the logarithmic phase of growth. To confirm that the P. salmonis 
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isolate was in the correct phase when the inoculums were prepared (article I and II), a growth curve 
was developed in article III. In that growth curve, was described that the logarithmic phase was reach 
at 40 hours and lasted for 56 hours. This demonstrated that the bacteria was harvested in the correct 
growth phase. Subsequently, in article III, phylogenetic and phenotypic characterization of the EM90-
like isolate was done and a protein profile of the bacterium was described under different growth 
conditions, as well as after inactivation with formaldehyde. After the phylogenetic study, it was 
possible to confirm that the isolate used in this study belongs to the EM90 genogroup and differ to 
the LF89.  
In article II, experimental vaccines were developed and utilized in the challenge trial. The results 
were not clear in terms of protection, possibly because the vaccines were not able to induce a 
sufficiently strong immune stimulation to elicit a reasonable amount of specific antibodies against 
P. salmonis. Also, was not able to stimulate the immune response based on T-cell. To try to identify 
the differences between an inactivated bacterium and a fresh culture of P. salmonis a Western blot 
protein profile was described in article III. The  differences seen could reflect the reduction of the 
immunogenicity of the pathogen as a result of the treatment with formaldehyde152, but this has not 
been proved. It is worth noting that several vaccines against extracellular pathogens have been 
developed based on inactivation with formaldehyde and are capable of inducing a successful long-
lasting protection. The results from the Western blot revealed some bands that were only present in 
non-inactivated bacteria cultivated in FN2 broth. For characterization of these bands, a proteomic 
analysis would be necessary, with the objective to define the function of these proteins, which could 
have a role in the immune response against P. salmonis.  
Detailed knowledge about the bacterium is important due to the fact that the more you know your 
enemy; the easier it is to fight him. In this case, the more we know P. salmonis it should be easier to 
find a long-term solution to prevent piscirickettsiosis and its consequences to the Chilean aquaculture. 
 
Methodological considerations  
 
Importance of considering the bacterial strain for challenge trials   
The bacterial species, strain and isolate that should be used in a challenge is linked with the aim of 
the study. The results from a challenge trial may be affected by the isolate of choice as a consequence 
of different virulence139. These differences have been demonstrated in a study described by Rozas-
Serri, et al (2018)23 in which it was shown that two P. salmonis isolates induced significantly different 
levels of mortality. The study showed that i.p. injected and cohabitant fish infected with an EM90-like 
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isolate died significantly faster than fish infected with an LF89-like isolate. The findings were consistent 
with results from a trial performed at VESO Vikan (unpublished data) where an LF89-like isolate 
(FIUCHILE-89L01, isolated from Atlantic salmon in a commercial farm in Puerto Montt, Chile) did not 
induce any mortality (Figure 8). Similar results were obtained in a challenge with the Norwegian isolate 
NVI-5692 (obtained from the Norwegian Veterinary Institute) generating moderate mortality (Figure 
10). The reason why the Norwegian isolate was not chosen for the present study is related to the 
geographical differences in the virulence of the bacteria described previously153. Based on this, it was 
more relevant to work with the EM90-like isolate which is described as the most widespread strain in 
the Chilean salmon industry52.    
The bacterial isolate used for experimental challenge should be representative for field outbreaks 
of the disease. Bacteria often target one fish species in particular, which is typically the case for 
P. salmonis. The current work was conducted using Atlantic salmon since this fish species accounted 
for 74% of the salmon harvest in Chile in 2018.  
 
 
Figure 10. Mortality curve of unvaccinated Atlantic salmon (Salmo salar L.) challenged by cohabitation and i.p. 
injection with the Norwegian isolate, NVI-5692 (kindly provided by the Norwegian Veterinary Institute).  Smolts 
were kept in seawater at 15°C. Atlantic salmon smolts challenged: 50% by i.p. injection (shedders) and 50% by 








Expression of immune genes, antibody kinetics and the immune response are important variables 
to have under consideration in the development of a vaccine study 
When the immune gene expression is studied by RT-qPCR it is essential to adjust the method by 
the use of house-keeping genes. Normalization to a reference house-keeping gene is done to reduce 
the errors related to variations in samples and technical variables as extraction, RNA quality among 
others154. How many house-keeping genes that should be considered for studies related with gene 
expression must be evaluated for each individual study. Relative quantification of expression of 
immune genes by qPCR is a well-established method. The stability of house-keeping gene expression 
has been evaluated and described in several studies155-157. The elongation factor 1 alfa beta (EF1αβ) 
was selected for the analysis performed in article II based on a previously reported trial performed by 
Løvoll, Austbø, Jørgensen, Rimstad and Frost (2011)158.  
The selection of the immune genes of study should be defined depending on which genes are likely 
to contribute to obtaining the major amount of information. In article II, one of the aims of the study 
was to obtain more information related to the immune response developed by fish vaccinated against 
P. salmonis. Previous descriptions indicate that the expression of genes associated with the adaptive 
immune response showed significant correlation with genes related to cell mediated immunity in fish 
infected with P. salmonis23. The genes of choice for article II were thus selected based on this.  
In addition, in article II, specific antibodies kinetic was measured and some insights about 
vaccination/immune response interaction were obtained like the expression of CD8α immune gene, 
associated with cytotoxicity in infected cells, was down-regulated through the challenge trial for i.p. 
injection and cohabitation models, and the CD4-1, associated with T-helper cell, was up regulated. In 
case of the CD8α, in the i.p. injected fish a dose-response relation with the vaccines was observed at 
2 wpc. Where a higher expression of CD8α, was observed in the vaccine with higher concentration of 
antigen. However, the half-life of specific antibodies against P. salmonis and their efficacy in 
protection are still unknown. It has been described that for some intracellular pathogens the 
development of specific antibodies take longer than expected, on the other hand, could be that the 
duration of the specific antibodies is short103. The efficacy of vaccines against piscirickettsiosis has 
been controvert due to the absence of long lasting protection, even though in some cases boosters 
are applied. Perhaps, the vaccination protocol has been administering incorrectly in terms of periods 
of administration, to define this could be necessary to do more analysis related with the half-life and 




Specific P. salmonis primers and probes for bacterial DNA detection facilitate bacterial 
quantification 
Primers, probes and antibodies for P. salmonis detection were developed several years ago using 
limited genomic information28. During the years, more sequence information was obtained, and more 
specific assays could be designed.   
For detection of bacterial DNA, the specificity of the primers was tested to avoid cross-reaction 
with other bacteria that may be present. Due to some unspecific background, the use of a probe was 
decided. The probe used for the analysis described in article I and II was a result of a modification of 
the probe originally designed by Karatas, Mikalsen, Steinum, Taksdal, Bordevik and Colquhoun 
(2008)159. The primers used in article I and II were obtained from the same study and kept as the 
originals. Primers and probes were difficult to design because the whole genome of the EM90 
genogroup utilized in this project was not available at the time of designing. Accordingly, identification 
of conserved and unique areas of the genome was challenging. In article I, the aim was to identify the 
presence of bacterial DNA in different tissues. The amount of DNA in each sample was not 
standardized, and accordingly no calculations of bacterial load could be made. Consequently, it was 
not possible to identify the highest bacterial load, which could have contributed to obtain more 
information related to the organ of preference or could have helped to clarify the port of entrance of 
P. salmonis to the host. Nevertheless, it was possible to corroborate the preference of P. salmonis for 
visceral tissue. In article II, the quantity of DNA in the samples was standardized, generating the 
possibility to identify liver as the visceral tissue that is most affected by P. salmonis. 
From the results obtained in article I and II, it is possible to suggest that for further analysis, the 
tissue of study should be the liver.  
Phenotypic and phylogenetic description of the EM90-like isolate of P. salmonis used in the studies 
described in article I and II was presented in article III. The isolate was confirmed to belong to the 
group of EM90-like isolates. New information about the bacterial genome such as conserved 
sequences opens for the possibility to design specific primers that may be used without an additional 
probe, thereby reducing the cost of the qPCR analysis. A fully sequenced P. salmonis genome may also 
contribute to identify, in the future, new antigens that may be evaluated with regard to immunogenic 







Necropsy: strong diagnostic tool, but difficult to standardize   
Necropsy is the examination of the dead animal with the objective to corroborate the cause of the 
death of the animal. The examination is performed based on the observation of pathological changes. 
The pathological changes recorded in article I and II were described previously in the literature as part 
of the piscirickettsiosis development24, 29, 38, 43, 50, 57, 61, 73.  
The setup of the necropsy was a standard procedure established previously by VESO Vikan. The 
necropsy involved registration of pathological changes consistent with piscirickettsiosis. The 
registration was performed as presence or absence of a defined set of different pathological changes 
as ascites (A), pale focal nodes in the liver (PFNL), swollen kidney (SK), splenomegaly (SP), hemorrhages 
in the digestive tract (HDT), distended ventricle with gelatinous content (DV/GC) and general 
hemorrhages (GH). The main challenge with this kind of registration relates with the subjective 
classification of mild or more severe changes. Although the criteria are well-defined, it is difficult to 
maintain an objective evaluation. Necropsy is a valuable tool for diagnostic and for the study of 
pathogenesis. The amount and quality of the information obtained could be improved by 
implementing a more detailed scoring system.  
The fish described in article I and II were starved prior to handling for challenge and samplings. 
Starvation of fish for a certain number of day degrees before handling or treatment is a well-
established procedure160, 161. The procedure of starvation was implemented mainly to reduce the 
intestinal content in the fish, promoting a cleaner environment avoiding contamination of the 
samples. Additionally, the method is used to reduce the trauma of the remaining fish that were not 
sampled. The method of starvation of fish is frequently discussed, and several publications claim that 











CONCLUSION AND FUTURE PERSPECTIVES 
 
Experimental challenge models are time consuming to develop and must be fully validated before 
use. A well-established challenge model aims to be robust and reproducible and must be optimized 
for each individual pathogen. The infectious material must be carefully selected and representative 
for field outbreaks of the disease.  
Changes in the media for bacterial cultivation could improve the challenge trial by reducing the 
time of inoculum preparation. In the current study, a new FN2 broth media was used and validated in 
two challenge trials. The results with regards to mortality were similar compared with the old 
cultivation method on solid agar.  
The challenge model of choice must be carefully selected based on the objective of the study. For 
evaluation of the efficacy of vaccines against piscirickettsiosis, this study showed that there are no 
major differences between the results obtained after challenge by i.p. injection or cohabitation.  
Without considerable differences, it may be recommended to use the i.p. injection challenge model 
to evaluate vaccine efficacy. This model offers a short duration of the trial, which is valuable with 
regards to animal welfare since the fish are exposed to the pathogen for a shorter period of time. 
Otherwise, if the objective of the study is evaluation of disease pathogenicity, the cohabitation 
challenge model may be preferred.  
The analysis that today are employed to evaluate fish vaccines may not apply for all the various 
diseases because each disease has a different pathogenicity. This difference could affect how the fish 
reacts to vaccines and how the vaccines should be evaluated to prove their efficacy, potency and 
safety. New outcome parameter for evaluation of vaccine efficacy should be implement for animal 
welfare reasons. Regulation for vaccines registration, in Chile, should be established, defined and 
regularly updated by the authorities.   
Additional studies should be performed to better understand the pathogenicity of P. salmonis and 
the effect on the fish. It should keep studying the fish immune response and specific antibody kinetic 
against P. salmonis and their half-life. Aforementioned, could add more knowledge in the 
development of prophylactic measurements against piscirickettsiosis. Likewise, all documentation in 
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Piscirickettsiosis is the most challenging disease present in the 
Chilean salmon industry generating economical annual losses of 
around USD 700 millions (Maisey, Montero, & Christodoulides, 
2017). The disease was reported for the first time in 1989 in Calbuco, 
Los Lagos, Chile, followed by isolation and characterization of the 
causative bacterium Piscirickettsia salmonis (Fryer, Lannan, Garcés, 
Larenas, & Smith, 1990; Garcés et al., 1991). Piscirickettsiosis is a 
septicaemia that affects mainly salmonid species resulting in high 
mortality rates (Otterlei et al., 2016). The last year, the most affected 
specie was Atlantic salmon (Salmo salar) followed by rainbow trout 
(Oncorhynchus mykiss) ([SERNAPESCA], 2018). At the beginning, 
Coho salmon (Oncorhynchus kisutsch) was the most affected salmo-
nid species (Almendras & Fuentealba, 1997), but after a reduction in 
the production, the cases of piscirickettsiosis decreased.
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Piscirickettsiosis, caused by the intracellular Gram-negative bacteria Piscirickettsia 
salmonis, is at present the most devastating disease in the Chilean salmon industry. 
The aim of this study was to analyse disease development after challenge with a 
P. salmonis strain (EM90-like) under a controlled environment by comparing intraperi-
toneal challenge with cohabitation challenge. The P. salmonis EM90-like isolate was 
Salmo salar) 
smolts. Cumulative mortality was registered, necropsy was performed, and bacterial 
distribution in the tissues and histopathological changes were analysed. The results 
revealed a similar progression of the disease for the two different challenge models. 
Pathological and histopathological changes became more visible during the develop-
ment of the clinical phase of the disease. Bacterial DNA was identified in all the ana-
lysed tissues indicating a systemic infection. Bacterial tropism to visceral organs was 
demonstrated by real-time quantitative PCR and immunohistochemistry. Better 
knowledge of disease development during P. salmonis infection may contribute to 
further development of challenge models that mimic the field situation during piscir-
ickettsiosis outbreaks. The models can be used to develop and test future preventive 
measures against the disease.
Atlantic salmon, challenge model, cohabitation, intraperitoneal, Piscirickettsia salmonis, 
Piscirickettsiosis
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Various isolates of P. salmonis have been characterized and 
are grouped based on genotyping as LF89-like (Fryer, Lannan, 
Giovannoni, & Wood, 1992) or EM90-like (Mauel, Giovannoni, & 
Fryer, 1999). The EM90-like genotype has been demonstrated to be 
widely distributed when piscirickettsiosis is diagnosed in field cases 
in Chilean salmon farms and is responsible for a high number of pi-
scirickettsiosis outbreaks (Saavedra et al., 2017). Piscirickettsiosis 
has also been described in Canada (Brocklebank, Evelyn, Speare, 
& Armstrong, 1993), Ireland (Rodger & Drinan, 1993) and Norway 
(Olsen, Melby, Speilberg, Evensen, & Håstein, 1997). However, the 
incidences and losses from the disease are lower in these countries 
than the ones reported in Chile (Birkbeck, Griffen, Reid, Laidler, & 
Piscirickettsia salmonis is an aerobic Gram-neg-
ative, facultative intracellular and non-motile bacterium (Bravo & 
Martinez, 2016). During disease development, the most affected 
organs are liver, spleen, intestine and the hematopoietic tissue in 
the head kidney (Almendras & Fuentealba, 1997; Evensen, 2016). 
Histopathological lesions have been classified in the categories of 
necrosis and inflammation (Almendras & Fuentealba, 1997; Mauel 
& Miller, 2002). The presence of the bacteria has been described in 
liver and heart (Rozas-Serri et al., 2017). The bacterial cells have also 
been detected in hepatocytes and blood (Mauel & Miller, 2002).
Prophylactic treatment against piscirickettsiosis is widely used in 
the Chilean industry. Around 70 million vaccinated Atlantic salmon 
smolts were transferred to sea in 2016 (Navarro, 2018). In 2017, 32 
different vaccines against this disease were available in Chile ([SAG], 
2017). Nevertheless, vaccination is currently unable to stop out-
breaks and the industry highly depends on antibiotics to treat the 
disease. In 2016, the Chilean salmon industry reported the use of 
382.5 tons of antibiotics in total, of which piscirickettsiosis treat-
ment accounted for 89.3% of the total use ([SERNAPESCA], 2017). 
Thus, there is a strong need for the development of more efficient 
vaccines against piscirickettsiosis. More knowledge about the differ-
ent genotypes of the bacterium and their interaction with the host is 
crucial to develop protective vaccines.
Controlled challenge models represent an essential tool to study 
disease development in fish. The experimental models are designed 
to mimic authentic infections in a controlled environment and are 
typically performed by intraperitoneal (i.p.) injection of the patho-
gen, by cohabitation of naïve fish with i.p. injected shedder fish or 
by immersion. Intraperitoneal injection of the pathogen typically re-
sults in faster disease development and therefore provides results 
in a cost-efficient manner. Even when cohabitation and immersion 
challenges may seem to be more representative for comparison with 
field infection conditions compared to i.p. challenge in terms of route 
of infection, the challenge models have not been compared to assess 
their similarity and/or differences.
The aim of the study was to describe the disease development 
after infection with a P. salmonis EM90-like isolate by comparing an 
i.p. challenge model with cohabitation challenge. The pathological 
findings were evaluated in relation to bacterial distribution. The se-
quential development of pathological changes in the fish challenged 
with P. salmonis throughout the study was described with regard to 
challenge method and tissue tropism.
|
|
Experimental fish were produced at the VESO Vikan hatchery. The 
fish were smoltified at the hatchery by manipulating the photoper-
iod using artificial light. The fish were exposed to 6 weeks of alterna-
tion between 12 hr light and 12 hr darkness followed by a 6 weeks 
Atlantic salmon with an average weight of 102.3 g were used. The 
fish population was confirmed negative for antibodies against 
Aliivibrio salmonicida, Vibrio anguillarum O1 and O2a, Vibrio ordalii, 
Aeromonas salmonicida and Moritella viscosa. The absence of P. sal-
monis, infectious pancreas necrosis virus (IPNV), infectious salmon 
anaemia virus (ISAV), salmon pancreas disease virus (SPDV), piscine 
orthoreovirus (PRV) and piscine myocarditis virus (PMCV) was con-
firmed by qPCR (PatoGen Analyse AS) prior to trial start. Non-vac-
cine was used for this study.
|
A Piscirickettsia salmonis EM90-like isolate (VESO Vikan) originally 
used. This isolate was previously confirmed by BLAST® alignment 
after sequencing. This P. salmonis isolate was aerobically cultured 
(unpublished media, original recipe provided by FAVET-INBIOGEN, 
Spectrophotometric analysis (Jenway 6300) was used to measure 
the density of the liquid culture. Control of contamination was evalu-
ated by visual examination of the liquid culture under a phase con-
trast microscope, and in addition, 100 μl of culture was plated on 
cysteine heart agar (CHAB) supplemented with ovine blood (5%) 
(Norwegian Veterinary Institute) and on blood agar with 2% NaCl 
(Kystlab-PreBio, Namsos, Norway). The CHAB plate was incubated 
P. sal-
monis were observed on CHAB plates. No bacterial colonies were 
observed on blood agar plates.
|
The challenge trial was approved by the Norwegian Animal Welfare 
-
ity (Namsos, Norway). Fish were acclimatized in sea water with a 
duplicated tanks (tank A and tank B). The tanks had a capacity of 
3 for 
the trial. Each tank included 100 i.p. injected fish (shedders) and 
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100 cohabitant fish (naïve). The shedders were anesthetized with 
0.001% benzocaine chloride (Sykehusapoteket Oslo, Ullevål) and 
marked by shortening the adipose fin. The bacterial inoculum for 
i.p. injection of shedder fish was adjusted to OD600nm = 1.0 and then 
further diluted by four tenfold dilutions giving a theoretical dose of 
1.0 × 105 cfu/ml. Each shedder fish was injected with 0.1 ml of the 
bacterial inoculum on day 0. The concentration used was based on 
a previous publication where OD600nm = 1.0 of the bacterial culture 
was estimated to be 1.0 × 1010
fish were fed with a commercial diet (Skretting AS) twice a day from 
day 1 post-challenge (dpc). The fish were monitored daily, and dead 
fish were registered. Fish in the terminal stage with clear signs of 
disease (erratic swim, lethargic, ulcer in the skin, pale gills, among 
other) were euthanized with an overdose of benzocaine chloride and 
registered as dead. Bacteriological examination of dead fish was per-
formed daily by inoculating head kidney samples on blood agar with 
|
The fish were selected randomly by netting from tanks A and B and 
euthanized with an overdose of 0.002% benzocaine chloride. Ten 
control fish were sampled prior to challenge on day 0. Samples were 
and six cohabitants per tank.
|
Blood samples were obtained immediately after euthanizing the fish 
and before the necropsy was performed. Blood was drawn from the 
dorsal vein (Vena caudalis) and/or dorsal artery (Aorta caudalis) by 
puncturing the fish lateroventrally behind the anal fin. Vacutainer® 
blood collection tubes containing ethylenediaminetetra-acetic acid 
(EDTA) anticoagulant were used (BD, New Jersey, USA). After sam-
pling, the tubes were centrifuged at 797 g
|
Necropsy was performed immediately after blood sampling. No nec-
ropsy was performed in control (untreated) fish. The pathological 
changes were classified as ascites (A), pale focal nodes in the liver 
(PFNL), swollen kidney (SK), splenomegaly (SP), haemorrhages in the 
digestive tract (HDT), distended ventricle and/or with gelatinous 
content (DV/GC) and general haemorrhages (GH). The pathological 
changes were registered as percentage of the occurrence among the 
12 sampled fish per group.
|
Tissue samples were dissected from spleen, skeletal muscle, liver and 
head kidney. The samples for qPCR were submerged in RNAlater® 
DNA extraction. Samples for immunohistochemistry and histology 
|
-
ples were from control fish, and 336 tissue samples (72 from i.p. 
-
lenged fish. Tissue samples were weighed (up to 10 mg of spleen and 
25 mg for other tissues) in OHAUS® Analytical plus (Sigma-Aldrich) 
scale before they were homogenized using sterile steel beads and 
TissueLyser II (Qiagen) for 15 s at 25 Hz and incubated with protein 
-
formed using QIAcube and QIAGEN DNeasy® Blood & tissue kit 
(Qiagen) according to the manufacturer's protocol. The quality of the 
DNA was confirmed using NanodropTM ND-1000 spectrophotome-
ter (Thermo Scientific). Primer and probe sequences targeting P. sal-
monis were obtained from Karatas et al. (2008). Primer sequences 
probe sequence was modified to increase the specificity using the 
software Primer Express v 2.0 (Thermo fisher Scientific). The result-
For the detection of bacterial DNA, qPCR was performed. Each 
reaction contained 10 μl TaqMan qPCR Supermix, 300 nM of spe-
cific forward and reverse primer, 100 nM of a specific probe and 2 μl 
DNA template in a total volume of 20 μl. The qPCR thermal profile 
-
triplicate. Results with Ct values above 35 were considered negative.
|
All sampled fish (n = 70) were evaluated subjected to histological 
and immunohistochemical analysis. Formalin-fixed samples from 
liver, head kidney, spleen and skeletal muscle were processed 
for histological analysis and immunohistochemistry according 
to standard procedure (Suvarna, Layton, & Bancroft, 2018). For 
haematoxylin and eosin staining (HE), paraffin-embedded tissues 
were sectioned at 2 μm thickness. HE sections were evaluated 
in a blinded manner by two independent scientists with a scor-
ing system from 0 to 3. The criteria for scoring the samples are 
shown in Table 1. After scoring the samples, the average of both 
values was calculated. For immunohistochemistry (IHC), tissues 
L-lysine-
coated slides (KF FROST, VWR International BV, Amsterdam, The 
Netherlands). Protocol for immunohistochemistry was adapted 
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from Dalum et al. (2016) including a primary antibody against 
P. salmonis (kindly provided by Duncan Colquhoun, NVI). The 
-
tion in xylene. Heat-induced epitope retrieval was performed at 
-
ing in 0.01 M phosphate-buffered saline (PBS, pH 7.3). The sec-
0.05% phenyl-hydrazine (Aldrich chemistry, MO, USA) followed by 
washing with PBS. Slides were blocked with a solution of 0.05 M 
tris-buffered saline (TBS, pH 7.6) with 0.2% goat normal serum 
and 5% bovine serum albumin (BSA) for 20 min. The primary poly-
The antibody was labelled with polymer-HRP anti-rabbit (Dako 
EnVision + System-HRP) and developed with 3-amino-9-ethyl 
carbazol (AEC) producing a red staining when reacting with tis-
sue-bound primary antibody. Counterstaining was performed with 




Similar mortality curves were obtained from tank A and tank B 
(Figure 1). In the i.p. injected group, dead smolts were recorded from 







































































Score system for 
haematoxylin–eosin slides
Cumulative mortality after experimental challenge with Piscirickettsia salmonis (EM90-like). Parallel groups of i.p. injected 
shedders and naïve cohabitant fish were included in both tanks A and B. Discontinuous vertical lines indicate time of sampling
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A and 21 dpc in tank B. In the cohabitant (naïve) group, dead smolts 
were detected from 29 dpc in tank A and 28 dpc in tank B. In this 
respectively. A minor tank effect was observed between tanks A and 
B during the challenge experiment (Figure 1). The mortality curve of 
the i.p. challenged fish was slightly steeper compared with the more 
prolonged mortality curve of the cohabitant challenge fish. A long 
from challenge to onset of disease outbreak was observed in i.p. 
injection challenge model and 28 days for cohabitation model. The 
duration of the disease until all smolts were dead was in average 
5.5 and 7.0 days in the i.p. and cohabitation challenge, respectively 
(Figure 1).
|
The type and frequency of pathological findings are shown in 
Figure 2. All the sampled fish were alive at the time of sampling. 
Pathological changes such as ascites, pale focal nodes in the liver, 
splenomegaly and haemorrhages in the digestive tract were ob-
served from 1 week post-challenge (wpc) in both challenge models. 
Swollen kidney and distended ventricle with gelatinous content 
and 5 wpc in cohabitant fish. Pathological signs were more present 
except from swollen kidney and distended ventricle with gelatinous 
content that were identified in 100% (12/12) and 92% (11/12) of co-
habitant fish compared with 25% (3/12) and 50% (6/12) of the i.p. 
injected group, respectively.
Pathological changes were observed from 1 wpc in the i.p. in-
jected fish. Ascites was observed in 75% (9/12) of the sampled 
fish, pale focal nodes in the liver in 83% (10/12), swollen kidney 
in 25% (3/12), splenomegaly in 75% (9/12), haemorrhages in the 
digestive tract in 92% (11/12) and distended ventricle with gelat-
inous content in 17% (2/12) of the sampled fish 1 wpc. Ascites 
and pale focal nodes in liver were observed in 100% (12/12) of 
the sampled fish in 2 wpc, splenomegaly in 92% (11/12), haemor-
rhages in the digestive tract in 83% (10/12), swollen kidney in 25% 
(3/12) and distended ventricle with gelatinous content in 50% of 
the sampled fish. General haemorrhages were not observed after 
i.p. challenge.
Fish challenged by cohabitation developed pathological 
changes differently compared with the i.p. challenged fish. Ascites 
was observed in less than 25% (3/12) of the fish from 1 wpc to 
during 5 wpc. Pale focal nodes in the liver were observed in more 
than 75% (9/12) of the sampled fish at 1 and 2 wpc. Pale focal 
nodes in the liver were observed in 100% (12/12) of the fish at 
and 5 wpc, respectively. Splenomegaly was observed in less than 
reach 100% (12/12) at 5 wpc. Haemorrhages in the digestive tract 
where no haemorrhages were observed but then reach 100% 
(12/12) at 5 wpc. Distended ventricle with gelatinous content was 
the frequency reaching an 8% (1/12) of the sampled fish at 5 wpc. 
General haemorrhages in the fish were observed at 5 wpc in 83% 
(10/12) of the sampled fish.
|
The histopathological changes were evaluated according to an estab-
lished scoring system from 0 (no changes) to 3 (extensive changes) 
(Table 1). The scoring of sampled fish throughout the challenge ex-
periment is presented in Figure 3. Scores 0–2 were observed dur-
ing disease development in the i.p. injected fish. In the cohabitant 
fish, however, score 3 was described at 5 wpc. In the i.p. injected 
fish, a slight increment in histopathological changes was observed 
Pathological findings in sampled fish after (a) challenge by intraperitoneal injection and (b) challenge by cohabitation. wpc: 
weeks post-challenge. % Frequency = number of sampled fish that showed pathological changes divided by the total number of sampled fish 
per time point
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between 1 and 2 wpc. For the cohabitant group, a slight increment 
Histopathological changes representative for each scoring value are 
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Immunohistochemistry (IHC) revealed the presence of bacteria 
in different host tissues, demonstrating that the histopathological 
findings may be due to the bacterial infection (Figure 5). The bacte-
ria were identified in all types of analysed tissues, with an increas-
ing number of positive reactions in the last period of the challenge, 
especially at 5 wpc in cohabitants compared with 2 wpc in the i.p. 
injected fish. Results of the IHC observation are summarized in 
Table 2. No bacteria were detected at 1 wpc in either challenge 
model. At 2 wpc, the bacteria were detected in all tissue in i.p. chal-
lenge but no bacteria were observed in the cohabitant fish. At 3 wpc, 
the bacteria were detected in spleen and head kidney. The bacteria 
The IHC demonstrated the presence of the bacteria free in the 
tissue and inside cells resembling macrophage as a red coloured 
reaction. P. salmonis was found to be focally distributed in liver 
(Figure 5m) tissue in contrast to spleen (Figure 5o), head kidney 
(Figure 5n) and skeletal muscle (Figure 5l) tissues where the bacterial 
distribution was more spread and homogenous. No bacteria were 
detected in tissues with a histopathological score 0 (Figure 5a–c). 
A sparse amount of bacteria (score 1, Figure 5e–h) was mainly ob-
served in liver tissue (Figure 5e). A clear increase in the red staining 
is demonstrated in Figure 5i–l representing score 2. The most exten-
sive occurrence of positive reactions of P. salmonis was observed in 
the liver of cohabitant fish at 5 wpc shown in Figure 5m where focal 
necrotic areas were visualized.
|
The presence of P. salmonis DNA was confirmed by qPCR. The de-
tection limit of P. salmonis was set to a Ct value of 35; all samples 
with a Ct value lower or equal to 35.0 were considered positive. The 
10 control fish were negative for the presence of P. salmonis DNA.
In the first wpc, P. salmonis DNA was detected in spleen tissue 
of 58% (7/12) of the i.p. challenged fish. All tested tissues were posi-
tive in 91.7% (11/12) of the sampled fish in the i.p. challenged group 
2 wpc. Bacterial DNA was detected 2 wpc in the spleen and skeletal 
muscle of 8.3% (1/12), and in the head kidney of 50% (6/12) of the 
cohabitant fish. The presence of P. salmonis was detected in head 
kidney, liver and muscle samples 3 wpc in 16.6% (2/12), 8.3% (1/12) 
and 8.3% (1/12) of the sampled fish, respectively. All tissues were 
5 wpc, respectively. The results are summarized in Table 3.
|
For the present study, the bacteria were cultured in liquid medium 
Díaz et al., 2017; Garcés et al., 1991; Rozas-Serri et al., 2017; Smith 
et al., 2015) have cultivated the bacteria for challenge on solid media 
or cell culture. To our knowledge, this is the first report on P. sal-
monis cultivation in liquid medium for challenge in Atlantic salmon. 
The results indicate that bacteria cultivated in liquid media show 
similar virulence as bacteria cultivated on solid media (CHAB plates) 
(unpublished data from VESO Vikan research station) with the ad-
vantage of shorter incubation period for the former. This is positive 
in terms of shortening the preparation time for the challenge trial 
and reduces the number of bacterial generations in each cultivation, 
reducing the probabilities to produce genetic changes in the isolate.
Distribution of the average of the histopathological scoring after i.p. and cohabitation challenge. The vertical bars show the 
average standard deviation of the scoring. Score 0 represents no changes in the tissue. Scores 1 and 2 represent mild and moderate changes 
in the tissue, respectively. Score 3 represents extensive changes in the architecture of the tissue
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Piscirickettsiosis is known as an aggressive disease that 
causes high mortality and significant economic losses (Almendras, 
Fuentealba, Jones, Markham, & Spangler, 1997; Dettleff, Bravo, 
Patel, & Martinez, 2015; Rozas-Serri et al., 2017). An incubation 
which is in agreement with a previous report by Rozas-Serri et al. 
(2017). In the present study, the incubation period was followed 
by an aggressive and short outbreak with fish mortality reaching 
100% in both challenged groups. In contrast to the former report, 
fish death of the cohabitant group was in our study recorded signifi-
cantly earlier (28 dpc vs. 36 dpc). Several factors such as challenge 
conditions (water quality and temperature) and fish species could 
influence the disease development (Almendras et al., 1997; Arkush 
et al., 2005; Díaz et al., 2017). In our challenge experiment, fish were 
to the experiment of Rozas-Serri et al. (2017) in which the fish were 
It is likely to assume that the challenge dose for cohabitant 
fish was considerably lower compared with shedder fish that was 
receiving a high dose of bacteria injected directly into the intra-
peritoneal cavity. In the present study, the disease development 
and mortality progressed faster in the i.p. challenged fish com-
pared with the cohabitant fish group (Figure 1), thus indicating 
that piscirickettsiosis has a dose-dependent pathogenesis. This 
Representative histomorphological images (HE). Representative images from liver, kidney, spleen and skeletal muscle with 
scores 0, 1, 2 and 3 (score 3 was not observed for skeletal muscle in this experiment). Score 0: no visible changes in the tissue. Score 1: focal 
changes with inflammation in the liver, oedema in head kidney, mild congestion in the spleen and oedema causing interfibre space increase 
in skeletal muscle. Score 2: focal changes with inflammation and necrosis in liver, inflammation and oedema in head kidney, loss of tissue 
architecture in spleen and fibre degeneration in skeletal muscle. Score 3: extensive necrosis in liver, necrosis with oedema in head kidney, 
oedema and congestion and loss of architecture in the spleen. Scale bar = 100 μm
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is in agreement with the results of a study made by Smith et al. 
(2015) in which a high mortality of rainbow trout was recorded 
at a short time post-immersion with a high dose (105 TCID 50/ml) 
of P. salmonis. The mortality curves of the two fish groups were 
otherwise similar when comparing the results from 1 and 2 wpc 
-
lenged fish (Figure 1). This observation is supported by similari-
ties in the development of the disease. No major differences in 
Representative immunohistochemistry images of liver, kidney, spleen and skeletal muscle sections from fish challenged by 
Piscirickettsia salmonis. The bacteria are visualized by red staining (AEC). The corresponding histopathological scores are indicated. Score 3 
was not observed for skeletal muscle in this experiment. Scale bar = 100 μm in a–c, e–g, i–k and m–o; 50 μm in d, h and l
Presence of Piscirickettsia salmonis detected by IHC in different tissues after challenge by intraperitoneal injection or 
cohabitation
1
2 + + + +
3 n/a n/a n/a n/a + +
n/a n/a n/a n/a + + + +
5 n/a n/a n/a n/a + + + +
Note
|MEZA ET AL.
pathological changes were found when comparing samples from 
1 and 2 wpc of the i.p. challenged fish with samples from 3 and 
-
tered in 5 wpc were probably due to terminal development of the 
disease (Figure 2).
Several trials with different EM90-like isolates have been con-
ducted at VESO Vikan. In conclusion, the virulence varies signifi-
cantly between isolates, also with regard to the capacity of horizontal 
transfer of bacteria by cohabitation. The mortality rate in challenge 
trials with P. salmonis is typically high, and a lower challenge dose 
will often lead to lack of horizontal transfer of the infection (VESO 
Vikan, unpublished data). The concentration of the inoculum used in 
this trial was based on previous experience with the isolate at VESO 
Vikan, and the mortality obtained was in line with previous results.
Surprisingly, the detection of P. salmonis DNA in tissue anal-
ysed by qPCR and by IHC suggests less relation between the num-
ber of bacteria in the tissues and the necropsy and HE-staining 
results. The bacteria were first detected by qPCR in cohabitant 
fish 15 days before mortality was recorded in this group. Thus, 
the cohabitants were exposed to P. salmonis from one day before 
onset of the outbreak in the i.p. injected fish, suggesting that 
P. salmonis is excreted in numbers to reach the infective dose only 
a short period of time before fish death occurs. On the other hand, 
pathological changes such as pale focal nodes in the liver were 
detected by necropsy and HE-staining from 1 wpc. These early 
changes could be fibrin clots present in the organ, suggesting liver 
injury and/or disease, and the pathological findings present at later 
tempting to suggest that the bacteria were excreted by the i.p. fish 
already from the early stage of the challenge inducing an immune 
response in the cohabitant fish, thus explaining the longer incuba-
tion period observed in the cohabitation outbreak. The challenge 
dose of P. salmonis through the waterborne transmission route 
should in the future be elucidated by water samplings during chal-
lenge experiments. Piscirickettsia salmonis is described to secrete 
extracellular molecules that are suggested to cause tissue damage 
in fish (Rojas et al., 2013). A cytotoxic effect of the bacteria could 
explain the observed pathological changes in different organs be-
fore bacterial detection by qPCR or IHC. The bacterium may pro-
duce and secret toxins in remote tissues. In this case, toxins could 
have been secreted from the site of initial infection, for example 
the gut or the gills. Nevertheless, another possible explanation to 
the conflicting results may be the insufficient sensitivity of the 
methods to detect the bacteria.
Pathological changes were observed in all tissue analysed and pre-
viously been described in fish naturally and experimentally infected 
by P. salmonis. (Almendras et al., 2000; Fryer & Hedrick, 2003; Fryer 
et al., 1992; Mauel & Miller, 2002; Rozas-Serri et al., 2017; Yáñez et 
al., 2016). Also, and in accordance with the present results, it is well 
known that not all observed pathological signs are necessarily present 
in all diseased fish (Fryer & Hedrick, 2003; Mauel & Miller, 2002). The 
intermittent presence of the pathological changes could be explained 
by individual differences between fish and a low number of sampled 
fish that result in low representation of the fish population.
The authors of several previous studies of field cases have re-
ported the liver as the organ with most prominent tissue damage 
(Almendras et al., 2000; Arkush et al., 2005; Cvitanich, Garate, & 
Smith, 1990; Fryer & Hedrick, 2003; Mauel & Miller, 2002; Olsen 
et al., 1997; Rozas-Serri et al., 2017). In contrast, the study by 
Almendras et al. (2000) reported no gross lesions in the liver, which 
emphasizes the variation of pathological manifestations of piscir-
ickettsiosis. The necropsy results of this study reveal that the most 
affected tissue during early pathogenesis was the spleen presenting 
splenomegaly from 1 wpc in both challenge groups. Significant liver 
damages were observed later in the challenge experiment around 
and after onset of disease outbreak.
In this study, the qPCR protocol was not normalized to quantify 
P. salmonis DNA. For this reason, the results were only qualitative 
and a quantitative comparison of bacterial load in different tissues 
is not applicable. Piscirickettsia salmonis was detected in all types 
of examined tissues by qPCR and IHC confirming septicaemia. The 
qPCR and IHC results demonstrate that P. salmonis has a higher 
preference for several visceral organs such as liver, spleen and 
head kidney than for skeletal muscle tissue and plasma. Bacteria 
were present in spleen, head kidney and liver of the analysed fish 
as early as 1 wpc in the i.p. injected fish and in the head kidney 
of 50% of the analysed fish in the cohabitant fish 2 wpc. The ob-
served differences in tissue tropism between challenge models 
could strengthen the assumption about a dose-dependent patho-
genesis of piscirickettsiosis.
Presence of Piscirickettsia salmonis DNA detected by qPCR in different tissues after challenge by intraperitoneal injection or 
cohabitation
1 + + +
2 + + + + + + + +
3 n/a n/a n/a n/a n/a + + + +
n/a n/a n/a n/a n/a + + + + +
5 n/a n/a n/a n/a n/a + + + + +
Note
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This study contributes with information to understand the patho-
genicity of the bacteria under controlled conditions and reveals the 
bacterial tropism to the visceral organs (liver, spleen and head kid-
ney) instead of skeletal muscle and plasma.
This is to our knowledge, the first documentation available 
comparing two different challenge models against P. salmonis 
under controlled conditions. Cohabitation challenge is typically 
considered to be superior to challenge by i.p. injection with regard 
to mimicking natural infection. This study shows that there are 
only minor differences between the two different challenge mod-
els with respect to mortality, pathological and histopathological 
changes. The mortality onset is faster in i.p. challenge model most 
likely because the bacteria are injected directly to the individual 
fish making the bacterial load higher, resulting in a shorter trial 
with reduced operating expenses. At the same time, a lower num-
ber of fish (research animals) are needed for this type of challenge 
model, contributing to the ethical aspect of using research animals.
Further research is necessary not only to be able to understand 
the bacterial behaviour but at the same to have better control of 
the challenge models to test prophylactic measurements against 
piscirickettsiosis.
This project was funded by VESO and the Norwegian Research 
Council, Project number 258783. We would like to acknowledge 
all VESO Vikan staff for the technical support during the trial, and 
the histology laboratory staff at Department of Basic Sciences and 
Aquatic Medicine, NMBU for the technical support related to his-
tology and IHC. Duncan Colquhoun/NVI is acknowledged for pro-
viding the antibody for IHC. Thanks to Turhan Markussen, Elisabeth 
Furuseth Hansen, Simen Foyn Nørstebø, Aud Kari Fauske, Øystein 
Wessel and Cristian Bravo for valuable input.
The authors declare that they have no competing interests.
Karla Meza   
[SAG], S. n. a. y. g. (Producer). (2017). Productos biológicos inmunológi-
cos con registro provisional uso en salmónidos. Retrieved from http://
www.sag.gob.cl/sites/default/files/salmonidos_registro_provi-
sional_20-3-2017.pdf
[SERNAPESCA], S. n. d. p. y. a. (Producer). (2017). Informe sobre uso de 
antimicrobianos por la salmonicultura nacional año 2016.
[SERNAPESCA], S. n. d. p. y. a. (Producer). (2018). Informe sanitario de 
salmonicultura en centros marinos. Primer semestre 2018. Retrieved 
from http://www.sernapesca.cl/sites/default/files/informe_sani-
tario_salmonicultura_en_centros_marinos_1_semestre_2018.pdf
Almendras, F. E., & Fuentealba, I. C. (1997). Salmonid rickettsial septice-
mia caused by Piscirickettsia salmonis. Diseases of Aquatic Organisms, 
29
Almendras, F., Fuentealba, I., Jones, S., Markham, F., & Spangler, 
E. (1997). Experimental infection and horizontal transmission 
of Piscirickettsia salmonis in freshwater-raised Atlantic salmon, 
Salmo salar L. Journal of Fish Diseases, 20
Almendras, F. E., Fuentealba, I. C., Markham, R. F. F., & Speare, D. J. 
(2000). Pathogenesis of liver lesions caused by experimental infec-
tion with Piscirickettsia salmonis in juvenile Atlantic salmon, Salmo 
salar L. Journal of Veterinary Diagnostic Investigation, 12(6), 552–557. 
Arkush, K. D., McBride, A. M., Mendonca, H. L., Okihiro, M. S., Andree, K. 
B., Marshall, S., … Hedrick, R. P. (2005). Genetic characterization and 
experimental pathogenesis of Piscirickettsia salmonis isolated from 
white seabass Atractoscion nobilis. Diseases of Aquatic Organisms, 
63
Piscirickettsia salmonis: Characterization and infection in 
the zebrafish model. Oslo, Norway: University of Oslo.
Birkbeck, T. H., Griffen, A. A., Reid, H. I., Laidler, L. A., & Wadsworth, S. 
Piscirickettsia salmonis to high titers in insect tissue 
culture cells. Infection and Immunity, 72
Bravo, C., & Martinez, V. (2016). Whole-genome comparative analysis 
of the pathogen Piscirickettsia salmonis. Veterinary Microbiology, 196, 
Brocklebank, J. R., Evelyn, T. P., Speare, D. J., & Armstrong, R. D. (1993). 
Rickettsial septicemia in farmed Atlantic and chinook salmon in 
British Columbia: Clinical presentation and experimental transmis-
sion. The Canadian Veterinary Journal, 34
Cvitanich, J., Garate, O., & Smith, C. (1990). Etiological agent in a Chilean 
coho disease isolated and confirmed by Koch’s postulates. FHS/AFS 
Newsletter, 18, 1–2.
Dalum, A. S., Griffiths, D. J., Valen, E. C., Amthor, K. S., Austbø, L., 
Koppang, E. O., … Kvellestad, A. (2016). Morphological and func-
tional development of the interbranchial lymphoid tissue (ILT) in 
Atlantic salmon (Salmo salar L). Fish & Shellfish Immunology, 58, 153–
Dettleff, P., Bravo, C., Patel, A., & Martinez, V. (2015). Patterns of 
Piscirickettsia salmonis load in susceptible and resistant families of 
Salmo salar. Fish & Shellfish Immunology, 45(1), 67–71. https://doi.
org/10.1016/j.fsi.2015.03.039
Díaz, S., Rojas, M., Galleguillos, M., Maturana, C., Smith, P., Cifuentes, 
F., … Smith, P. (2017). Apoptosis inhibition of Atlantic salmon (Salmo 
salar) peritoneal macrophages by Piscirickettsia salmonis. Journal of 
Fish Diseases, 40(12), 1895–1902. https://doi.org/10.1111/jfd.12660
Evensen, Ø. (2016). Immunization strategies against Piscirickettsia salmo-
nis infections: Review of vaccination approaches and modalities and 
their associated immune response profiles. Frontiers in Immunology, 
7
Fryer, J., & Hedrick, R. (2003). Piscirickettsia salmonis: A Gram-negative 
intracellular bacterial pathogen of fish. Journal of Fish Diseases, 26(5), 
Fryer, J., Lannan, C., Garcés, L., Larenas, J., & Smith, P. (1990). Isolation 
of a rickettsiales-like organism from diseased coho salmon 
(Oncorhynchus kisutch) in Chile. Fish Pathology, 25
Fryer, J. L., Lannan, C. N., Giovannoni, S. J., & Wood, N. D. (1992). 
Piscirickettsia salmonis gen. nov., sp. nov., the causative agent of 
an epizootic disease in salmonid fishes. International Journal of 
Systematic and Evolutionary Microbiology, 42(1), 120–126. https://doi.
|MEZA ET AL.
Garcés, L. H., Larenas, J. J., Smith, P. A., Sandino, S., Lannan, C. N., & 
Fryer, J. L. (1991). Infectivity of a rickettsia isolated from coho salmon 
Oncorhynchus kisutch. Diseases of Aquatic Organisms, 11, 93–97. 
Karatas, S., Mikalsen, J., Steinum, T., Taksdal, T., Bordevik, 
M., & Colquhoun, D. (2008). Real time PCR detection of 
Piscirickettsia salmonis from formalin-fixed paraffin-embedded 
tissues. Journal of Fish Diseases, 31
Maisey, K., Montero, R., & Christodoulides, M. (2017). Vaccines for pis-
cirickettsiosis (salmonid rickettsial septicaemia, SRS): The Chile per-
spective. Expert Review of Vaccines, 16(3), 215–228. https://doi.org/1
Mauel, M., Giovannoni, S., & Fryer, J. (1999). Phylogenetic analysis of 
Piscirickettsia salmonis by 16S, internal transcribed spacer (ITS) and 
23S ribosomal DNA sequencing. Diseases of Aquatic Organisms, 35(2), 
Mauel, M. J., & Miller, D. L. (2002). Piscirickettsiosis and piscirickettsi-
osis-like infections in fish: A review. Veterinary Microbiology, 87
279–289. https://doi.org/10.1016/S0378-1135(02)00085-8
Navarro, L. (2018). Camanchaca slashes antibiotic use with live SRS vaccine. 
camanchaca-slashes-antibiotic-use-with-live-srs-vaccine?utm_
medium=email&utm_source=free_ar ticle_access&utm_con-
Olsen, A., Melby, H., Speilberg, L., Evensen, Ø., & Håstein, T. (1997). 
Piscirickettsia salmonis infection in Atlantic salmon Salmo salar in 
Norway-epidemiological, pathological and microbiological findings. 
Diseases of Aquatic Organisms, 31
dao031035
Otterlei, A., Brevik, Ø. J., Jensen, D., Duesund, H., Sommerset, I., Frost, 
P., … Apablaza, P. (2016). Phenotypic and genetic characterization 
of Piscirickettsia salmonis from Chilean and Canadian salmonids. 
BMC Veterinary Research, 12(55), 1–11. https://doi.org/10.1186/
s12917-016-0681-0
Rodger, H., & Drinan, E. (1993). Observation of a rickettsia-like or-
ganism in Atlantic salmon, Salmo salar L., in Ireland. Journal of Fish 
Diseases, 16
tb00869.x
Rojas, M., Galleguillos, M., Díaz, S., Machuca, A., Carbonero, A., & Smith, 
P. (2013). Evidence of exotoxin secretion of Piscirickettsia salmonis, 
the causative agent of piscirickettsiosis. Journal of Fish Diseases, 
36(8), 703–709. https://doi.org/10.1111/jfd.12019
Piscirickettsia 
salmonis in fish: A review. Journal of Fish Diseases, 37(3), 163–188. 
https://doi.org/10.1111/jfd.12211
Rozas-Serri, M., Ildefonso, R., Peña, A., Enríquez, R., Barrientos, S., & 
Maldonado, L. (2017). Comparative pathogenesis of piscirickett-
siosis in Atlantic salmon (Salmo salar L.) post-smolt experimentally 
challenged with LF-89-like and EM-90-like Piscirickettsia salmonis 
isolates. Journal of Fish Diseases, 40
org/10.1111/jfd.12671
Saavedra, J., Hernandez, N., Osses, A., Castillo, A., Cancino, A., Grothusen, 
H., … Bustamante, F. (2017). Prevalence, geographic distribution and 
phenotypic differences of Piscirickettsia salmonis EM-90-like isolates. 
Journal of Fish Diseases, 40(8), 1055–1063. https://doi.org/10.1111/
jfd.12581
Smith, P., Díaz, F., Rojas, M., Díaz, S., Galleguillos, M., & Carbonero, A. 
(2015). Effect of Piscirickettsia salmonis inoculation on the ASK con-
tinuous cell line. Journal of Fish Diseases, 38
Suvarna, K. S., Layton, C., & Bancroft, J. D. (2018). Bancroft's theory 
and practice of histological techniques e-book. Sheffield, UK: Elsevier 
Health Sciences.
Yáñez, J. M., Bangera, R., Lhorente, J. P., Barría, A., Oyarzún, M., Neira, 
R., & Newman, S. (2016). Negative genetic correlation between re-
sistance against Piscirickettsia salmonis and harvest weight in coho 
salmon (Oncorhynchus kisutch). Aquaculture, 459, 8–13. https://doi.
org/10.1016/j.aquaculture.2016.03.020
 Meza K, Inami M, Dalum AS, Bjelland 
AM, Sørum H, Løvoll M. Development of piscirickettsiosis in 
Atlantic salmon (Salmo salar L.) smolts after intraperitoneal 
and cohabitant challenge using an EM90-like isolate: A 





Comparative evaluation of experimental challenge by intraperitoneal injection 1 
and cohabitation of Atlantic salmon (Salmo salar L) after vaccination against 2 
Piscirickettsia salmonis (EM90-like).  3 
Running title: Evaluation of P. salmonis challenge models after vaccination. 4 
 5 
Karla Meza1,2, Makoto Inami1, Alf S. Dalum3, Hege Lund2, Ane M. Bjelland2, Henning Sørum2, Marie 6 
Løvoll1.   7 
1 VESO Vikan, Namsos, Norway  8 
2 Norwegian University of Life Sciences (NMBU), Faculty of Veterinary Medicine, Oslo, Norway 9 
3 Pharmaq Analytiq, Oslo, Norway 10 
* Corresponding author email address: karla.meza.parada@nmbu.no  11 
 12 
Acknowledgments  13 
This project was funded by VESO and the Norwegian Research Council, Project number 258783. 14 
We would like to acknowledge all VESO Vikan staff for the technical support during the trial. Duncan 15 
Colquhoun/ NVI is acknowledged for providing the antibody for IHC. Thanks to Aud Kari Fauske for 16 
technical support in the research vaccine’s production employed in this study. Thanks to Alexander 17 
Jaramillo, Simen Foyn Nørstebø, Elisabeth Furuseth Hansen, Stine Braaen, Anne Bakke, Ingvild Berg 18 
Nyman and Øystein Wessel for valuable inputs. 19 
 20 
Conflict of Interests 21 
The authors declare that they have no competing interests. 22 
 23 
Abstract 24 
The Chilean aquaculture has been challenged for years by piscirickettsiosis. A common prophylactic 25 
measurement to try to reduce the impact from this disease is vaccination, but the development of 26 
vaccines that induce satisfactory protection of the fish in the field has so far not been successful. 27 
Experimental challenge models are used to test vaccine efficacy. The aim of this study was to evaluate 28 
the performance of experimental vaccines after challenge by the two most widely used challenge 29 
routes; intraperitoneal injection and cohabitation. A total of 1120 Atlantic salmon  were vaccinated 30 
with non-commercial experimental vaccines with increasing amounts of an inactivated Piscirickettsia 31 
salmonis EM90-like isolate. Differences in mortality, macroscopic and microscopic pathological 32 
changes, bacterial load and immune gene expression were compared after challenge by different 33 
routes. The results revealed a similar progression of the diseases after challenge by both routes and 34 
no gross differences reflecting the efficacy of the vaccines could be identified. The analysis of the 35 
immune genes suggest a possible suppression of the cellular immunity by CD8 T-cell and with this 36 
stimulation of bacterial survival and replication. Comparative studies of experimental challenge 37 
models are valuable with regards to identifying the best model to mimic real-life conditions and 38 
vaccines’ performance.     39 
 40 
Keywords 41 
Piscirickettsia salmonis, Atlantic salmon, vaccines, cohabitation, intraperitoneal injection, challenge 42 
model.  43 
 44 
1. Introduction 45 
Chilean salmon industry has been challenged by piscirickettsiosis for almost 30 years (Almendras 46 
& Fuentealba, 1997; Mauel & Miller, 2002; Carril, Gómez, & Marshall, 2017) and, currently, the disease 47 
produce economical losses around USD 700 million yearly (Maisey, Montero, & Christodoulides, 48 
2017). Piscirickettsiosis has also been identified as the main reason for the use of 322.7 tons of  49 
antibiotics in Chile in 2018, where 95.5% was intended to treat this disease (SERNAPESCA, 2019). 50 
Several vaccines have been developed as a prophylactic measurement against Piscirickettsia salmonis, 51 
the etiological agent of piscirickettsiosis (Fryer, Lannan, Garcés, Larenas, & Smith, 1990; Garcés et al., 52 
1991), but commercial fish populations remain susceptible to outbreaks of piscirickettsiosis (Rozas & 53 
Enríquez, 2014; Otterlei et al., 2016; Maisey et al., 2017). There are currently 32 vaccines against P. 54 
salmonis registered by  the Chilean Agriculture and Livestock Service (SAG), of which 28 are inactivated 55 
vaccines, three are subunit vaccines and one is a live-attenuated vaccine (SAG, 2017). 56 
Piscirickettsia salmonis is a pleomorphic, non-motile, facultative intracellular Gram-negative 57 
bacterium (Almendras & Fuentealba, 1997; Marshall, Gómez, Ramírez, Nilo, & Henríquez, 2012; 58 
Henríquez et al., 2013; Vera, 2016). In addition to Chile, the bacterium has been detected in Canada 59 
(Brocklebank, Evelyn, Speare, & Armstrong, 1993), Scotland (Grant, Brown, Cox, Birkbeck, & Griffen, 60 
1996), Ireland (Rodger & Drinan, 1993) and Norway (Olsen, Melby, Speilberg, Evensen, & Håstein, 61 
1997). In Chile, different isolates of P. salmonis have been classified by genotyping into two main 62 
groups as LF89-like (Fryer, Lannan, Giovannoni, & Wood, 1992) and EM90-like (Mauel, Giovannoni, & 63 
Fryer, 1999). Due to the intracellular nature of the bacteria, the pathogenicity and the interaction with 64 
the immune system of the host has been difficult to understand.  65 
The efficacy of vaccines is typically evaluated by experimental challenge. The most commonly used 66 
challenge methods in fish are immersion, intraperitoneal injection or cohabitation with 67 
intraperitoneally injected shedder fish. Experimental challenge models that mimic real life conditions 68 
are essential to document the efficacy of vaccines, both for proof of concept studies as well as for 69 
release of vaccine batches with market authorization (Cowan, Smith, & Christofilogiannis, 2016; 70 
Midtlyng, 2016).  71 
The aim of this study was to compare the disease development and the protection afforded by 72 
experimental test vaccines against piscirickettsiosis after challenge through two of the most 73 
commonly used routes; by i.p. injection and by cohabitation. The results of the study will provide 74 
valuable input to the decision process when selecting the challenge model for documentation of the 75 
efficacy of vaccines against piscirickettsiosis. 76 
 77 
2. Materials and Methods 78 
2.1 Fish 79 
Experimental Atlantic salmon were produced at the VESO Vikan hatchery (Namsos, Norway). Fish 80 
were smoltified by manipulating the photoperiod using artificial light; six weeks of 12 hours light and 81 
12 hours darkness followed by six weeks of 24 hours light. A total number of 1232 Atlantic salmon 82 
with an average weight of 30 grams at vaccination were used. From the total number of fish, 112 were 83 
left unvaccinated and the rest were divided into five groups of 224 fish. The fish population was 84 
analyzed prior to vaccination and confirmed negative for specific antibodies against Aliivibrio 85 
salmonicida, Vibrio ordalii, Aeromonas salmonicida and Moritella viscosa (Norwegian Veterinary 86 
Institute (NVI), Oslo, Norway). Absence of P. salmonis, infectious pancreas necrosis virus (IPNV), 87 
infectious salmon anemia virus (ISAV), salmon pancreas disease virus (SPDV), piscine orthoreovirus 88 
(PRV) and piscine myocarditis virus (PMCV) was confirmed by qPCR (PatoGen, Ålesund, Norway). 89 
 90 
2.2 Bacterial cultivation 91 
A Piscirickettsia salmonis EM90-like isolate (VESO Vikan) originally isolated from a field outbreak in 92 
Atlantic salmon (Salmo salar L.) in 2004 (Calbuco, Los Lagos, Chile) was used for vaccine production 93 
and experimental challenge. This P. salmonis isolate was aerobically cultured from an ampule stored 94 
at -80°C in 10 mL of FN2 liquid medium (unpublished media, original recipe provided by FAVET-95 
INBIOGEN Universidad de Chile) with agitation (150 rpm) at 18°C for four days. A spectrophotometric 96 
analysis (Jenway 6300) was used to measure the density of the liquid bacterial culture. Possible 97 
contamination was evaluated by visual examination of the liquid culture under a phase contrast 98 
microscope. Furthermore, 100 μL of bacterial culture was plated on cysteine heart agar plates (CHAB) 99 
supplemented with bovine blood (Norwegian Veterinary Institute, Oslo, Norway) and on blood agar 100 
plates with bovine blood and 2% NaCl (Kystlab PreBio, Namsos, Norway). The CHAB plates were 101 
incubated aerobically at 18°C and the blood plates were incubated aerobically at 22°C, both for ten 102 
days. No bacterial colonies were observed on the blood agar plates. No bacterial colonies other than 103 
P. salmonis were observed on the CHAB plates.  104 
 105 
2.3 Test vaccines  106 
Test vaccines were developed in the Bacteriology laboratory at the Faculty of Veterinary Medicine, 107 
Norwegian University of Life Sciences (NMBU, Oslo, Norway). The bacterium, P. salmonis, EM90-like, 108 
was cultured in liquid medium FN2 at 18°C with agitation (150 rpm) for four days, followed by bacterial 109 
inactivation with 0.6% formaldehyde (Sigma-Aldrich, Darmstadt, Germany). A spectrophotometric 110 
analysis (Genesys 20, Thermo scientific) was used to measure the density of the liquid bacterial 111 
culture. Four vaccines (A-D) were developed with different concentrations of the target antigen 112 
Vaccines A, B, C and D contained 5, 3, 2 and 0.5 times (×) the concentration of the antigen, respectively. 113 
Vaccine E (control) consisted of a saline solution of 0.9% NaCl. The bacterin solution was thoroughly 114 
mixed with 50% Freund’s Incomplete adjuvant (Sigma) and stored at 4°C until vaccination. The 115 
vaccines were developed for experimental use only.    116 
 117 
2.4 Vaccination and experimental challenge  118 
The trial was approved by the Norwegian Animal Welfare Authority (ID 13703) and conducted at 119 
VESO Vikan research facility (Namsos, Norway). The fish were starved 48 hours prior to vaccination. 120 
The fish were sedated with 0.001% benzocaine chloride (Sykehusapoteket Oslo, Ullevål, Norway), 121 
marked by shortening of the maxilla and/or adipose fin and intraperitoneally injected with 0.1 mL of 122 
experimental vaccines A-E. The immunization period was seven weeks (735 day-degrees). The fish 123 
were acclimatized in brackish water (25‰) at 15°C for 14 days and starved for 48 hours prior to 124 
challenge. At day 0, fish were distributed into four identical tanks (tank 1, 2, 3 and 4) with a capacity 125 
of 1100 L and a stocking density not higher than 40 kg m-3. Tanks 1 (challenge by i.p. injection) and 2 126 
(challenge by cohabitation) were used for mortality registration with 35 fish per group. Tanks 3 127 
(challenge by i.p. injection) and 4 (challenge by cohabitation) were used for sampling, and each tank 128 
included 77 fish per group. Tanks with fish challenged by cohabitation included 20% shedders. 129 
Shedders were anesthetized with 0.001% benzocaine chloride. The bacterial inoculum dose for i.p. 130 
injected fish was obtained from a previous study elaborated by Meza et al. (2019), where a theoretical 131 
dose of 1.0 × 105 cfu mL-1 was used. The fish were kept in brackish water with a salinity of 25‰ at 15°C 132 
and 24 hours light. The fish were fed with a commercial diet (Skretting AS) twice a day. The fish were 133 
monitored daily, and mortality was registered. Fish in the terminal stage were euthanized with an 134 
overdose of benzocaine chloride and registered as dead. Bacteriological examination of dead fish was 135 
performed daily by inoculating head kidney samples on blood agar with 2% NaCl and incubation at 136 
22°C for 48 - 72 hours. 137 
Statistical analysis of mortality curves was executed by JMP® Pro (SAS Institute Inc.) program 138 
version 13.0.0. Survival analysis was performed by application of Log-rank (p < 0.05) and Wilcoxon test 139 
(p < 0.05).  140 
 141 
2.5 Sampling and necropsy 142 
Fish for sampling were selected randomly by netting from tank 3 and 4 and euthanized with an 143 
overdose of benzocaine chloride (0.002%). Six unvaccinated and 30 vaccinated fish (six fish per vaccine 144 
group (A-D) and six from control group (E)) were sampled prior to challenge on day 0. After challenge, 145 
samples were collected weekly (7, 14, 21, 28 and 35 dpc) by selection of six fish per group (A-E) per 146 
tank. 147 
 148 
2.5.1 Blood samples 149 
Blood samples were obtained immediately after euthanizing the fish and before the necropsy was 150 
performed. Blood was drawn from the dorsal vein (Vena caudalis) and/or dorsal artery (Aorta 151 
caudalis) by puncturing the fish lateroventrally behind the anal fins. Vacutainer® blood collection 152 
tubes containing ethylenediaminetetra-acetic acid (EDTA) anticoagulant were used (BD, New Jersey, 153 
USA). After sampling, the plasma was obtained by centrifugation of the tubes at 797 g at 4°C for 10 154 
minutes, followed by transfer to eppendorf tubes and storage at -80°C.    155 
 156 
2.5.2 Necropsy 157 
Necropsy was performed immediately after blood sampling. The pathological changes were 158 
classified as ascites (A), pale focal nodes in the liver (PFNL), swollen kidney (SK), splenomegaly (SP), 159 
hemorrhages in the digestive tract (HDT), distended ventricle with gelatinous content (DV/GC) and 160 
general hemorrhages (GH). The pathological changes were registered as percentage of the occurrence 161 
among the six sampled fish per group. 162 
 163 
2.5.3 Tissue samples  164 
Tissue samples were dissected from the spleen, liver and head kidney. The samples for real-time 165 
quantitative PCR (qPCR) were submerged in RNAlater® (Sigma-Aldrich) and stored at 4°C overnight, 166 
followed by -20°C until DNA extraction. Samples for immunohistochemistry and histology were fixated 167 
in 4% formaldehyde for 24 hours followed by transfer to 70% ethanol and storage at 4°C. 168 
 169 
2.6 Histology and Immunohistochemistry  170 
All sampled fish (n=209) were subjected to histological and immunohistochemical analysis at 171 
Pharmaq Analytiq (Oslo, Norway). Formalin-fixed samples from liver, head kidney and spleen were 172 
processed for histological analysis and immunohistochemistry according to standard procedure 173 
(Suvarna, Layton, & Bancroft, 2018). For haematoxylin and eosin- staining (HE), paraffin-embedded 174 
tissues were sectioned at 2 μm thickness. HE-sections were evaluated in a blinded manner by two 175 
independent scientists with a scoring system from 0 to 3. The criteria for scoring the samples are 176 
shown in Table 1. After scoring the samples, the average of both values was calculated. Only 177 
representative samples from each score were evaluated by immunohistochemistry (IHC). For IHC, 178 
tissues were sectioned at 4 μm thickness and mounted on poly-L-lysine-coated slides (KF FROST, VWR 179 
International BV, Amsterdam, The Netherlands). Protocol for immunohistochemistry was adapted 180 
from Dalum et al. (2016) including a primary antibody against P. salmonis (provided by Duncan 181 
Colquhoun, Norwegian veterinary institute (NVI)). The slides were incubated at 58°C overnight prior 182 
to deparaffinization in xylene. Heat induced epitope retrieval was performed at 121°C for 10 minutes 183 
in 0.01 M citrate buffer, pH 6, followed by washing in 0.01 M phosphate-buffered saline (PBS, pH 7.3). 184 
The sections were incubated for 40 minutes at 37°C in pre-heated PBS with 0.05% phenyl-hydrazine 185 
(Aldrich chemistry, MO, USA) followed by washing with PBS. Slides were blocked with a solution of 186 
0.05 M tris-buffered saline (TBS, pH 7.6) with 0.2% goat normal serum and 5% bovine serum albumin 187 
(BSA) for 20 minutes. The primary polyclonal rabbit antibody was diluted 1:40 000 in TBS with 1% BSA. 188 
The antibody was labelled with polymer-HRP anti-rabbit (Dako EnVision + System-HRP) and developed 189 
with 3-amino-9-ethyl carbazol (AEC) producing a red staining when reacting with tissue-bound primary 190 
antibody. Counterstaining was performed with haematoxylin followed by washing in distilled water. 191 
A descriptive observation was performed.  192 
 193 
Table 1. Score system for haematoxylin-eosin slides.  194 
 195 
2.7 DNA extraction and qPCR 196 
A total of 627 samples were analyzed for bacterial DNA by quantitative PCR (qPCR). Out of these, 197 
18 tissue samples were from unvaccinated fish, and 609 tissue samples were from vaccinated fish (90 198 
from unchallenged fish, 144 from i.p. injected fish and 375 from cohabitant fish). Tissue samples were 199 
weighed in OHAUS® Analytical plus (Sigma-Aldrich) scale, before they were homogenized using sterile 200 
steel beads (5 mm) and TissueLyzer II (Qiagen) for 15 seconds at 25 Hz, followed by incubation with 201 
protein kinase (Qiagen) at 56°C overnight. The DNA extraction was performed using QIAcube and 202 
QIAGEN DNeasy® Blood & tissue kit (Qiagen) according to the manufacturer’s protocol. The DNA 203 
concentration was measured using NanodropTM ND-1000 spectrophotometer (Thermo Scientific) and 204 
diluted to a concentration of 20 ng/μl. Primer and probe sequences targeting P. salmonis were 205 
obtained from Meza et al. (2019). Primer sequences were 5’-AGG GAG ACT GCC GGT GAT A-3’ for 206 
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forward primer and 5’-ACT ACG AGG CGC TTT CTC A-3’ for the reverse primer. The probe sequence 207 
was 5'-TCG CTC CAC ATC GC-3'. 208 
Each qPCR reaction contained 10 μL TaqMan qPCR Supermix, 300 nM of specific forward and 209 
reverse primer, 100 nM of a specific probe and 60ng DNA template in a total volume of 20 μL. The 210 
qPCR thermal profile started with 10 min denaturation at 95°C followed by 40 cycles applying a melting 211 
point at 95°C for 15 seconds, annealing and elongation at 58°C for 45 seconds. Samples were analyzed 212 
in triplicate. Results with Ct values above 35 were considered negative.  213 
For normally distributed data, a two-way ANOVA test (p < 0.05) was performed, and for non-214 
normally distributed data, a Kruskal-wallis test (p < 0.05) was performed. Statistical analysis was 215 
executed by JMP® Pro (SAS Institute Inc.) program version 13.0.0.  216 
 217 
2.8 RNA extraction and reverse transcription qPCR (RT-qPCR) 218 
A total of 209 spleen samples (36 from unchallenged fish, 48 from fish challenged by i.p. injection 219 
and 125 from fish challenged by cohabitation) were analyzed for immune gene expression by RT-qPCR. 220 
Tissue samples were weighed in OHAUS® Analytical plus (Sigma-Aldrich) scale. Qiazol lysis reagent 221 
(Qiagen) was added in a volume of 650 μL before the tissue was homogenized using sterile steel beads 222 
(5 mm) and TissueLyzer II (Qiagen) for 5 min at 25 Hz. After the disruption of the tissue, 130 μL of 223 
chloroform was added followed by vigorous shaking by hand for 15 seconds. Samples were incubated 224 
at room temperature (RT) for 2-3 min and centrifuged at 12000 g for 15 min at 4°C. The aqueous phase 225 
was transferred to a clean tube, and the RNA extraction was performed using QIAcube and QIAGEN 226 
RNeasy® mini kit (Qiagen) according to the manufacturer’s protocol. The quality of the RNA was 227 
measured using NanodropTM ND-1000 spectrophotometer (Thermo Scientific). After the RNA 228 
extraction, cDNA was prepared with QuantiTect® Reverse Transcription kit (Qiagen) according to the 229 
manufacturer’s protocol.  230 
Primer sequences targeting the immune genes sIgM, mIgM, CD8α and CD4-1 as well as the 231 
reference gene EF1αβ were obtain from previous studies and are listed in Table 2.  232 
Each reaction contained 10 μL Maxima SYBR Green Supermix (Thermo scientific), 300 nM of 233 
forward and reverse primer for the reference gene, 450 nM of forward and reverse primer of target 234 
gene and 15 ng cDNA template in a total volume of 20 μL. The qPCR thermal profile started with 2 min 235 
UDG pre-treatment at 50°C followed by initial denaturation of 10 min at 95°C. This was followed by 236 
denaturation at 95°C for 15 seconds and annealing and extension at 60°C for 60 seconds were applied 237 
for 40 cycles. Samples were analyzed in duplicates. Results with Ct values above 35 were considered 238 
negative. The Ct-values were normalized to the expression of the reference gene EF1αβ. 239 
For the statistical analysis, the mean normalized expression of the target genes was calculated from 240 
raw Ct values by relative quantification. Kruskal-wallis test (p < 0.05) was performed due to the non-241 
normally distributed data. Statistical analysis was executed by JMP® Pro (SAS Institute Inc.) program 242 
version 13.0.0. 243 
 244 
Table 2. Genes to be quantified by RT-qPCR and the corresponding primer sequences. 245 
Gene    Sequence Reference 




Forward 5’-CCTACAAGAGGGAGACCGA-3’ Iliev, Thim, Lagos, Olsen, and 




Forward 5’- CTACAAGAGGGAGACCGGAG-3’ 
Iliev et al. (2013) Reverse 5’- AGGGTCACCGTATTATCACTAGTTT -3’ 
CD8α Forward 5’-CGTCTACAGCTGTGCATCAATCAA-3’ Grove et al. (2013) 
Reverse 5’-GGCTGTGGTCATTGGTGTAGTC-3’ 
CD4-1  Forward 5’-GAATCTGCCGCTGCAAAGAC-3’ Tadiso et al. (2011) Reverse 5’-AGGGATTCCGGTCTGTATGATATCT-3’ 
 246 
2.9 Bead based multiplex immunoassay 247 
2.9.1 Antigens and bead coupling  248 
Piscirickettsia salmonis EM90-like was cultured in 10 mL of FN2 medium for four days at 18°C and 249 
with agitation (150 rpm), after this period the culture was diluted until the concentration reached 250 
OD600nm = 1.0.  The bacterial culture was centrifuged at 2500 g at 4°C for 10 min, followed by 251 
resuspension of the bacterial pellet in 5 mL of physiological saline. The inactivation of P. salmonis was 252 
performed by the addition of formalin (0.6%). Samples were kept on ice and sonicated at 40 Hz for 6 253 
× 20 seconds. For detection of specific antibodies, P. salmonis whole cell sonicate was coupled to 254 
distinct MagPlex® -C Microspheres (Luminex Corp. Austin, TX, USA) according to the manufacturer’s 255 
protocol using the Bio-Plex® amine coupling kit (Bio-Rad) and as previously described (Lund et al., 256 
2019). Briefly, 1× scale of stock beads at a concentration of 1.25 × 106 were washed in wash buffer 257 
using a magnetic separator and resuspended in bead-activation buffer. Beads were activated by 258 
addition of N-Hydroxysulfosuccinimide sodium salt and N-(3-Dimethylaminopropyl)-N’-ethylcarbid 259 
(Sigma-Aldrich) prepared in bead-activation buffer and incubated for 20 min at RT and at constant 260 
rotation. Beads were protected from light at all times. Following bead activation, a range of 261 
concentrations of the P. salmonis whole cell sonicate varying between 3 μg and 12 μg were coupled 262 
onto beads of different bead regions. After incubation for 2 hours (RT, constant rotation), beads were 263 
washed twice in PBS, resuspended in blocking buffer and incubated for 30 min (RT, constant rotation). 264 
After blocking, beads were washed and re-suspended in storage buffer and kept at 4°C in the dark 265 
until used. The bead concentrations were determined using Countess™ automated cell counter 266 
(Invitrogen). 267 
 268 
2.9.2 Multiplex immunoassay 269 
To determine the optimal P. salmonis’ antigen concentration for bead conjugation, beads coupled 270 
with a range of antigen concentrations varying between 3 μg and 12 μg were tested against different 271 
samples included in the study. Optimal sample dilutions were established by initial titrations of 272 
positive (vaccinated fish 7 weeks post vaccination (wpv), n = 4) and negative (unvaccinated fish, n = 4) 273 
pooled plasma in serial two-fold dilutions. Dilutions providing assay readout values falling between 274 
the upper and lower detection limit of the assay were chosen.  275 
Piscirickettsia salmonis coupled beads were diluted in assay buffer consisting of PBS with 0.5% BSA 276 
(Rinderalbumin; Bio-Rad Diagnostics GmbH, Dreieich, Germany) and 0.05% azide (Merck, Darmstadt, 277 
Germany), and 5000 beads per region were added to each well on Bio-Plex® Pro™ Flat Bottom Plates. 278 
Beads coupled with antigens not included in the vaccination and challenge trial, the A-layer protein 279 
from Aeromonas salmonicida subsp. salmonicida and Moritella viscosa whole cell sonicate (Lund et 280 
al., 2019), were included in all wells. Beads were washed three times with 200 μL assay buffer for 30 281 
seconds in the dark and on a shaker at 800 rpm, then kept for 120 seconds in a BioPlex handheld 282 
magnetic washer before the supernatant was poured off. Plasma samples were diluted 1:100 in assay 283 
buffer, before 50 μL sample was added to each well and in duplicates. Positive and negative plasma 284 
pools in duplicates or triplicates were included on every plate, together with antibody controls and 285 
blanks (wells added assay buffer instead of sample). The plate was incubated for 30 min at RT in the 286 
dark and on a shaker at 800 rpm. All subsequent incubation and washing steps were performed 287 
similarly. Following incubation, beads were washed, and all wells were added Anti Salmonid-IgH 288 
monoclonal antibody (1:400, clone IPA5F12, Cedarlane, Burlington, Ontario, Canada). After incubation 289 
and washing, biotinylated goat Anti-Mouse IgG2a antibody (1:1000, Southern Biotechnology 290 
Association, Birmingham, AL, USA) was added to each well, and finally, after incubation and washing, 291 
Streptavidin-PE (1:50, Invitrogen) was applied. After the final incubation, beads were washed and 292 
suspended in assay buffer. Plates were analyzed using a Bio-Plex® 200 in combination with Bio-Plex® 293 
Manager 5.0 software (Bio-Rad). The reading was carried out using a low PMT target value, the DD-294 
gate was set to 5000-25000, and 100 beads from each region were read in each well. Each bead is 295 
classified by its signature fluorescent pattern and then analyzed for the mean fluorescence intensity 296 
(MFI) of the reporter molecule.  297 






3 Results 304 
3.1 Mortality and challenge data 305 
The mortality curves of the i.p. challenge model and cohabitation challenge model revealed similar 306 
mortality rates, however different incubation periods and outbreak durations (Figure 1). After i.p. 307 
challenge, the first fish mortality was recorded in the saline injected control group E at 11 dpc, 308 
followed by outbreaks in vaccine group D (12 dpc) and group A, B and C (13 dpc). The incubation period 309 
after challenge by cohabitation was calculated from the time mortality occurred in shedder fish (9 310 
dpc) until mortality occurred in the cohabitant fish. After cohabitation challenge, vaccine group B and 311 
control group E demonstrated the shortest incubation period with 15 days (24 dpc) followed by 312 
vaccine group C and D (16 days, 25 dpc) and vaccine group A (17 days, 26 dpc).  313 
The disease outbreak lasted from two to five days with an average of 3.8 days after i.p. challenge, 314 
and from six to nine days with an average of eight days after challenge by cohabitation. All fish groups 315 
irrespective of challenge model and vaccine group reached 100% mortality with the exception of 316 
vaccine group A after i.p. challenge where three fish were humanely sacrificed the last day of challenge 317 
due to severe symptoms of disease.  318 
After i.p. challenge, vaccine group D and control group E reached 100% mortality on 14 dpc, 319 
followed by vaccine group B (17 dpc) and vaccine group C (18 dpc). After challenge by cohabitation, 320 
vaccine group D reached 100% mortality six days after onset of outbreak (6 days, 31 dpc), followed by 321 
control group E (7 days, 31 dpc), vaccine group B (9 days, 33 dpc), vaccine group C (9 days, 34 dpc) and 322 
vaccine group A (9 days, 35 dpc). One fish from control group E died at 13 dpc. Microbiological 323 
examination did not reveal any bacteria including P. salmonis.  324 
The mortality curves of each group were compared with the mortality curve of control group E 325 
(saline). After i.p. challenge, there was a significant difference in all the groups in relation with control 326 
group E, in contrast with the cohabitation challenge model where there was significant difference in 327 
vaccine group A and B in comparison with control group E (Figure 1C). Mortality curves are shown in 328 
Figure 1A and Figure 1B.  329 
 330 
Figure 1. Cumulative mortality after a) intraperitoneal injection challenge and b) cohabitation 331 
challenge against P. salmonis. Challenge by IPCM was terminated according to humane endpoint 332 
criteria at 91.4% mortality in group A. c) The table shows p values of vaccine group A, B, C, and D 333 
compared with control group (E), where p values < 0.05 were presented as (*), < 0.001 were presented 334 
as (**) and < 0.0001 were presented as (***). n.s. = not significant. IPCM = intraperitoneal challenge 335 
model, CCM = cohabitation challenge model. 336 
 337 
3.2 Pathological changes 338 
After i.p. challenge, fish from all groups were sampled at 1 wpc, however relatively few pathological 339 
findings were detected at this time point. Ascites was found in 50% (3/6) and 17% (1/6) of the fish in 340 
control group E and vaccine group A, respectively, and splenomegaly was identified in 33% (2/6) of 341 
the fish in vaccine group D. General hemorrhages were detected in 33% (2/6) of the sampled fish in 342 
vaccine group A and C, and in 17% (1/6) of the fish in vaccine group B and control group E. 343 
At 2 wpc, only fish from vaccine group A, B and C were sampled due to 100% mortality in vaccine 344 
group D and control group E. All sampled fish in all examined groups presented ascites, pale focal 345 
nodes in the liver, swollen kidney and splenomegaly at this sampling point. Necropsy detected 346 
hemorrhages in the digestive tract more frequently in sampled fish of vaccine group C (83% (5/6)) 347 
compared to vaccine group A and B (67% (4/6)). Similarly, fish with distended ventricle with gelatinous 348 
content were detected more frequently in vaccine group C (67% (4/6)) followed by fish in vaccine 349 
group A (33% (2/6)) and less frequently in vaccine group B (17% (1/6)). General hemorrhages were, in 350 
contrast, more often detected in sampled fish of vaccine group A (67% (4/6)) compared to sampled 351 
fish of vaccine group B and C (33% (2/6)).   352 
Fish from all groups were sampled at 1 to 5 weeks after challenge by cohabitation. The severe 353 
pathological changes reported at 5 wpc reflects that the mortality curve of all groups reached 100% 354 
at the sampling date. One of the first reported pathological changes in this challenge model were 355 
hemorrhages in the digestive tract. In fact, this pathological sign was observed at an earlier time point 356 
in the cohabitation model (1 wpc) compared to the i.p. model (2 wpc). Also, a tendency of a dose-357 
response relationship between pathology and vaccine dose was shown; hemorrhages in the digestive 358 
tract were reported in 17% (1/6) of the sampled fish in vaccine group D and control group E at 1 wpc, 359 
followed by 33% (2/6) of the sampled fish in vaccine group B, D and control group E at 2 wpc, and in 360 
17% (1/6) of the sampled fish in vaccine group D at 3 wpc. General hemorrhages were also detected 361 
early in the disease development however only in sampled fish of vaccine group A (17% (1/6)) at 1 362 
wpc and in no sampled fish regardless of group at 2 wpc. At 3 wpc, these pathological changes were 363 
more frequently identified in sampled fish of vaccine group A (67% (4/6)) compared to examined fish 364 
of vaccine group B, C, control group E (17% 1/6)) and vaccine group D (0/6). Splenomegaly was 365 
reported in sampled fish of vaccine group B at 1 wpc (17% (1/6)). However, splenomegaly was not 366 
detected at 2 and 3 wpc. Similarly, ascites was present in 17% (1/6) of the fish in control group E at 2 367 
wpc, but not detected in any groups at 3 wpc. 368 
From 4 wpc, swollen kidney, splenomegaly and distended ventricle was detected in all sampled fish 369 
in all groups. Hemorrhages in the digestive tract were also a dominating finding at this time point; in 370 
all examined fish of vaccine group A, B, C and control group E (100% (6/6)), and 83% (5/6) of the 371 
sampled fish of vaccine group D. Similarly, pale focal nodes in the liver were identified in 100% (6/6) 372 
of fish in vaccine group C and control group E, and 83% (5/6) of the fish of vaccine group A, B and D. 373 
In contrast to the i.p. challenge model, a dose-response relationship between the vaccine antigen and 374 
development of ascites was observed at 4 wpc by the cohabitation model. This pathological sign was 375 
present in all sampled fish of control group E (100% (6/6)), in 83% (5/6) for vaccine group C and D, 376 
67% (4/6) for vaccine group B and 50% (3/6) for vaccine group A at this time point. General 377 
hemorrhages were the least frequent finding at 4 wpc and only present in 33% (2/6) of the fish of 378 
vaccine group B and D, and in 17% (1/6) of the sampled fish in vaccine group A, C and control group E. 379 
Despite no bacterial challenge, 17% (1/6) of the control fish in vaccine group D presented ascites. 380 
Also, pale focal nodes were found in 17% (1/6) of unvaccinated (UV) fish at 0 wpc. All vaccinated fish 381 
that were examined showed adherences and melanosis in the abdomen (results are not shown). The 382 
presence of pathological changes after challenge is shown in Figure 2.  383 
Figure 2. Pathological changes after challenge by i.p. injection or cohabitation against P. salmonis. The 384 
frequency (%) was measured as percentage of the sampled fish that showed pathological changes 385 
where 100% corresponded to n = 6. A: vaccine A (5×), B: vaccine B (3×), C: vaccine C (2×), D: vaccine D 386 
(0.5×) and E: saline. IPCM = intraperitoneal challenge model, CCM = cohabitation challenge model. 387 
 388 
3.3 Histology  389 
The average of HE-scoring in liver, spleen and head kidney from fish challenged by i.p. injection or 390 
cohabitation is shown in Figure 3. The results demonstrate an increment of the histopathological 391 
changes throughout time after challenge by both routes. 392 
In the unchallenged fish, significant differences in average HE-scoring of liver were found when 393 
comparing UV fish with vaccine group B (p = 0.0081), vaccine group D (p = 0.0081) and control group 394 
E (p = 0.0269). In spleen there was significant difference when control group E was compared with 395 
vaccine group A (p = 0.0067), vaccine group B (p = 0.0341) and UV fish (p = 0.0067) being control group 396 
E with the highest HE-score.   397 
After i.p. challenge, no significant difference in histopathological changes in liver, spleen and head 398 
kidney were observed between the groups at each time point. The highest average HE-score for the 399 
i.p. challenged fish in the liver (2.5), spleen (2.2) and head kidney (2.1) was found in group C at 2 wpc. 400 
After challenge by cohabitation, significant differences were found when comparing HE-scores in 401 
liver of un-vaccinated fish with vaccine group A (p = 0.0379) and B (p = 0.0145) at 1 wpc, control group 402 
E presented the lowest HE-score. Significant differences were also identified when comparing vaccine 403 
group B with vaccine group A (p = 0.0289), vaccine group D (p = 0.0203) and vaccine group C (p = 404 
0.0289) at 3 wpc; vaccine group B presented the lower HE-score. At 4 wpc, significant differences in 405 
HE-scores of head kidney were found when comparing vaccine group A (p = 0.0034), vaccine group B 406 
(p = 0.0031) and vaccine group C (p = 0.0096) with control group E, and when vaccine group C was 407 
compared with vaccine group D (p = 0.0236). The highest average scores for the cohabitation model 408 
in the liver (2.8) was found at 5 wpc in vaccine group C (morbid fish). In the spleen (2.3) the highest 409 
average score was obtained in vaccine group D and in head kidney (2.6) it was obtained in group E at 410 
4 wpc.  411 
Significant difference between challenge models was only identified in spleen when comparing 1 412 
wpc by i.p. injection with 3 wpc by cohabitation (p = 0.0448).  413 
Figure 4, Figure 5 and Figure 6 illustrate examples of the HE-scoring (A-D) and their corresponding 414 
IHC staining targeting P. salmonis (E-H) to demonstrate the bacterial distribution in relation with the 415 
tissue lesions (score).  416 
Figure 3. Average of HE-scoring per tissue samples from fish challenged by intraperitoneal injection 417 
and cohabitation against P. salmonis. UV: unvaccinated fish, A: vaccine A (5×), B: vaccine B (3×), C: 418 
vaccine C (2×), D: vaccine D (0.5×) and E: control (saline). IPCM = intraperitoneal challenge model, CCM 419 
= cohabitation challenge model.  420 
Figure 4. Histopathological manifestation of infection with P. salmonis in the liver. (A) and (E) 421 
represents negative controls of un-challenged fish. (B) Score 1; Changes dominated by focal 422 
inflammation, where only slight numbers of bacteria are seen (F). (C) Score 2; Focal changes consisting 423 
of a combination of inflammation and necrosis, where moderate numbers of bacteria are seen (G). 424 
(D) Score 3; Focal changes consisting of central necrosis surrounded by inflammation and necrosis, 425 
where extensive numbers of bacteria are seen particularly at the margins of the lesions (H). A-D; 426 
haematoxylin and eosin staining, scale bar 100 m. E-H; immunohistochemistry targeting P. salmonis 427 
(red reaction), scale bar 50 m. 428 
 429 
Figure 5. Histopathological manifestation of infection with P. salmonis in the head kidney. (A) and (E) 430 
represents negative controls of un-challenged fish. (B) Score 1; Changes dominated by mild, diffuse 431 
inflammation, congestion and partly disrupted tissue architecture, where only slight numbers of 432 
bacteria are seen in a random fashion throughout the tissue (F). (C) Score 2; In addition to changes as 433 
seen for score 1, focal changes consisting of a combination of inflammation and necrosis, where 434 
moderate numbers of bacteria are seen particularly in the focal changes (G). (D) Score 3; In addition 435 
to changes as seen for score 1, focal changes consisting of central necrosis surrounded by 436 
inflammation and necrosis, where extensive numbers of bacteria are seen throughout the lesions (H). 437 
A-D; haematoxylin and eosin staining, scale bar 100 m. E-H; immunohistochemistry targeting P. 438 
salmonis (red reaction), scale bar 50 m. 439 
 440 
Figure 6. Histopathological manifestation of infection with P. salmonis in the spleen. (A) and (E) 441 
represents negative controls of un-challenged fish. (B) Score 1; Changes dominated by mild, diffuse 442 
inflammation, mild congestion and partly disrupted tissue architecture, where only slight numbers of 443 
bacteria are seen in a random fashion throughout the tissue (F). (C) Score 2; In addition to changes as 444 
seen for score 1, single cell necrosis is seen throughout the tissue, where moderate numbers of 445 
bacteria are seen at highest numbers in necrotic cells as well as lower numbers of bacteria dispersed 446 
throughout the tissue. (G). (D) Score 3; In addition to changes as seen for score 1 and 2, focal changes 447 
consisting of necrosis with complete disruption of tissue architecture, where extensive numbers of 448 
bacteria are seen throughout the lesions as well as lower numbers of bacteria dispersed throughout 449 
the tissue. (H). A-D; haematoxylin and eosin staining, scale bar 100 m. E-H; immunohistochemistry 450 
targeting P. salmonis (red reaction), scale bar 50 m. 451 
 452 
3.4 Bacterial DNA qPCR 453 
The detection of P. salmonis bacterial DNA in all visceral tissues is shown in Figure 7. No bacterial 454 
DNA was detected in unvaccinated fish and fish sampled at time point 0. After challenge by i.p. 455 
injection, bacterial DNA was detected in all groups at week 1 post challenge (wpc) in liver, head kidney 456 
and spleen. After challenge by cohabitation, P. salmonis was detected as early as 2 wpc in liver (vaccine 457 
group A, C and D) and spleen (vaccine group B, C and control group E). The bacterium was not 458 
identified in head kidney until 3 wpc (all groups). The highest concentration of P. salmonis was 459 
identified in the liver at 2 wpc by i.p. injection with a Ct value of 17.5. After challenge by cohabitation, 460 
the highest bacterial concentration was recorded in liver at 4 wpc with a Ct value of 19.4.  461 
In the fish challenged by i.p. injection, the liver did not present significant differences in the 462 
bacterial load. In the spleen at 1 wpc significant differences was detected demonstrating that vaccine 463 
group D presented higher bacterial load than vaccine group A and vaccine group C, and control group 464 
E higher than vaccine group A. In the head kidney there was also a significant difference between 465 
groups at 1 wpc where control group E presented a higher bacterial load compared with the rest of 466 
the groups. Furthermore, vaccine group D had a higher bacterial load compared with vaccine group A. 467 
These differences suggest a vaccine dose-response between the groups (Supplementary table 1). No 468 
significant differences were detected between groups at 2 wpc.  469 
After challenge by cohabitation, no significant differences were detected between groups in liver, 470 
spleen and head kidney at 1 wpc, 2 wpc, 3 wpc and 4 wpc. Significant differences in bacterial DNA load 471 
were identified by comparing samples from the two challenge models before (1 wpc by i.p. injection 472 
versus 3 wpc by cohabitation) and after (2 wpc by i.p. injection versus 4 wpc by cohabitation) onset of 473 
the disease outbreak. In liver, there was a significant difference in bacterial load before (p = 0.0382) 474 
and after (p = 0.0428) the outbreak. In spleen, there was a significant difference in the bacterial load 475 
just before (p = 0.0011) the onset of the outbreak. In head kidney, no difference between the 476 
challenge models was detected before and after the outbreak.  477 
Figure 7. Average of Ct value for P. salmonis bacterial DNA per group and tissue after i.p. challenge 478 
and cohabitation challenge. UV: unvaccinated fish, A: vaccine A (5×), B: vaccine B (3×), C: vaccine C 479 
(2×), D: vaccine D (0.5×) and E: control (saline). IPCM = intraperitoneal challenge model, CCM = 480 
cohabitation challenge model. 481 
 482 
3.5 Expression of selected immune gene transcripts 483 
The fish immune response against P. salmonis was analyzed by measuring the expression level of 484 
immune genes transcripts encoding the T cell markers (CD8 and CD4) (Medzhitov, 2007) and two 485 
genes related to humoral immunity (membrane bound (m) IgM and soluble (s) IgM). IgM has been 486 
described as part of the response to systemic infection (Adams, Thompson, & Roberts, 2016). mIgM 487 
is bound to B cells serving as antigen specific receptors and sIgM is produced by plasma cells and 488 
secreted in body fluids (Gao et al., 2014). The immune genes were analyzed in samples from spleen 489 
tissue due to previous reports of this organ’s high expression of CD4 in Atlantic salmon (Moore, 490 
Dijkstra, Koppang, & Hordvik, 2009).  491 
The mIgM expression was consistent throughout the time points in both challenge models. The 492 
expression of sIgM, however, showed more variation throughout the infection. The expression of 493 
CD8α showed a trend towards reduced expression after challenge through both administration routes, 494 
but particularly in fish challenged by cohabitation. CD4-1 expression increased during the weeks after 495 
challenge for both challenge models.  496 
A tendency of a dose response was observed in the expression of sIgM and CD8α at 2 wpc after i.p. 497 
challenge. In both cases the dose-response was reflected by a higher expression in vaccine group A 498 
and lower in vaccine group C (Figure 8).  499 
After i.p. challenge, no significant differences were found between vaccine groups in mIgM 500 
expression at 1 and 2 wpc. Significant differences were, however, found in sIgM expression when 501 
comparing vaccine group A and vaccine group C where the highest expression were demonstrated in 502 
vaccine group C at 2 wpc. The expression of CD8α was less pronounced in control group E compared 503 
with vaccine group B, C and D at 1 wpc. At 2 wpc, vaccine group A showed significant higher CD8α 504 
expression compared to vaccine group C (Supplementary table 2).  505 
After challenge by cohabitation, mIgM expression was significant different between groups at 3 506 
wpc, demonstrating higher expression level in vaccine group A and control group E when compared 507 
to vaccine group B, C and D. At 3 wpc, sIgM expression level was significant higher for control group E 508 
compared to vaccine group B, C and D. Similar results were observed for vaccine group A compared 509 
to vaccine group B, C and D. At 4 wpc, the expression of sIgM was significant higher for vaccine group 510 
B compared to vaccine group D. No significant differences were observed in the expression of CD8α 511 
and CD4-1 between groups at any time point (Supplementary table 2).  512 
Before challenge, significant differences in the expression of sIgM (p = 0.0351) and CD8α (p < 513 
0.0001) were identified between challenge models. The immune gene expression profiles are shown 514 
in Figure 8. 515 
Figure 8. Relative gene expression of mIgM, sIgM, CD8α and CD4-1 in spleen after challenge of Atlantic 516 
salmon with P. salmonis by i.p. injection or cohabitation. The gene expression levels are shown in fold 517 
change compared with EF1αβ. The fish were vaccinated 7 weeks prior to challenge with vaccines A-E 518 
where vaccine A (5×), vaccine B (3×), vaccine C (2×), vaccine D (0.5×) and vaccine E (saline) (n = 6). 519 
IPCM = intraperitoneal challenge model, CCM = cohabitation challenge model.   520 
 521 
3.6 Multiplex immunoassay 522 
To determine the optimal antigen concentration for bead conjugation in the immunoassay, a range 523 
of concentrations of the inactivated and the non-inactivated P. salmonis whole cell sonicate ranging 524 
from 3 to 12 μg per 1× scale beads were tested against different samples included in the study.  525 
Inactivated P. salmonis whole cell sonicate at an amount of 6 μg per 1× scale coupling reaction was 526 
chosen for the immunoassay.  527 
Beads coupled with inactivated P. salmonis were screened against individual serum samples from 528 
fish immunized with experimental vaccine formulations A to D with graded P. salmonis antigen 529 
content and a control group E (saline). The results demonstrated a dose-response relationship 530 
between antigen content in the administered vaccine and the antibody titers in the samples (Figure 531 
9). A significant difference in measured IgM antibody responses was found between vaccine A and 532 
vaccine C, and vaccine A and vaccine D (p ≤ 0.05). The positive control P. salmonis plasma pool was 533 
within the same MFI range as antibody values from fish vaccinated with Vaccine A. Antibody levels in 534 
saline-injected controls were low and within the same range as the negative P. salmonis plasma pool 535 
and individual values of samples from non-vaccinated fish.  536 
No significant difference was found between the challenge models concerning the levels of P. 537 
salmonis specific antibodies after vaccination with vaccine A or B (Figure 10A and B). A slower onset 538 
of titer increment was demonstrated after cohabitation challenge compared with i.p. challenge, and 539 
also in vaccinated fish in group B compared with vaccine group A. Fish vaccinated in group C and D 540 
had significantly lower antibody titers compared to fish in group A in both challenge models (Figure 541 
10C and D). Specific antibody levels in saline-injected fish (group E) remained low throughout the 542 
sampling period (Figure 10E). No sampled fish were positive for specific antibodies against non-P. 543 
salmonis antigens; A-layer from A. salmonicida or M. viscosa whole cell sonicate, throughout the 544 
sampling period (not shown). 545 
Figure 9. Dose-response systemic IgM against P. salmonis seven wpv. Vaccines with different antigen 546 
concentration (P. salmonis). MFI= mean fluorescence intensity. UV: unvaccinated fish, A: vaccine A 547 
(5×), B: vaccine B (3×), C: vaccine C (2×), D: vaccine D (0.5×) and E: control (saline).  548 
 549 
Figure 10. Antibody titers of plasma samples from fish challenged by intraperitoneal injection (IPCM) 550 
and cohabitation (CCM) against P. salmonis. A, fish vaccinated with vaccine A (5×); B, fish vaccinated 551 
with vaccine B (3×); C, fish vaccinated with vaccine C (2×); D, fish vaccinated with vaccine D (0.5×); E, 552 
fish injected with saline solution (control). MFI= mean fluorescence intensity.  553 
 554 
4 Discussion 555 
The main approach in testing efficacy and potency of fish vaccines is the use of experimental 556 
challenge either by i.p. injection, cohabitation or immersion. The three routes of infection each have 557 
their advantages and disadvantages. Challenge by i.p. injection represents an efficient route of 558 
infection that shortens the time to develop signs of disease and is often preferred due to reduced time 559 
and costs. Challenge by cohabitation or immersion typically leads to a longer period of time to develop 560 
signs of disease, but is considered a more natural way of infection that more closely mimics real-life 561 
conditions (Nordmo, 1997; Birkbeck, Rennie, Hunter, Laidler, & Wadsworth, 2004). Which model to 562 
use depends on the pathogen of interest and is directed by monographs for vaccine testing (EMA, 563 
2011) as well as experience from previous comparative trials. Experimental challenge with Moritella 564 
viscosa after immunization is, for example, well-known to reveal different degree of protection 565 
provided by the vaccines dependent on whether the challenge is done by i.p. injection or immersion 566 
(unpublished results from VESO Vikan). In addition, environmental factors such as temperature, light, 567 
water flow and water quality strongly influence the development of disease and must be taken into 568 
consideration when designing experimental challenge models. Previously reported challenge studies 569 
with P. salmonis show variation in onset of mortality and disease development compared to the 570 
present study, which could be related to differences in water temperature and salinity between trials 571 
(Vásquez, 2012; Rozas-Serri et al., 2017; Meza et al., 2019). The aim of the present study was to 572 
compare the disease development of two P. salmonis challenge models; i.p. injection and cohabitation 573 
to elucidate the pathogenesis of P. salmonis and evaluate the challenge models’ proficiency to 574 
differentiate the protection afforded by vaccines against piscirickettsiosis. 575 
P. salmonis is an intracellular facultative bacterium and hence the development of cellular 576 
immunity after vaccination is the key in protection against the disease (Beck & Peatman, 2015). CD8α 577 
and CD4-1 are co-receptors found on cytotoxic T-cells and T-helper cells, respectively, which are key 578 
players in the development of cellular immunity (Medzhitov, 2007; Beck & Peatman, 2015; Secombes 579 
& Belmonte, 2016). In the present study, the CD8α expression was downregulated and CD4-1 580 
expression was upregulated in the spleen after challenge by both routes. This is in agreement with the 581 
results obtained in the study performed by Rozas-Serri, Peña, Arriagada, Enríquez, and Maldonado 582 
(2018). The upregulation of CD4-1 expression indicates an involvement of T-helper cells in the immune 583 
response. Although the kinetics of lymphocyte receptor expression in the current study may provide 584 
some insight into the pathogenesis of P. salmonis, the results should be interpreted with caution 585 
bearing in mind that the expression of cellular markers in the spleen may be influenced by the traffic 586 
of lymphocytes in and out of the organ.  587 
The pathological changes found in the present study also suggest a hypothesis related to the 588 
pathogenesis of P. salmonis. Short time after challenge (1 wpc), hemorrhages in the digestive tract 589 
were only identified in fish challenged by cohabitation and only in the two fish groups that received 590 
less or no antigen (vaccine group D and control group E). This result suggests that the digestive tract 591 
is the natural port of entry of P. salmonis. In addition, general bleedings were found in highest 592 
frequency in fish vaccinated with the highest antigen dose (Group A) at 2 wpc (i.p. injection) and 3 593 
wpc (cohabitation). Thus, it is tempting to speculate that these pathological signs are caused by the 594 
teleost’s acquired immune response after vaccination.  595 
All macro- and microscopic pathological changes observed in this study were consistent with those 596 
previously described after both natural and experimental outbreaks (Almendras, Fuentealba, 597 
Markham, & Speare, 2000; Fryer & Hedrick, 2003; OIE, 2003; Evensen, 2016a; Meza et al., 2019). 598 
The fish were considered healthy and free of known pathogens before the study started. 599 
Nevertheless, two unchallenged fish were found to have pale focal nodes in the liver and ascites, 600 
respectively. This could be related to individual differences between fish, iatrogenic harm caused by 601 
vaccination or necropsy, or artefacts during preparation of tissue for analysis. The presence of 602 
histological alterations in unchallenged, but vaccinated fish and the presence of adhesion and 603 
melanosis in all vaccinated fish might also be due to side effects of vaccine components. Adhesions 604 
and melanosis presented in vaccinated fish are well-known side effects derived from oil adjuvant 605 
present in the vaccines (Shoemaker, Klesius, Evans, & Arias, 2009).  606 
The mortality rates in both challenge models were identical (100%). However, fish challenged by 607 
i.p. injection demonstrated a shorter incubation period (11-13 dpc) compared to the fish challenged 608 
by cohabitation (15-17 days). Furthermore, the duration of the outbreak was shorter after i.p. 609 
challenge compared to challenge by cohabitation. These differences could be related to the route of 610 
infection and challenge dose. Challenge by i.p. injection of bacteria directly into the fish, ensures a 611 
high and instant challenge dose. In contrast, when fish are challenged by cohabitation, the bacteria 612 
are transmitted from shedder fish. The challenge dose could be adjusted through the number of 613 
shedders; nevertheless, the cohabitant fish are exposed to a lower challenge dose for a longer time 614 
compared to the fish challenged by injection. The more prolonged duration of the outbreak and thus 615 
the extended period for pathological changes and immune responses to develop suggests that 616 
challenge by cohabitation could be a more proficient model to study the disease pathogenesis than 617 
challenge by injection.  618 
The bacterial load of P. salmonis in head kidney, spleen and liver was analyzed by qPCR. A higher 619 
bacterial load was found in fish challenged by injection before the disease outbreak and could be 620 
related to the higher challenge dose compared to the cohabitation challenge. However, the bacterial 621 
load was found to be similar in both challenge models during the disease outbreaks. This could suggest 622 
that the fish started to die at the time when the bacterial load reached a certain level, independent of 623 
the challenge model. A dose-response relationship was identified between vaccine antigen dose and 624 
bacterial load in the different tissues after challenge by injection, especially in the head kidney and 625 
spleen, suggesting an ability to use qPCR to discriminate between the potency of different vaccines 626 
after injection challenge. In addition, a dose-response relationship between CD8α expression and 627 
vaccines A, B and C was observed after challenge by injection, with the highest CD8α expression 628 
identified in the spleen of fish vaccinated with vaccine A. It has been described that P. salmonis is able 629 
to modulate cell-mediated immunity and thus promoting intracellular replication of the bacteria and 630 
its survival inside the host cells (Rozas-Serri et al., 2018). Thus, the acquired immune response 631 
developed in fish after vaccination against P. salmonis could avoid downregulation of CD8α. However, 632 
the vaccine did not provide enough protection to develop a strong immune response in the fish 633 
challenged by cohabitation. These results point to that the i.p. injection route could be the model of 634 
choice for evaluation of protection afforded by vaccines against P. salmonis. When compared to the 635 
cohabitation or bath challenge models, the injection model will not only reduce the cost and duration 636 
of the challenge trial, but also potentially provide improved animal welfare due to the shortened time 637 
that fish will be exposed to disease.  638 
Inactivated or subunit vaccines have been shown to be ineffective in stimulating cellular immunity 639 
and mainly stimulate the production of humoral immunity (Seder & Hill, 2000; Shoemaker et al., 2009). 640 
This is also evident in the current study, with results showing increased expression of sIgM after 641 
vaccination and challenge in parallel to detectable antibody titers against P. salmonis, whereas the 642 
expression of CD8α decreased after challenge. These results warrant further studies. There has been 643 
described that increased cell density in vaccines could improve their efficacy (Makrinos & Bowden, 644 
2016). Therefore, future studies should include an increased concentration of antigen in the vaccine 645 
formulation, for example from 5× to 10×, with the objective to stimulate a protective immune 646 
response. Especially the antigen-specific CD8 T-cell response, described as essential for the immune 647 
protection against intracellular pathogen (Rozas-Serri et al., 2018). Other alternatives to improve the 648 
stimulation of a specific immune response could be by live-attenuated vaccines, which have been 649 
described to stimulate a stronger cellular immune response to intracellular pathogens (Evensen, 650 
2016b; Tandberg et al., 2017).  651 
After vaccination, a dose-response of antibody titers related to the antigen contents in the 652 
different vaccine formulations was evident, with the highest antibody levels found in fish vaccinated 653 
with vaccine A. This was consistent with the response elicited in rainbow trout (Oncorhynchus mykiss) 654 
immunized with different antigenic concentrations of P. salmonis bacterin (Smith et al., 1997). 655 
Following challenge, the antibody levels in fish vaccinated with vaccines A and B further increased, 656 
indicating a secondary immune response to the pathogen. Furthermore, after challenge by injection, 657 
a dose-response in sIgM expression in fish vaccinated with vaccines A, B and C was evident, with the 658 
highest sIgM expression in the spleen of fish vaccinated with vaccine A. These results show the 659 
initiation of a humoral immune response in fish vaccinated with the highest doses of antigen. 660 
However, the antibody titers showed no statistical correlation to the protection or lack of protection 661 
induced by vaccination. Taken together, results of antibody kinetics and immune gene expression 662 
indicate that vaccine A produces a better secondary response after P. salmonis challenge than the 663 
other vaccines present in the study. This underlines the possibility in finding prophylactic measures 664 
that contribute to the development of a robust primary immune response before the fish are 665 
transferred to seawater, which could potentially give a better secondary response when the 666 
individuals get in contact with the pathogen in the rearing phase.  667 
In this study, fish were immunized before challenge for a period of seven weeks. That period 668 
applied to the i.p. injected fish but for those challenged by cohabitation the period of immunization 669 
could be considered as longer. Therefore, this could be thought as a variable that could affect the 670 
experiment outcome. However, this was not reflected in the mortality curves where the cohabitants’ 671 
mortality curves were similar between both challenge models.    672 
Histology and IHC are valuable tools and techniques for disease diagnostic. However, in the case of 673 
a septicemia like piscirickettsiosis, these tools are not suitable for interpretation or evaluation of 674 
vaccine efficacy. Measurement of bacterial load by qPCR after challenge may be a promising approach 675 
to document the efficacy of vaccines. In the present study differences between vaccine groups were 676 
seen one week after challenge by injection; vaccine group A presented the lowest bacterial load and 677 
control group E the highest. Furthermore, liver displayed high loads of bacteria, and could be 678 
suggested as the preferred tissue for bacterial load quantification. Expression of CD8α measured by 679 
RT-qPCR, could also add some information in the evaluation of vaccines after challenge by i.p. 680 
injection.  681 
The statistical variability observed in the present study could have been reduced by increasing the 682 
numbers of experimental fish included at each sampling point. Similar, an increment in sampling time 683 
points could have elucidated more details related to the pathogenesis by covering critical stages 684 
during disease development. However, for ethical reasons, the number of experimental animals is 685 
kept to a minimum.  686 
Further research is necessary to optimize a challenge model for efficacy testing of vaccines against 687 
P. salmonis. Traditional efficacy testing based on the assessment of mortality after challenge is not 688 
optimal for evaluation of vaccines against piscirickettsiosis due to the low degree of differentiation 689 
between vaccine groups.  Taken together with the ethical aspects of using mortality as outcome 690 
parameter, efforts should be made to find an alternative to mortality-based evaluation of vaccine 691 
efficacy. With this, the analysis for documentation of the vaccines can be improved and may probably 692 
result in a more selective scale for new vaccines.  693 
 694 
5 Conclusion  695 
The present study reveals no major differences in the efficacy induced by vaccines after challenge 696 
by either i.p. injection or cohabitation. The choice of challenge model will depend on the aim of the 697 
study. In case of studying the disease and pathogenicity, the challenge by cohabitation would be 698 
preferred. In case of studying vaccine potency and efficacy, the suggestion could be  challenge by i.p. 699 
injection. Further research is needed to identify alternatives to mortality-based evaluation of the 700 
efficacy of vaccines against piscirickettsiosis. Other outcome parameters than mortality, such as 701 
bacterial load, antibody titers or immune gene expression may be able to better differentiate between 702 
the protection induced by different vaccines.  703 
 704 
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Supplementary table1. Bacterial load statistical differences between groups in different challenge 874 
models; by i.p. injection (IPCM) and by cohabitation (CCM). A, vaccine A (5×); B, vaccine B (3×); C, 875 
vaccine C (2×); D, vaccine D (0.5×); E, control (saline).  876 
  
Liver Spleen  Head kidney 
IPCM 




 D n.s.       D n.s.       D *       
C n.s. n.s.     C n.s. *     C ** n.s.     
B n.s. n.s. n.s.   B n.s. n.s. n.s.   B ** n.s. n.s.   




 D       D       D       
C       C       C       
B   n.s.   B   n.s.   B   n.s.   
A   n.s. n.s. A   n.s. n.s. A   n.s. n.s. 
  
Liver Spleen  Head kidney 
CCM 





D n.s.       D n.s.       D n.s.       
C n.s. n.s.     C n.s. n.s.     C n.s. n.s.     
B n.s. n.s. n.s.   B n.s. n.s. n.s.   B n.s. n.s. n.s.   




 D n.s.       D n.s.       D n.s.       
C n.s. n.s.     C n.s. n.s.     C n.s. n.s.     
B n.s. n.s. n.s.   B n.s. n.s. n.s.   B n.s. n.s. n.s.   




 D n.s.       D n.s.       D n.s.       
C n.s. n.s.     C n.s. n.s.     C n.s. n.s.     
B n.s. n.s. n.s.   B n.s. n.s. n.s.   B n.s. n.s. n.s.   




 D n.s.       D n.s.       D n.s.       
C n.s. n.s.     C n.s. n.s.     C n.s. n.s.     
B n.s. n.s. n.s.   B n.s. n.s. n.s.   B n.s. n.s. n.s.   
A n.s. n.s. n.s. n.s. A n.s. n.s. n.s. n.s. A n.s. n.s. n.s. n.s. 
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Piscirickettsia salmonis is one of the most widespread fish pathogens in the Chilean 18 
aquaculture and the causal agent of piscirickettsiosis, a disease that is responsible for big 19 
economical losses in the salmon industry. P. salmonis is a facultative intracellular bacterium 20 
classified in two different genogroups, LF89 and EM90. A majority of the published studies of 21 
P. salmonis are related with the reference strain LF89. The aim of this study was to characterize 22 
phylogenetically and phenotypically a P. salmonis EM90-like isolate cultured in FN2 liquid 23 
medium. The isolate has previously been used in experimental challenge trials of Atlantic 24 
salmon (Salmo salar L.). The growth dynamics of the bacteria in different media was studied, 25 
and the enzyme activity and the protein expression profile of the bacterium was described after 26 
cultivation in a new liquid medium. Optimization of cultivation is essential to ensure that the 27 
bacterial culture remains pure, maintains bacterial yield and virulence. Some differences were 28 
observed in the protein expression profile after cultivation of P. salmonis on CHAB agar plates 29 
compared with liquid FN2 medium. Furthermore, differences in protein expression were 30 
identified when comparing fresh bacteria with bacteria inactivated with formalin. A 31 
2 
 
morphological difference in the color of the colonies was observed when comparing the P. 32 
salmonis EM90-like isolate cultured on CHAB agar plates with the bacteria cultured in FN2 33 
medium. Results from in vivo challenge trials with fish indicated that the virulence of the 34 
bacteria was conserved independent of cultivation method.  35 
 36 
Keywords 37 
Piscirickettsia salmonis, phylogeny, phenotype, western blot, broth medium.  38 
 39 
1. Introduction  40 
Piscirickettsia salmonis is a Gram-negative, non-motile and facultative intracellular bacterium. 41 
The bacterial cells are pleomorphic, however mainly coccoid in shape (Almendras et al., 1997; 42 
Henríquez et al., 2013; Otterlei et al., 2016). P. salmonis is the etiological agent of 43 
piscirickettsiosis (Fryer et al., 1990), which is the most significant disease in the Chilean 44 
salmon industry (Rozas‐Serri et al., 2018) causing an annual loss of around USD 700 millions 45 
(Maisey et al., 2017).  46 
The bacterium was initially described as strictly intracellular (Mauel and Miller, 2002) and  47 
typically cultivated in the chinook salmon cell line CHSE 214 (Henríquez et al., 2013). In 2007,  48 
cultivation of a P. salmonis LF89-like isolate on cell-free agar plates was reported  (Mikalsen 49 
et al., 2008). Subsequently, several free-cell media were successfully developed (Henríquez et 50 
al., 2013; Mandakovic et al., 2016; Mikalsen et al., 2008). The transition from cultivation in 51 
cell cultures to cultivation on cell-free agar was considered a milestone that significantly 52 
reduced the time and cost spent on in vitro cultivation.  53 
There are two genogroups of P. salmonis; LF89 and EM90. The genogroups differ in 54 
geographic location, antibiotic resistance, host specificity and clinical manifestations 55 
(Nourdin-Galindo et al., 2017). The EM90 genogroup is widely spread and responsible for  56 
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most of the disease cases in the geographical area where the salmon farms are (Saavedra et al., 57 
2017). The LF89 genogroup is located more concentrated in the Los Lagos region in the 58 
southern part of Chile, and accounts for less than 50% of the reported piscirickettsiosis cases 59 
(Saavedra et al., 2017). Whole genome sequences have been published for an LF89-like isolate 60 
(Bravo and Martinez, 2016), as well as partial sequences have been reported for EM90-like 61 
isolates (Nourdin-Galindo et al., 2017). 62 
Antibiotics and vaccines are well-known measures to reduce the impact of piscirickettsiosis in 63 
the Chilean industry (Rozas‐Serri et al., 2018). Antibiotics have been the preferred treatment 64 
of the disease in situ and have also been used as a prophylactic measurement. In addition, 65 
several vaccines have been developed with the objective to prevent the disease (SAG, 2017).  66 
The efficacy of vaccines is evaluated using experimental challenge of immunized fish under 67 
controlled conditions. For experimental challenge with P. salmonis, it is essential to establish 68 
consistent and reproducible cultivation of the bacteria. The bacteria thrive in nutrition rich 69 
media, which may lead to contamination with unrelated non-pathogenic microorganisms. It is 70 
beneficial to optimize the cultivation procedure by reducing the time of growth needed to reach 71 
a high concentration of the bacterium, ensuring a pure inoculum and maintaining the bacterial 72 
virulence.  73 
P. salmonis is considered a particularly tedious and difficult bacterium to work with (Birkbeck 74 
et al., 2004). Thus, the optimization of cell-free media is an important contribution to further 75 
studies of the bacteria. The aim of this study was to characterize phylogenetically and 76 
phenotypically a P. salmonis EM90-like isolate used for in vivo studies. Furthermore, a new 77 
cell-free medium, FN2, has been described.    78 
 79 
2. Materials and Methods 80 
2.1. Bacterial strain and culture conditions 81 
4 
 
The P. salmonis EM90-like strain (VESO Vikan) was originally isolated from Atlantic salmon 82 
during a disease outbreak in Calbuco, Los Lagos, Chile in 2004. The bacteria were stored at -83 
80°C until use. The isolate was cultured on cysteine heart agar (CHAB) plates (Norwegian 84 
Veterinary Institute, Oslo, Norway), FN2 agar plates, and in FN2 broth at 18°C for 4-7 days 85 
depending on the type of medium. Broth cultures were incubated with an agitation of 150 rpm.  86 
 87 
2.2. FN2 culture medium 88 
The FN2 cell free medium included 10 g peptone (Sigma-Aldrich), 5 g yeast extract (Merck & 89 
co., Inc.), 12.5 g NaCl, 5 g glucose (Merck & co., Inc.), 50 mL (5%) fetal bovine serum (FBS) 90 
(Sigma-Aldrich), 0.5 g L-cysteine (Sigma-Aldrich), 55.6 mg FeSO47H2O, 10 mL (1%) 91 
minimum essential media (MEM) (Sigma) and distilled water to a total volume of 1 L.  92 
Peptone, yeast extract, NaCl and distilled water were sterilized by autoclaving and cooled to 93 
room temperature (RT). Glucose, L-cysteine and FeSO47H2O were sterile filtrated (0.2μm) and 94 
added to the solution together with MEM and FBS after autoclaving. For FN2 agar preparation, 95 
15 g of agar for microbiology (VWR chemicals) was added to the initial solution prior to 96 
autoclaving. 97 
 98 
2.3. Growth curve experiment 99 
One mL of P. salmonis EM90-like culture was transferred from a freeze stock ampule and 100 
cultivated in 10 mL FN2 broth at 18°C with agitation (150 rpm) for four days. The bacterial 101 
culture was further diluted in FN2 medium to an optical density of 0.2 ± 0.02 at 600 nm 102 
(OD600nm) using a Genesys 20 spectrometer (Thermo scientific) and split in six replicates of 10 103 
mL each. The cultures were further incubated at 18°C with agitation (150 rpm), and the OD600nm 104 
was measured every 4 hours for a total of 160 hours. An average and standard deviation (SD) 105 
of the six OD600nm measurements was calculated, and growth curves were plotted using OD600nm 106 
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measurements as a function of time. Control of contamination was develop by plating 100 μL 107 
of culture on CHAB and blood agar plates every 24 hours.  108 
 109 
2.4. Bacterial enzyme profiling 110 
From freeze stocks, P. salmonis EM90-like bacteria were thawed and inoculated in FN2 broth 111 
at 18°C for seven and four days, respectively. Bacteria cultured in FN2 broth were pelleted by 112 
centrifugation (4000g) for 10 min at 4°C, resuspended in saline water (0.9% NaCl) until the 113 
turbidity was equivalent to a McFahrland standard of 5-6, and finally applied to an API® ZYM 114 
strip. The incubation temperature and length were adjusted to 18°C for 96 hours. Otherwise, 115 
the manufacturer’s instructions were applied. The API® ZYM gallery allowed a rapid and 116 
semiquantitative detection of 19 enzymatic reactions including alkaline phosphatase, esterase 117 
(C 4), esterase lipase (C 8), lipase (C 14), leucine arylamidase, valine arylamidase, cysteine 118 
anylamidase, trypsin, α-chymotrypsin, acid phosphatase, naphthol-AS-BI-phosphohydrolase, 119 
α-galactosidase, β-galactosidase, β-glucuronidase, α-glucosidase, β-glucosidase, N-acetyl-β-120 
glucosaminidase, α-mannosidase and α-fucoidase. Each reaction was classified as positive, 121 
moderate or negative according to the manufacturer’s instructions.       122 
 123 
2.5. Bacterial sequencing 124 
2.5.1. Bacterial cultivation and identification of P. salmonis EM-90 125 
The P. salmonis strain was cultured using the broth culture medium FN2. The culture was 126 
performed in triplicate, with a negative control (culture medium only) and incubated at 22°C 127 
with gentle agitation. Growth dynamic was periodically evaluated by measuring the OD600nm 128 
(Epoch, BioTek Instruments, USA). At an OD600nm between 0.6-0.8, the culture was harvested 129 
and stored at -80°C for further analysis. For confirmation of bacterial identity a qPCR assay 130 




2.5.2. Genomic DNA extraction 133 
The bacterial genomic DNA was extracted with the NucleoSpin DNA purification kit 134 
(Macherey-Nagel) according to the manufacturer’s instructions. The concentration was 135 
measured using dsDNA BR Assay kit (QUBIT) and the purity was measured using an 136 
absorbance ratio of 260/280. 137 
 138 
2.5.3.  Genomic library preparation and sequencing 139 
The DNA quality was verified through capillary electrophoresis using High Sensivity DNA 140 
genomic kit (Fragment analyzer). Once the quality was checked, the library was constructed 141 
using the Nextera XT DNA kit (Illumina) following the manufacturer's instructions. 142 
Subsequently, the size of the library was assessed by capillary electrophoresis using High 143 
Sensivity NGS Fragment Analysis kit (Advanced Analytical). Library quantification was 144 
performed by qPCR using a commercial kit (Kapa Biosystems, USA) and by Qubit using 145 
dsDNA High Sensitivity kit (Life Technology). The sequencing was done in a MiSeq 146 
equipment (Illumina Platform) using V3 version and 600 cycles paired end kit in the FAVET-147 
INBIOGEN laboratory. 148 
 149 
2.5.4. Analysis of sequence data 150 
Raw reads were trimmed based on quality of the sequence using Trimmomatic software 151 
(Bolger et al., 2014), using the default parameters. Then, trimmed sequences were assembled 152 
using Spades v3.5.0 (Nurk et al., 2013).  153 
 154 
2.5.5. Phylogenetic analyses. 155 
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The analysis involved 11 whole genome sequences, retrieved from a subset of genomes 156 
available online for P. salmonis from NCBI (accession numbers; ASM30029v4; 157 
ASM40151v2; ASM75641v3; ASM75643v3; ASM75848v1; ASM76407v1; ASM102993v1; 158 
ASM193259v1; ASM193279v1; ASM255662v1) in addition to the P. salmonis isolate used in 159 
the current study. These retrieved genome sequences represent the two genogroups that have 160 
been previously assessed using isolates from disease outbreaks in Chile (Bravo and Martinez, 161 
2016). Alignments were obtained using the Realphy pipeline using the merge option (Bertels 162 
et al., 2014). Estimates of evolutionary divergence between the sequences (Jukes-Cantor 163 
distances) and phylogenies were reconstructed using the Bayesian algorithm BEAST 2.5 164 
(Bouckaert et al., 2019) in order to obtain the posterior distribution of the tree topology 165 
assuming uninformative priors. The posterior distribution was inspected using tracer, in order 166 
to check for local convergence.  167 
 168 
2.6. Western blot  169 
2.6.1.  Sample preparation  170 
The P. salmonis EM90-like isolate was cultured from two ampules stored at -80°C. The first 171 
ampule was divided in three bottles with 10 mL FN2 broth each and from the second ampule 172 
100 μL were plated on CHAB and FN2 agar plates. The bacteria were incubated at 18°C for 173 
up to 96 hours for the broth culture and up to six days for the agar plates before harvesting. 174 
Inactivation by formalin was done in two of the bottles; one was subject to cold inactivation 175 
(4°C) and the other was inactivated at RT by adding 0.6% formalin. 176 
Plated colonies (FN2 and CHAB) were dissolved in PBS (8.0 g/L NaCl, 0.2 g/L KCl, 1.44 g/L 177 
Na2HPO4, 0.24 g/L KH2PO4, pH 7.4) and washed twice by centrifugation (12000g, 5 minutes, 178 
4°C) before resuspension in PBS. Broth medium (FN2) with inactivated (cold and RT) bacteria 179 
were collected by centrifugation (12000g, 5 minutes, 4°C) and washed three times in PBS (pH: 180 
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7.4). All samples were adjusted to an OD600nm of 0.90 (Genesys 20, Thermo Scientific) in PBS 181 
before collection by centrifugation (12000g, 5 minutes, 4°C). For protein isolation the resulting 182 
pellets were re-suspended in 50 μl 2% Triton-X 100 (Sigma) and 50 μl 2× Sample Preparation 183 
Buffer (125mM Tris-HCl pH: 6.8; 4% SDS; 20% glycerol; 20mM EDTA; 150mM DTT). 184 
Samples were mixed by vortexing and incubated at 37°C for 15min.  185 
 186 
2.6.2.  SDS-PAGE  187 
SDS-PAGE was performed on a Criterion XT 12% Bis-Tris Precast Gel (BioRad) run with XT 188 
MES buffer (BioRad) driven by PowerPac™ HC transformer (BioRad) at 200V for 50 minutes. 189 
Precision Plus Protein Western C ladder (BioRad) was used as standard. 190 
Total protein staining was performed according to GelCode™ Blue Safe Protein Stain protocol 191 
(Thermo Scientific).  192 
Separated SDS-PAGE gel was enclosed in Trans-Blot® Turbo™ Midi PVDF Transfer Pack 193 
0.2μm (Bio-Rad) and proteins were transferred by mixed molecular weight program (MW) on 194 
the Trans-Blot® Turbo™ Transfer System (BioRad) as described by the manufacturer. The 195 
PVDF membrane was washed 2 × 10 minutes with TBS-T buffer (10mM Tris-HCl pH:7.4; 196 
150mM NaCl; 0.05% Tween 20) and blocked with TBS-T added 5% skimmed milk (Sigma) 197 
for 1 hour at RT. Staining with primary specific antibody (kindly provide by Duncan 198 
Colquhoun, Norwegian Veterinary Institute) diluted 1:60 000 in TBS-T added 1% skimmed 199 
milk was performed at 4°C overnight. Washing with TBS-T 3 × 10 minutes in RT was followed 200 
by staining with secondary antibodies (HRP-conjugated anti-rabbit) and Precision plus 201 
StrepTactin HRP both diluted 1:60 000 for 1 hour at RT. Further washing with TBS-T 4 × 10 202 
minutes in RT was followed by chemiluminescent detection by Amersham ECL Select 203 
Detection reagents (GE Healthcare Life Sciences). Total protein stain and Western blot were 204 




2.7. In vivo challenge trial  207 
The challenge trial was conducted at VESO Vikan research facility (Namsos, Norway). Fish 208 
were acclimatized in brackish water with a salinity of 25‰ at 15°C for 14 days prior to trial 209 
start and starved for 48 hours prior to challenge. At day 0, the fish were distributed into 210 
duplicated tanks (tank A and tank B). The tanks had a capacity of 130 L, and the stocking 211 
density was not higher than 40 kg/m3 for the trial. Each tank included 10 i.p. injected fish. The 212 
fish were sedated with 0.001% benzocaine chloride (Sykehusapoteket Oslo, Ullevål). The 213 
bacterial inoculum was prepared for tank A in FN2 broth and for tank B in CHAB agar plates. 214 
The bacterial inoculum for i.p. injection of fish was adjusted to OD600nm = 1.0 and further 215 
diluted by four tenfold dilutions giving a theoretical dose of 1.0 × 105 cfu/ml. Each fish was 216 
injected with 0.1 ml of the bacterial inoculum on day 0. The fish were kept in brackish water 217 
with a salinity of 25‰ at 15°C and 24 hours light. The fish were fed with a commercial diet 218 
(Skretting AS) twice a day from day 1 post‐challenge (dpc). The fish were monitored daily, 219 
and dead fish were registered.  220 
 221 
3. Results 222 
3.1. Bacterial colony morphology and growth rate  223 
Visible growth of P. salmonis appeared on CHAB plates after five days incubation. The P. 224 
salmonis colonies on CHAB plates were pinpoint size, grey-white, shiny and frequently 225 
confluent (Figure 1A). In contrast, bacterial colonies were visible on FN2 plates as early as on 226 
day three of incubation. On these agar plates, P. salmonis colonies were translucent with a pale-227 
yellow color that resembled the medium (Figure 1B) and they were equal in size to the bacterial 228 
colonies observed on CHAB plates.  229 
10 
 
The growth curve of the P. salmonis EM90-like isolate cultured in FN2 broth is shown in 230 
Figure 2. In the current experiment, the lag phase lasted for 40 hours followed by the 231 
logarithmic phase that continued for 56 hours. The bacterial growth reached stationary phase 232 
after 96 hours and lasted for 32 hours before onset of the decline phase. The highest bacterial 233 
concentration was measured after 104 hours representing an OD600nm of 5.65. No bacterial 234 
colonies other than P. salmonis were observed on CHAB agar and no bacterial colonies were 235 
observed on blood agar plates. 236 
 237 
 238 
Figure 1. P. salmonis grown on CHAB plates (A) and FN2 plates (B). The bacteria were 239 






Figure 2. Growth curve of the P. salmonis EM90-like isolate cultivated in FN2 broth. Vertical 244 
bars indicate the standard deviation. 245 
 246 
3.2. Genome sequencing and comparison 247 
The estimates of evolutionary divergence between sequences showed very little divergence 248 
inside each genogroup. The tree topology showed complete separation between the LF89 and 249 
EM90 genogroups (Figure 3). The differences between the EM90 and LF89 genogroups were 250 
about three percent of the number of base substitutions per site. The standard error estimates 251 
were obtained by a bootstrap procedure (50 replicates), and were essentially zero, which is 252 





Figure 3. Whole-genome phylogenetic analysis of eleven selected P. salmonis genomes 256 
including the P. salmonis EM90-like isolate. The tree was constructed using the Bayesian 257 
phylogenetic analysis using BEAST. The phylogenetic tree was obtained after considering 10 258 
genomes available at NCBI (ASM30029v4; ASM40151v2; ASM75641v3; ASM75643v3; 259 
ASM75848v1; ASM76407v1; ASM102993v1; ASM193259v1; ASM193279v1; 260 
ASM255662v) and the current EM-90 isolate.  261 
 262 
3.3. Profiling of bacterial enzyme production 263 
The API®ZYM kit was used for semi-quantitative detection of 19 enzymatic reactions of the 264 
P. salmonis EM90-like isolate cultured in FN2 broth. The enzymes registered with positive 265 
reactions (++) were alkaline phosphatase, leucine arylamidase, valine arylamidase, acid 266 
phosphatase and naphthol-AS-BI-phosphohydrolase. Those that were considered to be 267 
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moderate reactions (+) were esterase, esterase lipase and cystine arylamidase. The remaining 268 
enzymes; lipase, trypsin, α-chymotrypsin, α-galactosidase, β-galactosidase, β-glucuronidase, 269 
α-glucosidase, β-glucosidase, N-acetyl-β-glucosaminidase, α-mannosidase and α-fucoidase 270 
were negative (-). The results are summarized in Table 1.  271 
 272 
Table 1. Enzymatic activity of P. salmonis EM90-like bacteria cultivated in FN2 broth. (++) 273 
positive reaction; (+) moderate reaction; (-) negative reaction. 274 
Enzyme Reaction 
Alkaline phosphatase ++ 
Esterase (C 4) + 
Esterase lipase (C 8) + 
lipase (C 14) - 
Leucine arylamidase ++ 
Valine arylamidase ++ 
Cysteine aylamidase + 
Trypsin, - 
α-chymotrypsin - 













3.4. Protein profiling by Western blot 277 
Differences in protein expression were revealed after cultivation of the P. salmonis EM90-like 278 
isolate in different media followed by SDS-PAGE and Western blotting (Figure 4). Twelve 279 
major bands between approximately 13 and 100 kDa were identified in all three bacterial 280 
cultures that were non-inactivated by formalin prior to SDS-PAGE (Figure 4, lane A-C). An 281 
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additional band representing a protein of approximately 43 kDa was identified in bacteria 282 
cultivated on FN2 agar plates (Figure 4, lane B). In comparison, a double protein band of 283 
approximately 47 kDa was only identified after cultivation in FN2 broth (Figure 4, lane C). In 284 
addition, the lack of a protein band of approximately 10 kDa was identified in bacteria cultured 285 
on FN2 agar plates (Figure 4, lane B). 286 
Bacteria cultivated in FN2 broth at 18°C followed by inactivation with formalin at RT (Figure 287 
4, lane D) or 4°C (lane E) displayed less conserved protein bands compared to the non-288 
inactivated bacteria grown in FN2 broth (Figure 4, lane C). The main difference was the 289 
presence of the double band of approximately 47 kDa that was expressed in bacteria cultivated 290 
in FN2 broth (Figure 4, lane C), but that was absent in the inactivated bacteria (Figure 4, lane 291 
D and E). Additionally, the bands of approximately 45 and 20 kDa that were present in the 292 
non-inactivated bacteria, were absent in both the inactivated groups. Furthermore, in the 293 
bacteria inactivated at 4°C, the band of approximately 10 kDa was absent unlike in the bacteria 294 
cultivated in FN2 broth and on CHAB plates where this band was present. The Western blot 295 
also revealed that the temperature during formalin-inactivation of the bacteria affected the 296 
protein expression. A protein band of approximately 60 kDa was identified in the three non-297 
inactivated bacteria cultures as well as in the culture that was inactivated at 4°C. After 298 
inactivation at RT, however, the band was absent. Inactivation at RT (Figure 4, lane D) 299 
demonstrated in general poorly conserved protein bands and a thick smear of approximately 300 
200-250 kDa. In contrast, formalin-inactivated bacteria at 4°C (Figure 4, lane E) demonstrated 301 
more conserved protein bands, although with similar agglomeration of proteins of 302 




  305 
Figure 4. Protein expression profile of the P. salmonis EM90-like isolate cultured in different 306 
growth media (A-E) and inactivated in formalin at different temperatures (Lane D and E). A = 307 
CHAB plates, B = FN2 plates, C = FN2 broth, D = FN2 broth inactivated with formalin at 308 
room temperature, E = FN2 broth inactivated with formalin at 4°C.  Ladder in MW, kDa. 309 
 310 
3.5. In vivo challenge of fish  311 
To evaluate the potential impact of cultivation media on bacterial virulence, P. salmonis was 312 
cultured in FN2 broth and on CHAB plates, and used for in vivo challenge of Atlantic salmon 313 
split into tank A and B, respectively. The mortality curves in Figure 5 show that the disease 314 
developed faster and more progressive in tank A compared to tank B. In tank A, dead fish were 315 
registered from day 11 post challenge (dpc) reaching 100% mortality after one day (12 dpc). 316 
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In tank B, mortality was registered from 13 dpc and reached 100% after three days on 16 dpc. 317 
Even though the initial mortality rate was slightly higher in tank B, the mortality did not reach 318 
100% until 16 dpc. On the other hand, the mortality rate in tank A increased rapidly and reached 319 
100% mortality on 11 dpc.   320 
 321 
 322 
Figure 5. Mortality curve after challenge of Atlantic salmon (Salmo salar L.) with a P. salmonis 323 
EM90-like isolate. Ten fish were included in each tank. In tank A, the inoculum was prepared 324 
with bacteria cultured in FN2 broth. In tank B, the inoculum was prepared with bacteria 325 
cultured in CHAB plates.  326 
 327 
4. Discussion 328 
Previous studies on P. salmonis have commonly focused on the LF89 reference strain. The 329 
LF89 (ATCC(R) VR 1361) was established as a reference strain in 1992 (Fryer et al., 1992)  330 
and was the first isolate of P. salmonis to be described. The EM90 genogroup is, however, 331 
described to be the most widespread genogroup of P. salmonis as well as responsible for the 332 
majority of piscirickettsiosis outbreaks (Saavedra et al., 2017). EM90-like strains are therefore 333 
frequently used in experimental challenge trials, which aim to mimic real life conditions in 334 
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commercial aquaculture. The aim of this work was to study the genetic background of a Chilean 335 
isolate of P. salmonis that has previously been used in experimental challenge trials at VESO 336 
Vikan (Meza et al., 2019a; Meza et al., 2019b), and to describe the isolate’s phenotypical and 337 
virulence properties. The phylogenetic study confirms that the isolate used in the previous 338 
challenge trials performed by Meza et al. (2019a) belongs to the EM90 genogroup, where it 339 
clusters with eight previously sequenced P. salmonis EM90 genomes, this is in accordance 340 
with what has been seen previously (Bravo and Martinez, 2016).  The two different branches 341 
representing the two genogroups; EM90 and LF89, are shown in Figure 3. The results are  in 342 
agreement with a report published by Nourdin-Galindo et al. (2017) where P. salmonis isolates 343 
were classified as LF89 or EM90.  344 
The morphology of bacteria grown on agar plates observed in this study was in agreement with 345 
previous findings where grey-white pinpoint and no distinctive colonies were described 346 
(Mikalsen et al., 2008; Otterlei et al., 2016). The incubation time needed for bacterial colonies 347 
to become visible on solid agar media has previously been described to be between four and 348 
eight days when cultivated with 5% sheep blood, 0.1% cysteine and 1%glucose (BCG) and/or 349 
CHAB agar plates (Yañez et al., 2012). Similar results were observed in the current study, and 350 
interestingly, bacterial colonies cultured in FN2 broth or FN2 agar were found to require a 351 
shorter incubation time to achieve appropriate growth compared to bacteria grown on CHAB 352 
plates. Thus, the use of FN2 broth for cultivation of P. salmonis may reduce the time required 353 
to obtain a sufficient amount of bacteria for challenge trials. Meza et al. (2019a) demonstrated 354 
that the incubation time of bacterial pre-challenge cultures was reduced from ten to four days 355 
when using FN2 broth medium instead of CHAB plates. This difference in growth rate could 356 
be due to the composition of the growth media. In contrast to the CHAB medium, the FN2 357 
recipe lacks the addition of blood and hemoglobin. Furthermore, the FN2 medium contains a 358 
high concentration of NaCl, which is higher than the physiological concentration (0.9%), but 359 
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closer to the NaCl concentration of brackish water (0.5-35‰). The FN2 medium also contains 360 
less L-cysteine and glucose than the CHAB medium. It may be suggested that some 361 
components in blood are able to reduce or inhibit the bacterial growth, but on the other hand, 362 
the lower NaCl concentration in the CHAB medium may also account for the reduced growth 363 
of P. salmonis. High concentration of selected nutrients may not always be beneficial for 364 
organisms. This could be the case for L-cysteine and glucose, which may enhance bacterial 365 
growth at a lower concentration.  366 
The bacterial growth dynamics are particularly relevant for preparation of inoculums for 367 
challenge trials, since the bacteria must be harvested during the logarithmic phase of the growth 368 
curve. This is important to maintain the viability and virulence of the bacteria. The P. salmonis 369 
presented in this study demonstrated a shorter lag phase and a logarithmic and stationary phase 370 
that were extended compared to the report of Yañez et al. (2012). There are two important 371 
factors that affect the bacterial inoculum for challenging fish; bacterial viability and bacterial 372 
concentration. The different studies on bacterial growth rate should, however, be compared 373 
with caution due to the many factors that must be taken into consideration. An LF89-like P. 374 
salmonis isolate which was studied  by Yañez et al. (2012) was reported to have a lower optical 375 
density of 1.80 at OD620nm compared with the current study of OD600nm = 5.65. The differences 376 
may be related to the cultivation medium. The optimal initial concentration, based on 377 
theoretical concentration, for inoculum preparation of P. salmonis for challenge of fish is 378 
OD600nm = 1.0 of the bacterial culture was estimated to be 1.0 × 1010 cfu/ml (Berger, 2014). 379 
This concentration was obtained after cultivation of P. salmonis in the FN2 medium for 40 380 
hours compared with 96 hours of incubation in the AUSTRAL-SRS medium. The shorter 381 
incubation time required for cultivation of P. salmonis in FN2 medium is beneficial to avoid 382 
contamination of the bacterial culture. If the aim is to obtain a high bacterial concentration 383 
FN2, broth should be preferred.    384 
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The enzymatic expression profiles obtained in this study revealed  some differences when 385 
compared to the report on an EM90-like isolate (NVI-5786) made by Mikalsen et al. (2008). 386 
The results showed moderate reaction of lipase and no reaction of the cysteine arylamidase. 387 
The differences may arise from different cultivation media, but they may also be related to the 388 
different isolates tested. 389 
 Vaccines against intracellular pathogens are in general difficult to develop. New strategies are 390 
therefore sought to obtain protection against those types of infections (Evensen, 2016). It has 391 
been suggested  that vaccines based on live-attenuated bacteria could induce  better stimulation 392 
of the immune system compared to the inactivated vaccines (Tandberg et al., 2017). Live-393 
attenuated vaccines aim to stimulate the cellular pathways of the immune system based on T-394 
cell responses (Itano et al., 2006; Secombes and Belmonte, 2016). This response may be 395 
particularly helpful to the defense against intracellular pathogens mainly due to its relation with 396 
the antigen presentation (Secombes and Belmonte, 2016). 397 
Based on the results from the Western blotting we hypothesized that formalin inactivation 398 
could cause denaturation of proteins, which may possibly affect their antigenic properties. The 399 
efficacy of vaccines for some pathogens, may thus be compromised by   the reduction in the 400 
immunogenicity  caused by the formaldehyde treatment (Montero, 2003; Soto, 2007). In the 401 
Western blot analysis performed in this study, there is one band of approximately 60 kDa 402 
representing a protein expressed in all the non-inactivated bacteria as well as the bacteria 403 
inactivated at 4°C. These results are in agreement with the study developed by Tandberg (2018) 404 
where  Chilean, Norwegian and Canadian isolates were compared, and a 60 kDa protein; GroEl, 405 
was detected. This protein is known for its immunogenic capacities of stimulating the innate 406 
and adaptive parts of the immune system (Ranford and Henderson, 2002). In the same study, 407 
and similar to our observations of  non-inactivated bacteria, an SDS-PAGE separating bacterial 408 
cell membrane fractions and outer membrane vesicle proteins revealed the presence of a protein  409 
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of approximately 45 kDa. This band was, however, absent in the formalin-inactivated bacteria 410 
in the present study. This strengthens the suggestion that formalin-inactivation affects 411 
structures in the bacterial cell membrane. A proteomic analysis is necessary with the objective 412 
to identify the function of the 45 kDa protein as well as the proteins representing the double 413 
band of 47 kDa presented in the bacteria cultured in FN2 broth. 414 
The results from the in vivo challenge confirmed that the bacteria cultured in FN2 broth 415 
conserved their virulence and induced a mortality rate similar to the bacteria cultured on CHAB 416 
agar plates. The fish challenged with P. salmonis cultured in FN2 broth started to die two day 417 
before those challenge with CHAB agar plates, this could be related with the faster growth rate 418 
of the bacteria culture in broth.      419 
 420 
5. Conclusion  421 
The phylogenetic studies confirm that the P. salmonis isolate used in previous in vivo challenge 422 
trials belongs to the EM90 genogroup.   423 
The virulence of the P. salmonis isolate used in this study was not affected by changing the 424 
cultivation media from solid CHAB agar to liquid FN2 medium. Cultivation in liquid medium 425 
lead to a reduction in the incubation time needed for cultivation of bacteria for in vivo challenge 426 
of fish. This will reduce the risk of contamination.  427 
A study related with proteomics derived from the Western blot could be valuable with regards 428 
to determinate the function of bacterial proteins and how they may be involved in the 429 
immunogenicity against P. salmonis. 430 
 431 
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